

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A2	(11) International Publication Number: WO 96/12807
C12N 15/40, C07K 14/08, G01N 33/569, A61K 39/12		(43) International Publication Date: 2 May 1996 (02.05.96)
(21) International Application Number: PCT/US95/13703		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).
(22) International Filing Date: 23 October 1995 (23.10.95)		
(30) Priority Data: 08/327,952 24 October 1994 (24.10.94) US 08/542,634 13 October 1995 (13.10.95) US		
(71) Applicant: GENELABS TECHNOLOGIES, INC. [US/US]; 505 Penobscot Drive, Redwood City, CA 94063 (US).		Published <i>Without international search report and to be republished upon receipt of that report.</i>
(72) Inventors: FUERST, Thomas, R.; 1511 Blackbird Lane, San Antonio, TX 78248 (US). McATEE, C., Patrick; 1600 Villa Street #173, Mountain View, CA 94041 (US). YARBOUGH, Patrice, O.; 34173 Heather Terrace, Fremont, CA 94555 (US). ZHANG, Yi-Fan; 1600 Villa Street #152, Mountain View, CA 94041 (US).		
(74) Agent: FABIAN, Gary, R.; Dehlinger & Associates, P.O. Box 60850, Palo Alto, CA 94306-1546 (US).		

(54) Title: HEPATITIS E VIRUS ANTIGENS AND USES THEREFOR



(57) Abstract

Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HEPATITIS E VIRUS ANTIGENS AND USES THEREFOR

FIELD OF INVENTION

This invention relates to antigens derived from enterically transmitted nonA/nonB hepatitis viral agent, also referred to herein as hepatitis E virus (HEV), and to diagnostic methods, diagnostic assays, vaccine compositions and vaccine methods, which employ such antigens.

REFERENCES

10 Arankalle, V.A., *et al.*, *The Lancet* 550 (March 12, 1988).

Ausubel, F.M., *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley and Sons, Inc., Media PA.

Beames, *et al.*, *Biotechniques* 11:378 (1991).

Bradley, D., *et al.*, *J. Gen. Virol.* 69:731 (1988).

15 Bradley, D.W., *et al.*, *Proc. Nat. Acad. Sci., USA*, 84:6277-6281 (1987).

Chauhan, *et al.*, *Lancet*, 341:149 (1993).

Chomczynski, P., *et al.*, *Anal. Biochem.* 162:156 (1987).

Cleland, W.W., *Biochem.* 3:480-495 (1964).

Earl, P. L., *et al.*, "Expression of proteins in mammalian cells using vaccinia" In 20 CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (F. M. Ausubel, *et al.* Eds.), Greene Publishing Associates & Wiley Interscience, New York (1991).

Elliott, J.I., *et al.*, *Anal. Biochem.* 211:94-101 (1993).

Gellissen, G., *et al.*, *Antonie Van Leeuwenhoek*, 62(1-2):79-93 (1992).

Goeddel, D.V., *Methods in Enzymology* 185 (1990).

25 Guthrie, C., and G.R. Fink, *Methods in Enzymology* 194 (1991).

Harlow, E., *et al.*, ANTIBODIES: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Press (1988).

Haynes, J., *et al.*, *Nuc. Acid. Res.* 11:687-706 (1983).

Huang, C-C., *et al.*, *Virology*, 191:550-558 (1992).

30 Kaufman, R. J., "Selection and coamplification of heterologous genes in mammalian cells," in METHODS IN ENZYMOLOGY, vol. 185, pp537-566. Academic Press, Inc., San Diego CA (1991).

Kawasaki, E.S., *et al.*, in PCR TECHNOLOGY: PRINCIPLES AND APPLICATIONS OF DNA AMPLIFICATION (H.A. Erlich, ed.) Stockton Press (1989).

35 Khuroo, M.S., *Am. J. Med.*, 48:818 (1980).

Khuroo, M.S., *et al.*, *Am. J. Med.* 70:58 (1981).

Koonin, E.V., *et al.*, *Proc. Nat. Acad. Sci. USA* 89:8259 (1992).

Krawczynski, K. and D.W. Bradley, *J. Inf. Diseases* 159:1042-1049 (1989).

Lanford, R.E., *et al.*, *In Vitro Cellular and Devel Biol.*, 25(2):174 (1989).

5 Lau, Y.F., *et al.*, *Mol. Cell. Biol.* 4:1469-1475 (1984).

Maniatis, T., *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory (1982).

McCaustland, K., *et al.*, *J. Virological Methods* 35:331-342 (1991).

Moss, B., *et al.*, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Section IV, Unit 16

10 (1991).

Moss, B., *et al.*, U.S. Patent Number 5,135,855, issued 4 August 1992.

Mullis, K.B., U.S. Patent No. 4,683,202, issued 28 July 1987.

Mullis, K.B., *et al.*, U.S. Patent No. 4,683,195, issued 28 July 1987.

Pearson, W.R. and Lipman, D.J., *PNAS* 85:2444-2448 (1988).

15 Pearson, W.R., *Methods in Enzymology* 183:63-98 (1990).

Purdy, M.A., *et al.*, *J. Medical Virology* 41:90-94 (1993).

Reyes, G., *et al.*, *Science* 247:1335 (1990).

Reyes, G.R., *Arch. Virol. Supp. (Review)* 7:15 (1993).

Reilly, P.R., *et al.*, BACULOVIRUS EXPRESSION VECTORS: A LABORATORY MANUAL

20 (1992).

Romanos, M.A., *et al.*, *Yeast* 8(6):423-488 (1992).

Rosenfeld, J., *et al.*, *Anal. Biochem.* 203:173-185 (1992).

Rozanov, M.N., *et al.*, *J. Gen. Virol.*, 73:2129 (1992).

Sambrook, J., *et al.*, MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory (1989).

25 Schagger, E. and von Jagow, O., *Anal. Biochem.* 166:368-379 (1987).

Scoble, H.A., *et al.*, in A PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION (Matsudaira, P., Ed.) Academic Press, NY pp. 125-153 (1993).

Smith, D.B., *et al.*, *Gene* 67:31 (1988).

30 Summers, M.D., *et al.*, A MANUAL OF METHODS FOR BACULOVIRUS VECTORS AND INSECT CELL CULTURE PROCEDURES, Texas Agricultural Experimental Station Bulletin No. 1555, 1988.

Tam, A., *et al.*, *Virology*, 185:120-131 (1991-a).

Tam, A., *et al.*, "Hepatitis E virus: cDNA isolation and sequencing," In Hollinger, F.B. *et al.* (ed.), VIRAL HEPATITIS AND LIVER DISEASE Williams and Wilkens, Baltimore, p. 521-524 (1991-b).

5 Tsarev, S.A., *et al.*, *Proc. Natl. Acad. Sci. USA* 89:559-563 (1992).

Velazquez, O., *et al.*, *JAMA* 263:3281-3285 (1990).

Wang, A.M., *et al.* in PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS (M.A. Innis, *et al.*, eds.) Academic Press (1990).

Williams, K.R. and Stone, K.L., in TECHNIQUES IN PROTEIN CHEMISTRY VI (Crabb, J., Ed.) Academic Press, NY pp. 143-153 (1995).

10 Yarbough, P.O., "Serology of HEV in developed and developing countries," *INTERaction* 2:15-17 (1994).

Yarbough, P.O., *et al.*, *J. Virology* 65:5790-5797 (1991).

Yarbough, P.O., *et al.*, "Assay Development of Diagnostic Tests for Hepatitis E," In VIRAL HEPATITIS AND LIVER DISEASE, eds. K. Nishioka, H. Suzuki, S Mishiro, T. Oda, pp. 15 367-370 (1994).

BACKGROUND OF THE INVENTION

Enterically transmitted non-A/non-B hepatitis viral agent (ET-NANB; also referred to herein as HEV) is the reported cause of hepatitis in several epidemics and sporadic cases in 20 Asia, Africa, Europe, Mexico, and the Indian subcontinent. Infection is usually by water contaminated with feces, although there is some evidence of person to person transmission. The virus does not seem to cause chronic infection. The viral etiology in ET-NANB has been demonstrated by infection of volunteers with pooled fecal isolates; immune electron microscopy (IEM) studies have shown virus particles with 27-34 nm diameters in stools from infected 25 individuals. The virus particles reacted with antibodies in serum from infected individuals from geographically distinct regions, suggesting that a single viral agent or class is responsible for the majority of ET-NANB hepatitis seen worldwide. No antibody reaction was seen in serum from individuals infected with parenterally transmitted NANB virus (also known as hepatitis C virus or HCV), indicating a different specificity between the two NANB types.

30 In addition to serological differences, the two types of NANB infection show distinct clinical differences. ET-NANB is characteristically an acute infection, often associated with fever and arthralgia, and with portal inflammation and associated bile stasis in liver biopsy specimens (Arankalle, 1988). Symptoms are usually resolved within six weeks. Parenterally transmitted NANB, by contrast, produces a chronic infection in about 50% of the cases. Fever

and arthralgia are rarely seen, and inflammation has a predominantly parenchymal distribution (Khuroo, 1980). The course of ET-NANBH is generally uneventful in healthy individuals, and the vast majority of those infected recover without the chronic sequelae seen with HCV. Occasionally the course of disease can be severe, however, as was recently shown by a human 5 volunteer (Chauhan 1993). One peculiar epidemiologic feature of this disease, however, is the markedly high mortality observed in pregnant women; this is reported in numerous studies to be on the order of 10-20% (Khuroo 1981, Reyes 1993). This finding has been seen in a number of epidemiologic studies but at present remains unexplained. Whether this reflects viral pathogenicity, the lethal consequence of the interaction of virus and immune suppressed 10 (pregnant) host, or a reflection of the debilitated prenatal health of a susceptible malnourished population remains to be clarified.

The two viral agents can also be distinguished on the basis of primate host susceptibility. ET-NANB, but not the parenterally transmitted agent, can be transmitted to cynomolgus monkeys. The parenterally transmitted agent is more readily transmitted to 15 chimpanzees than is ET-NANB (Bradley, 1987).

SUMMARY OF THE INVENTION

The present invention includes a Hepatitis E Virus (HEV) polypeptide composition, consisting of at least one polypeptide derived from the carboxy-terminal 549 amino acids of 20 HEV open reading frame (ORF) 2. The composition may include polypeptides corresponding to this region where the polypeptides have amino acids deleted from the carboxy terminus of the 549 amino acid polypeptide. In one embodiment, at least one polypeptide of the composition contains a carboxy terminal deletion of up to about 24 carboxy terminal amino acids of said 549 amino acid HEV ORF2 polypeptide. Exemplary polypeptides include, but 25 are not limited to, the following: SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and homologous sequences to those presented herein.

In one embodiment, the composition of the present invention ("the 62K antigen") comprises at least two such polypeptides, for example, two polypeptides having the sequences presented as SEQ ID NO:25 and SEQ ID NO:27 or SEQ ID NO:26 and SEQ ID NO:28 (also 30 including homologous sequences).

The invention further includes a substantially isolated nucleic acid sequence encoding a polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame 2. Exemplary nucleic acid sequences include SEQ ID NO:3, SEQ ID NO:4 and homologous sequences thereto.

In another embodiment, the invention includes an expression vector for producing a Hepatitis E Virus polypeptide antigen composition. Such a vector contains a nucleic acid sequence encoding a polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame 2, where the nucleic acid sequence is (i) inserted into an expression vector, 5 and (ii) operably linked to a promoter able to initiate transcription in a selected host cell. The expression vector may be included in an expression system where the expression vector is carried in a suitable host cell, where the host cell allows the expression of the polypeptides of the present invention. In one embodiment, the expression system includes a baculovirus expression vector where the host cell is an insect cell. Numerous useful expression vectors and 10 systems are known to those skilled in the art and described herein.

In a further embodiment, the present invention includes a Hepatitis E Virus (HEV) polypeptide composition produced by culturing an insect cell containing an expression vector, as described above, under conditions sufficient to express a polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame 2. Such a composition may 15 contain at least one polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and homologous sequences therewith.

In yet another embodiment, the invention includes a Hepatitis E Virus (HEV) polypeptide composition produced by incubating an HEV capsid derived antigen having at least 20 549 carboxy terminal amino acids of an HEV capsid protein with a baculoviral infected lysate under conditions sufficient to cleave carboxy terminal sequences of the HEV capsid derived antigen.

The present invention also includes another method of producing a Hepatitis E Virus (HEV) polypeptide composition ("62K antigen"). In this method a cell contain one of the 25 above-described expression vectors is cultured under conditions sufficient to express a polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame 2.

The invention further includes a method of detecting hepatitis E virus infection in an individual. In this method, a Hepatitis E Virus (HEV) polypeptide composition, consisting of 30 at least one polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame (ORF) 2, is reacted with a serum sample taken from the individual. The HEV polypeptides are then examined for the presence of bound antibody. In this method, the polypeptides of the HEV polypeptide composition are attached to a solid support, said reacting includes contacting such serum with the support and said examining includes reacting the

support and bound antibody with a reporter-labeled anti-human antibody. The invention also includes a kit for ascertaining the presence of antibodies to HEV in a serum sample taken from an individual. Typically the kit includes a solid support with surface-bound antigens wherein the surface-bound antigens are polypeptides of the HEV polypeptide ("62K antigen") 5 composition described herein.

Further, the invention includes vaccine compositions employing the HEV polypeptide antigens of the present invention. A vaccine composition used in immunizing an individual against Hepatitis E Virus (HEV) contains at least one polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame (ORF) 2. The polypeptides of the 10 present invention can be formulated in a pharmaceutically acceptable carrier. The vaccine may include polypeptides corresponding to this region where the polypeptides have amino acids deleted from the carboxy terminus of the 549 amino acid polypeptide. In one embodiment, at least one polypeptide of the vaccine composition contains a carboxy terminal deletion of up to about 24 carboxy terminal amino acids of said 549 amino acid HEV ORF2 polypeptide. 15 Exemplary polypeptides include, but are not limited to, the following: SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and homologous sequences to those presented herein. The invention also includes a method of inhibiting infection of an individual by HEV. In this method, a vaccine composition of the present invention is administered to a subject using a therapeutically effective amount.

20 The invention also includes kits containing the polypeptides of the HEV polypeptide composition of the present invention for use in the practice of the above-described methods.

In a further embodiment, the present invention includes a Hepatitis E Virus (HEV) polypeptide composition, consisting of at least one polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame (ORF) 2, where the polypeptide(s) of 25 said composition are capable of forming virus-like particles (VLPs).

These and other objects and features of the invention will become more fully understood when the following detailed description of the invention is read in conjunction with the accompanying figures.

30

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1, presents a schematic diagram of the genomic organization of HEV, showing the HEV genome, the arrangement of open reading frames in the genome, and the approximate coding regions for HEV antigens 406.3-2, 406.4-2, SG3, and 62K;

Figures 2A to 2E, presents the nucleotide sequence of ORF2 and ORF3, showing the nucleotide sequences of the HEV ORF2 and ORF3 for Burma (upper line) and Mexico (lower line) strains of HEV;

Figure 3, presents the amino acid sequence of ORF3, showing the amino acid sequences of the ORF3 protein for Burma (upper line) and Mexico (lower line) strains of HEV;

Figures 4A and 4B, presents the amino acid sequence of ORF2, showing the amino acid sequences of the ORF2 protein for the Burma (upper line) and Mexico (lower line) strains of HEV as well as the amino-terminus of each of the 62K, C-2, SG3, 406.3-2 antigens;

Figure 5, presents a schematic diagram of the construction of a plasmid for expression of the re-engineered r62K antigen in baculovirus, showing a flow chart of the construction of pBBIII-62K. The bars represent the DNA fragments encoding r62K.

Figures 6a and 6b, present data concerning the generation of full length ORF2 73K protein in Sf9 suspension culture and cleavage of 73K to form the 62K species in Sf9 monolayer cells. Figure 6a shows PBS-soluble (S) and insoluble (I) proteins from lysate of Sf9 suspension culture cells infected with recombinant baculovirus ORF2-rAcMNPV at various days post infection (DPI) were analyzed by SDS-PAGE. The arrow points to the recombinant ORF-2 protein produced. Figure 6b is essentially the same as that in Figure 6a except that immunoblot, instead of Coomassi blue staining, was carried out. The arrows point to the migration of 73K and 62K proteins, respectively.

Figure 7, "Proteolytic Cleavage Of HEV ORF2 Protein *In Vitro*", shows the *in vitro* cleavage of the 73K full length ORF2 insoluble (I) protein to the 62K soluble (S) protein at various time points. The presence (+) or absence (-) of proteinase inhibitors are indicated.

Figure 8, "73-62K Conversion By Sf9 Suspension Culture Cells", is a comparison of the cleavage of 73K to 62K between the soluble extracts of wild type baculovirus-infected (top panel) or that of uninfected (bottom panel) suspension culture cells. The loading of the samples in two right-most lanes of the bottom panel was reversed.

Figure 9, "73K ORF2 Process Gel", shows various fractions taken during the 73K purification process and run on a 4-20% SDS PAGE and corresponding Western blot.

Lane 1, Hyper-D-S Load; lane 2, pooled fractions pH 8.5; lane 3, flow through pH 7.5; lane 4 flow through pH 8.5; lane 5, BioRad MW standards; lane 6, Hyper-D-S Load; lane 7, pooled fractions pH 8.5; lane 8, flow through pH 7.5; lane 9, flow through pH 8.5; lane 10, Promega MW standards. MW standards (Promega mid-range) as follows (top to bottom): phosphorylase B, 97-kDa; BSA, 66-kDa; glutamic dehydrogenase, 55-kDa; ovalbumin, 43-kDa; aldolase, 40-kDa; carbonic anhydrase, 31-kDa; soybean trypsin inhibitor, 21-kDa; lysozyme, 14-kDa.

Lanes 1-5, nonreducing conditions; lanes 6-10, reduced with beta mercaptoethanol in the sample preparation buffer.

Figure 10, "Final Purified 62K", shows purified soluble c62K protein run on a 4-20% SDS-PAGE. Lane 1, Novex "SeeBlue™" prestained MW standards; lane 2, final purified 5 c62K protein. MW standards range as follows (top to bottom): myosin, 250-kDa; BSA, 98-kDa; glutamic dehydrogenase, 64-kDa; alcohol dehydrogenase, 50-kDa; carbonic anhydrase, 36-kDa; myoglobin, 30-kDa; lysozyme, 16-kDa; aprotinin, 6-kDa; insulin B chain, 4-kDa. The purification process for c62K is described in detail in Example 6B.

Figures 11a and 11b, show a comparison between electron micrographs of the purified 10 recombinant ORF2 proteins c62K and 73K, respectively. Figure 11a has a magnification of x95,000 and Figure 11b x200,000. Figure 11b shows virus-like particle formation by 73K protein.

Figure 12, "Expression Of ORF2-62K In Baculovirus", shows the expression of multiple isolates of BBIII-62K in suspension culture cells.

15 Figure 13, "S-1000 Chromatography", shows the determination of re-engineered r62K and cleaved c62K viral particle size by Sephadryl S-1000 size exclusion chromatography. Virus particle standards (vaccinia virus and hepatitis B surface antigen, HBsAg), bovine serum albumin (BSA), and purified c62K and r62K preparations were chromatographed on a Waters AP-2 2 x 60 cm AP-2 column packed with Sephadryl S-1000 Superfine resin at a superficial 20 linear velocity of 120 cm/hr. Retention times (minutes) and relative absorbance (280 nm) are indicated for the individual samples.

Figures 14A and 14B present the results of an analysis of the r62-K purification process using 4-20% SDS-polyacrylamide gel electrophoresis (14A) and a corresponding western blot (14B).

25 Figure 15 presents results demonstrating the presence of neutralizing antibodies in r62K HEV antigen vaccinated cyno monkeys.

Figure 16 shows a homology comparison between Burma (B) and Mexico (M) strains for the 406.4-2 antigen.

30

DETAILED DESCRIPTION OF THE INVENTION

I. DEFINITIONS

The terms defined below have the following meaning herein:

A. "Enterically transmitted non-A/non-B hepatitis viral agent", "hepatitis E virus", or "HEV" means a virus, virus type, or virus class which (i) causes water-borne, infectious

hepatitis, (ii) is transmissible in cynomolgus monkeys, (iii) is serologically distinct from hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus, and (iv) includes a genomic region which is homologous to the 1.33 kb cDNA insert in plasmid pTZKF1(ET1.1) carried in *E. coli* strain BB4 identified by ATCC deposit number 5 67717.

B. "HEV variants" are defined as viral isolates that have at least about 40%, preferably 50%, or more preferably 70% global sequence homology, that is, sequence identity over a length of the viral genome polynucleotide sequence (e.g., ORF2) to known HEV polynucleotide sequences disclosed herein (e.g., SEQ ID NO:1 or SEQ ID NO:2).

10 "Sequence homology" is determined essentially as follows. Two polynucleotide sequences of the same length (preferably, the entire viral genome) are considered to be homologous to one another, if, when they are aligned using the ALIGN program, over 40%, preferably 50%, or more preferably 70% of the nucleic acids in the highest scoring alignment are identically aligned using a ktup of 1, the default parameters and the default PAM matrix.

15 The ALIGN program is found in the FASTA version 1.7 suite of sequence comparison programs (Pearson, *et al.*, 1988; Pearson, 1990; program available from William R. Pearson, Department of Biological Chemistry, Box 440, Jordan Hall, Charlottesville, VA).

20 In determining whether two viruses are "highly homologous" to each other, the complete sequence of all the viral proteins for one virus are optimally, globally aligned with the viral proteins or polyprotein of the other virus using the ALIGN program of the above suite using a ktup of 1, the default parameters and the default PAM matrix. Regions of dissimilarity or similarity are not excluded from the analysis. Differences in lengths between the two sequences are considered as mismatches. Alternatively, viral structural protein regions are typically used to determine relatedness between viral isolates. Highly homologous viruses have 25 over 40%, or preferably 50%, or more preferably 70% global polypeptide sequence identity.

C. Two nucleic acid fragments are considered to be "selectively hybridizable" to an HEV polynucleotide, if they are capable of (1) specifically hybridizing to HEV or a variant thereof or (2) specifically priming a polymerase chain reaction: (i) under typical hybridization and wash conditions, as described, for example, in Maniatis, *et al.*, pages 320-328, and 382-30 389, (ii) using reduced stringency wash conditions that allow at most about 25-30% basepair mismatches, for example: 2 × SSC, 0.1% SDS, room temperature twice, 30 minutes each; then 2 × SSC, 0.1% SDS, 37°C. once, 30 minutes; then 2 × SSC room temperature twice, 10 minutes each, or (iii) selecting primers for use in typical polymerase chain reactions (PCR)

under standard conditions (for example, in Saiki, R.K., *et al.*; Mullis; Mullis, *et al.*), which result in specific amplification of sequences of HEV or its variants.

The degrees of homology (sequence identity) discussed above can be selected for by hybridization using wash conditions of appropriate stringency for identification of clones from 5 gene libraries (or other sources of genetic material), as is well known in the art.

D. An "HEV polypeptide" is defined herein as any polypeptide homologous to an HEV polypeptide. "Homology," as used herein, is defined as follows. In one embodiment, a polypeptide is homologous to an HEV polypeptide if it is encoded by nucleic acid that selectively hybridizes to sequences of HEV or its variants.

10 In another embodiment, a polypeptide is homologous to an HEV polypeptide if it is encoded by HEV or its variants, as defined above, polypeptides of this group are typically larger than 15, preferably 25, or more preferably 35, contiguous amino acids. Further, for polypeptides longer than about 60 amino acids, sequence comparisons for the purpose of determining "polypeptide homology" are performed using the local alignment program 15 LALIGN. The polypeptide sequence, is compared against the HEV amino acid sequence or any of its variants, as defined above, using the LALIGN program with a ktup of 1, default parameters and the default PAM.

Any polypeptide with an optimal alignment longer than 60 amino acids and greater than 40%, preferably 50%, or more preferably 70% of identically aligned amino acids is considered 20 to be a "homologous polypeptide." The LALIGN program is found in the FASTA version 1.7 suite of sequence comparison programs (Pearson, *et al.*, 1988; Pearson, 1990; program available from William R. Pearson, Department of Biological Chemistry, Box 440, Jordan Hall, Charlottesville, VA).

25 E. A polynucleotide is "derived from" HEV if it has the same or substantially the same basepair sequence as a region of an HEV genome, cDNA of HEV or complements thereof, or if it displays homology as noted under "B" or "C" above.

A polypeptide or polypeptide "fragment" is "derived from" HEV if it is (i) encoded by 30 an open reading frame of an HEV polynucleotide, or (ii) displays homology to HEV polypeptides as noted under "B" and "D" above, or (iii) is specifically immunoreactive with HEV positive sera.

F. In the context of the present invention, the phrase "nucleic acid sequences," when referring to sequences which encode a protein, polypeptide, or peptide, is meant to include degenerative nucleic acid sequences which encode homologous protein, polypeptide or peptide sequences as well as the disclosed sequence.

G. An "epitope" is the antigenic determinant defined as the specific portion of an antigen with which the antigen binding portion of a specific antibody interacts. The terms "immunogenic region" or "epitope" are used interchangably.

H. An antigen or epitope is "specifically immunoreactive" with HEV positive sera 5 when the epitope/antigen binds to antibodies present in the HEV infected sera but does not bind to antibodies present in the majority (greater than about 90%, preferably greater than 95%) of sera from individuals who are not or have not been infected with HEV. "Specifically immunoreactive" antigens or epitopes may also be immunoreactive with monoclonal or polyclonal antibodies generated against specific HEV epitopes or antigens.

10 An antibody or antibody composition (*e.g.*, polyclonal antibodies) is "specifically immunoreactive" with HEV when the antibody or antibody composition is immunoreactive with an HEV antigen but not with unrelated hepatitis virus (*e.g.*, HAV, HBV, HCV or HDV) antigens. Further, "specifically immunoreactive antibodies" are not immunoreactive with antigens typically present in normal sera.

15 I. In two or more known peptide sequences which are more than about 70% homologous in amino acid sequence, a third amino acid sequence will be "internally consistent with the known sequences" if each amino acid in the third sequence is identical to at least one of the amino acids in the known sequences.

J. The "epitope formed by" a given amino acid sequence is the epitope produced by 20 the secondary/tertiary structure of that sequence in aqueous solution.

K. The "antigen binding site" is that region of an antibody molecule contained within the variable regions of the antibody which directly participates in binding the antigen.

L. A specified "peptide antigen containing the epitope formed by" a specified amino acid sequence includes the specified sequence itself or a portion thereof which is sufficient to 25 define the epitope present in the specified sequence, as evidenced by immunoreactivity to an antibody contained in a human sera sample. The specified peptide antigen may include amino acid substitutions which preserve the epitope.

M. "Substantially isolated" and "purified" are used in several contexts and typically refer to at least partial purification of an HEV virus particle, component (*e.g.*, polynucleotide 30 or polypeptide), or related compound (*e.g.*, anti-HEV antibodies) away from unrelated or contaminating components (*e.g.*, serum cells, proteins, non-HEV polynucleotides and non-anti-HEV antibodies). Methods and procedures for the isolation or purification of compounds or components of interest are described below (*e.g.*, purification of proteins and recombinant production of HEV polypeptides).

N. "62K antigen" is the generic term for a protein or mixture of proteins, where the protein or proteins are derived from the carboxy-terminal 549 amino acids encoded by HEV ORF2 (e.g., SEQ ID NO:15 or SEQ ID NO:16 or sequences homologous thereto); derived proteins may have a comparable amino terminus to the 549 amino acid protein and up to about 5 a 24 amino acid deletion from the carboxy terminal end (e.g., SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28).

Similar proteins from the carboxy-terminal amino acid sequence of other variants can be determined by alignment of the variants with, for example, the Burma or Mexico variants (PCT International Application US91/02368, filing date 05 April 1991; PCT International Application US89/02648, filed 16 June 1989, WO 89/12462; both herein incorporated by reference).

Exemplary "62K antigen" polypeptides include the following polypeptides derived from the Burma and Mexico HEV variants: SEQ ID NO:15 / SEQ ID NO:16, SEQ ID NO:25 / SEQ ID NO:26 and SEQ ID NO:27 / SEQ ID NO:28, or a homologous sequence therewith. 15 Further, "62K antigen" includes mixtures of such polypeptides, for example, a preparation containing the polypeptides whose sequences are given as SEQ ID NO:25 and SEQ ID NO:27.

Included within the meaning of "62K antigen" are proteins which are larger than 549 amino acids so long as they contain the just-specified carboxyl terminal sequences encoded by HEV ORF2. For example, a re-engineered 62K antigen "r62K" may optionally have an N-20 terminal methionine; i.e., a sequence of 550 amino acids. Alternatively, the 62K antigen may be generated as a fusion protein containing, for example, the carboxy-terminal 549 amino acid sequence of HEV ORF2 in addition to sequences encoding β -galactosidase.

II. HEV ANTIGENS

25 This section describes methods for preparing HEV antigens useful as diagnostic reagents and in vaccine compositions in accordance with the invention.

A. HEV GENOMIC SEQUENCES

HEV genomic clones, and sequences corresponding to the entire HEV genome for 30 different HEV strains were obtained according to published methods (Huang 1992, Yarbough 1991) and as described in PCT International Application US91/02368 (filing date 05 April 1991) and PCT International Application US89/02648 (filed 16 June 1989, WO 89/12462), both herein incorporated by reference. Briefly, RNA isolated from the bile of a cynomolgus monkey having a known HEV infection was cloned, as cDNA fragments, to form a fragment

library, and the library was screened by differential hybridization to radiolabeled cDNAs from infected and non-infected bile sources.

The basepair sequence of cloned regions of the HEV fragments in identified clones was determined by standard sequencing methods. With reference to Figure 1, HEV is a virus with an approximately 7.5 kilo base (kb) single-stranded and polyadenylated RNA genome of positive-sense polarity. Three open reading frames (ORFs) have been assigned to HEV as ORF1, encoding polypeptides with domains of the RNA-directed RNA polymerase and a helicase, ORF2, encoding the putative capsid protein of the virus, and ORF3, a second putative structural protein.

The genomic organization of HEV assigns its non-structural gene(s) at the 5' terminus with the structural gene(s) at the 3' end. Two subgenomic polyadenylated transcripts of approximately 2.0 kb and 3.7 kb in sizes are detected in infected liver and co-terminated at their 3' ends with the 7.5 kb full-length genomic transcript. The genomic organization and expression strategy of HEV suggest that it might be the prototype human pathogen for a new class of RNA virus or perhaps a separate genus within the Caliciviridae family.

The genomic and peptide sequences shown in Figure 2 correspond to the ORF-2 and ORF-3 regions of Burma (B) (upper lines) and Mexico (M) strains (lower lines) of HEV. The bases indicated in the middle lines represent conserved nucleotides. The numbering system used in the comparison is based on the Burma sequence. The region corresponding to ORF2 has SEQ ID NO:1 and SEQ ID NO:2 for the Burma and Mexico strains, respectively. The region corresponding to the 62 kDa antigen has SEQ ID NO:3 and SEQ ID NO:4 for the Burma and Mexico strains, respectively. The region corresponding to SG3 has SEQ ID NO:5 and SEQ ID NO:6 for the Burma and Mexican strains, respectively. The region corresponding to 406.3-2 has SEQ ID NO:7 and SEQ ID NO:8 for the Burma and Mexico strains, respectively. The region corresponding to ORF3 has SEQ ID NO:9 and SEQ ID NO:10 for the Burma and Mexico strains, respectively. The region corresponding to 406.4-2 has SEQ ID NO:11 and SEQ ID NO:12 for the Burma and Mexico strains, respectively.

B. HEV ANTIGEN SEQUENCES

The amino acid sequences corresponding to the third and second open reading frames of the Burma and Mexico strains of HEV are given in Figures 3 and 4, respectively. The sequence listings shown are as follows:

SEQ ID NO:13 and SEQ ID NO:14 correspond to the amino acid sequences for the entire putative capsid protein encoded by the Burma and Mexico strain ORF2, respectively.

SEQ ID NO:15 and SEQ ID NO:16 correspond to the amino acid sequences for the 62K antigens from the Burma and Mexico strain ORF2, respectively.

SEQ ID NO:17 and SEQ ID NO:18 correspond to the amino acid sequences for the peptides SG3 (B) and SG3 (M), respectively. Each peptide includes the carboxyl 327 amino 5 acids of the HEV capsid.

SEQ ID NO:19 and SEQ ID NO:20 correspond to the amino acid sequences for the 406.4-2 (B) and 406.4-2 (M), respectively (Figure 3). These are 33 amino acid sequences encoded by the ORF3.

SEQ ID NO:21 and SEQ ID NO:22 correspond to the amino acid sequences for the 10 entire protein encoded by ORF3 of the Burma and Mexico strains, respectively.

SEQ ID NO:23 and SEQ ID NO:24 correspond to the amino acid sequences for the peptides 406.3-2 (B) and 406.3-2 (M), respectively. Each peptide is a 42 amino acid peptide in the C-terminal end region of capsid protein encoded by the ORF2, as indicated in the ORF2 sequence (Figure 4).

15 Also contemplated are sequences which are internally consistent with the above specified sequences from different strains of HEV antigens. These include SEQ ID NO:13; SEQ ID NO:14, and internally consistent variations between SEQ ID NO:13 and SEQ ID NO:14;

SEQ ID NO:15; SEQ ID NO:16, and internally consistent variations between SEQ ID NO:15 20 and SEQ ID NO:16; SEQ ID NO:17; SEQ ID NO:18; and internally consistent variations between SEQ ID NO:17 and SEQ ID NO:18; SEQ ID NO:19; SEQ ID NO:20; and internally consistent variations between SEQ ID NO:19 and SEQ ID NO:20; SEQ ID NO:21; SEQ ID NO:22, and internally consistent variations between SEQ ID NO:21 and SEQ ID NO:22; SEQ 25 ID NO:23; SEQ ID NO:24, and internally consistent variations between SEQ ID NO:23 and SEQ ID NO:24.

For example, the HEV 406.4-2 antigens have the sequence homology shown in Figure 16 for the Burma (B) and Mexico (M) strains. The single dots in the sequence comparison indicate recognized high-probability or "neutral" amino acid substitutions. The blank spaces indicate a non-neutral substitution.

30 A sequence which is internally consistent with these two sequences would have one of the sequences presented in SEQ ID NO:31.

The ORF3 amino acid sequences, 124 amino acids in length, for the Burma and Mexico strains have an 87.1% identity in the 124 amino acids. The ORF2 amino acid sequences, having 659 amino acids of overlap, have a 93.0% identity in the 659 amino acids.

C. PREPARATION OF HEV ANTIGENS

To prepare the 406.3-2 (M) peptide, DNA fragments from the lambda gt11 406.3-2 described in Example 1 was subcloned into the glutathione S-transferase vector pGEX™ to express the 406.3-2(M) antigen, as detailed in Example 1, and in the Tam (1991-b) reference.

5 The 406.3-2(B) antigen can be prepared by PCR amplification of the Burma SEQ ID NO:5 from above by PCR amplification of the pBET1 plasmid (Tam 1991-b). This plasmid contains a 2.3 kb insert covering the ORF2 and ORF3 for Burma strain HEV sequence. The plasmid is amplified by PCR amplification, using a 5' primer containing an NcoI site and a 3' primer containing a BamHI site (Sakai). The amplified fragment is inserted into the 10 NcoI/BamHI site of a pGEX™ vector, and expressed in an *E. coli* expression system as described in Example 1.

The SG3(B) peptide was prepared by first amplifying the SEQ ID NO:7 sequence with 5' EcoRI-NcoI and 3' BamHI linkers, using a pBET1 clone plasmid containing the entire ORF2 and ORF3 regions of HEV (B). The amplified fragment was inserted into the EcoRI/BamHI 15 site of a Bluescript™ vector (Stratagene, La Jolla, CA), according to the manufacturer's instructions. After vector propagation and harvesting, the cloned insert was released by digestion with NcoI and BamHI, and gel purified. The purified fragment was inserted into the NcoI/BamHI site of a pGEX™ vector, and expressed in an *E. coli* expression system as described in Example 1. The SG3(M) peptide can be prepared similarly, using the SEQ ID 20 NO:8 in place of the SEQ ID NO:7.

The capsid protein (B) was prepared substantially as described above by PCR amplification of the SEQ ID NO:1, from a pBET1 plasmid using a 5' primer containing an NcoI site and a 3' primer containing a BamHI site. The amplified fragment was inserted into the NcoI/BamHI site of a pGEX™ vector, and expressed in an *E. coli* expression system as 25 described in Example 1. The capsid protein (M) is similarly prepared.

To prepare the 406.4-2(M) peptide, the lambda gt11 406.4-2 described in Example 1 was subcloned into the glutathione S-transferase vector pGEX™ to express the 406.4-2(M) antigen, as detailed in Example 1.

The 406.4-2(B) antigen can be prepared by PCR amplification of the Burma SEQ ID 30 NO:9 from above by PCR amplification, using a 5' primer containing an NcoI site and a 3' primer containing a BamHI site. The amplified fragment is inserted into the NcoI/BamHI site of a pGEX™ vector, and expressed in an *E. coli* expression system as described in Example 1.

D. MATURE CAPSID PROTEIN

HEV peptide antigens may also be obtained from purified HEV virus propagated in primary hepatocytes obtained from primate liver, preferably from human or cynomolgus monkey liver. Methods for preparing primary primate hepatocytes for culture, and culture 5 medium conditions effective to preserve liver-specific functions for extended periods in culture are detailed for human hepatocytes in Example 2 below.

After 3 days of growth in culture, the cells are infected with a pooled inoculum of HEV-infected cynomolgus monkey stool pool (fourth passage), as detailed in Example 3. The presence and level of propagating HEV virus in the cells can be measured by 10 indirect immunofluorescence. Where, for example, the primary cells are cynomolgus cells, the cells can be immunoreacted with human HEV anti-sera, followed by immunoreaction with rabbit anti-human IgG antibodies.

Alternatively, the HEV virus can be detected and measured by selective amplification methods involving initial cDNA formation, and PCR amplification of HEV cDNA sequences 15 by PCR amplification, as detailed in Example 3. Virus particles can be isolated from HEV infected human hepatocytes in culture medium by pelleting the virus through a 30% sucrose cushion by ultracentrifugation. The pelleted virus may be further purified, if desired, by zonal centrifugation through a 10-40% sucrose gradient, combining peak virus fractions.

Other methods for separating virus particles from soluble culture-medium components 20 may be used. For example, clarified culture medium can be passed through a size-exclusion matrix, to separate soluble components by size exclusion.

Alternatively, the clarified culture medium can be passed through an ultrafiltration membrane having a 10-20 nm pore size capable of retaining virus particles, but passing solute (non-particulate) culture medium components.

25 The present invention allows for glycosylation and other post-translation modifications in intact HEV capsid protein. Capsid isolation from the viral particles can be carried out by standard methods, such as ion exchange and size-exclusion chromatography, and HPLC purification, after solubilization of the virus particles in a solubilizing medium, such as a solution of a non-ionic surfactant. The protein may be purified by affinity chromatography, 30 employing, for example, antibodies purified from anti-HEV antisera. Degradative processes may be employed to obtain partial fragments and peptides from the intact capsid protein (as well as recombinantly produced proteins); e.g. proteases may be employed. Such procedures are known to those skilled in the art.

E. PRODUCTION OF CAPSID ANTIGEN, CLEAVED 62K ANTIGEN, AND RECOMBINANT 62K ANTIGEN, IN INSECT CELLS.

This section describes the production of a full length ORF2 (73K), cleaved 62K species of ORF2 (c62K), and re-engineered 62K species of ORF2 (r62K), produced in insect cells.

5

1. EXPRESSION OF ORF2 IN INSECT CELLS.

General methods, for example, for handling and preparing baculovirus vectors and baculoviral DNA, as well as insect cell culture procedures, are outlined in A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures (Summers, M.D. *et al.*, 10 1988), incorporated herein by reference. The recombinant baculovirus ORF2-*Autographica californica* Nuclear Polyhedrosis Virus (ORF2-rAcNPV) was constructed as described previously, He, J. *et al.*, *J. Clin. Microbiology*, 31:2167 (1993), herein incorporated by reference. Recombinant baculovirus ORF2-rAcMNPV expressing HEV ORF2 protein was used to infect both *Spodoptera frugiperda*-9 (Sf9) suspension culture and monolayer cell 15 cultures in accordance with the methods detailed in He (1993), and described in Example 4, below.

Infected cell lysates prepared after various times post infection were separated by centrifugation to generate both phosphate-buffered saline (PBS)-soluble and insoluble fractions. Proteins from both fractions were electrophoresed on SDS-polyacrylamide gels, which were 20 either stained with Coomassie-blue solution (Fig. 6A) or transferred to nitrocellulose paper followed by a Western blot analysis (Fig. 6B), in accordance with Example 5.

A prominent viral protein of approximately 73 kDa in size was observed almost exclusively in PBS-insoluble fractions of suspension culture cells from 2-7 days post infection (Fig. 6A). Migration of this protein correlates well with predicted molecular weight of full 25 length ORF-2. A separate Western blot confirmed that this 73K protein was reactive with ORF2 specific antiserum 1L6 that recognizes the extreme C-terminus of ORF2. Although degradation of host proteins is obvious at late stages of the infection (soluble fractions from days 4-7 post infection), the 73K ORF2 protein appeared to be stable throughout the infection.

When the same recombinant virus was used to infect the Sf-9 monolayer cells, a 30 different pattern of expression was observed (Fig. 6B). Instead of observing an insoluble 73K protein species, the ORF2 protein was converted to a soluble form banding at approximately 62 kDa in size from day 4-7 post infection. These observations suggested that the insoluble ORF-2 (73K) protein undergoes a proteolytic cleavage to generate a soluble or cleaved 62K protein, referred to as "c62K", in the monolayer cells. Several smaller species migrating

around or below 30 kDa were also observed at late stage of the infection. The smaller species were degradation products of the 73K protein.

2. PROTEOLYTIC PROCESSING OF ORF2.

5 The conversion of the 73K protein to the soluble c62K species was observed to occur progressively during the course of infection. Thus, this conversion could be the result of autocatalytic cleavage, stimulating protease activity during the course of infection or at the time of cell harvest, or the combination of these events. To address this question, cell lysates were prepared at day 5 post infection, followed by incubation for various times before proteins in
10 the lysates were denatured. The 73K to c62K conversion was monitored against incubation time as shown in Fig. 7.

When cell lysates were denatured immediately after the cell breakage (0 min. incubation time), the ORF2 protein was present mainly as a 73K insoluble polypeptide, and very little soluble c62K protein was observed. However, when the incubation time was increased between
15 30 to 300 minutes, the amount of c62K proteins in the soluble fractions increased proportionally. In contrast, the amount of 73K protein in the insoluble fractions decreased, indicating an important role played by proteinase after the cell breakage. The conclusion of this experiment is that the 73K protein could be cleaved to c62K by proteinase activity after cell breakage.

The c62K protein observed *in vivo* at late infections, as shown in Fig. 6B, could be
20 explained by the prolonged viral infection in which a significant percentage of cells were not viable, causing release of the proteinase activity.

3. CONVERSION OF 73K TO C62K MAY BE BACULOVIRUS INFECTION SPECIFIC.

The source of the proteinase responsible for the 73K to c62K cleavage could be from
25 Sf9 cells, baculovirus infected Sf9 cells, or both. To address this question, an extract mixing experiment was carried out to distinguish between these possibilities. An insoluble 73K preparation from Sf9 suspension culture cells was mixed with various soluble extracts and cleavage was monitored by immunoblot analysis (Fig. 8, top panel). Uninfected cell extracts, both from suspension culture and monolayer, had no effect on cleavage, suggesting that
30 cleavage was mediated by viral infection. PBS did not show any effect as expected. Only when extract from an infected cell extract was used, was the cleavage of the 73K protein observed.

The concurrent cleavage of the 73K and accumulation of the c62K protein was further demonstrated in a second experiment in which insoluble 73K preparation was mixed with

soluble extract from suspension culture cells infected by wild type baculovirus (Fig. 8, bottom panel). Although cleavage could be observed 1 hr after incubation, it did not occur for as long as 24 hr when an uninfected cell extract was substituted for the infected cell extract (Fig. 8, bottom panel).

5

4. PURIFICATION OF 73K AND C62K PROTEINS.

To determine whether the ORF2 proteins expressed in baculovirus infected cells were forming complex protein structures, as well as determining the cleavage site within ORF2 resulting in the formation of the c62K protein, highly purified protein preparations were 10 prepared. An SDS-PAGE analysis summarizing the purification of the 73K protein is shown in Fig. 9. Details of the purification process are described in Example 6A. The Hyper-D-S column load is shown in lanes 1 and 6 with subsequent flow through and eluted column fractions shown in lanes 2-4 and 7-9. In the lanes where beta mercaptoethanol was removed from the sample disruption buffer (lanes 2-4) it is clear that intrachain disulfide bonding is 15 occurring within the 73K protein and that this association is readily eliminated under reducing conditions.

Recombinant proteins expressed at high levels in both prokaryotic and baculovirus expression systems can accumulate inside the cell in the form of inclusion bodies as was observed for the 73K protein. Under these conditions, it was necessary to develop a procedure 20 for the extraction, solubilization, and refolding of the protein. Standard approaches were used to isolate and wash the inclusion bodies in a buffer to remove cellular contaminants followed by the solubilization of the pellets with 0.5% SDS as strong denaturant. The denaturant was then removed by rapid dilution and dialysis to allow the protein to refold to its native state. In order to avoid aggregation during the refolding process, polyethylene glycol (PEG) was 25 added to the dilution buffer as a co-solvent which seemed to enhance the refolding of the 73K protein into a stable, soluble form.

The final product of the c62K purification process is shown in Fig. 10. Details of the purification process are described in Example 6B. Briefly, the c62K/St9 cell lysate was spun out and the supernatant was then loaded onto an E. Merck DEAE EMD 650(S) column where 30 the 62-kDa was captured and eluted at greater than 80% purity. The DEAE peak fractions were pooled and chromatographed on a Sephadryl S-100 column. Fractions containing c62K from the Sephadryl S-100 column were then purified and concentrated on a Poros HQ/F column. The protein band seen in lane 2 of Fig. 10 represents the final purified protein from the Poros HQ/F column.

In order to facilitate purification of the c62K protein, a reducing agent, *e.g.*, DTT, was added to the lysis supernatant, followed by a two-step exchange of the reducing buffer to an initially lower reducing environment (50 mM DTT to 0.5 mM DTT) to a final nonreducing environment. Under these conditions potential aggregation of the c62K protein to contaminating cellular proteins is eliminated. The c62K protein is then easily recovered in a highly purified, homogenous form. Based on Coomassie blue stain, the estimated purity of both the 5 73K and c62K proteins to be 95 to 99 percent.

5. EVIDENCE OF VLPs-ELECTRON MICROSCOPY.

10 Purified recombinant 73K and c62K proteins were negative-stained and examined by direct electron microscopy (Example 7). Electron micrographs of c62K protein revealed determinant particles (Fig. 11A) approximately 30 nm in size which agrees well with published reports describing authentic virus particles (28-34 nm) found in stool and bile (Bradley, 1988; Reyes, 1993). Refolded 73K protein generated a range of pleiomorphic particles 25-40 nm in 15 size, most of which exhibit indeterminant morphology (Fig. 11b).

6. N-TERMINAL SEQUENCE OF C62K PROTEIN.

20 The virus-like particle structure displayed by the purified c62K protein, as well as its solubility, suggested that this protein may exhibit a conformational structure similar to the native virion; *i.e.*, a viral particle or virus-like particle. Accordingly, it was desirable to identify the coding sequence corresponding to the c62K protein, thus allowing subsequent expression in suspension cell culture that may permit the ability to by-pass the cleavage process for the production of this protein. For this reason, the N-terminal sequence analysis of purified c62K protein was performed.

25 The sequence of the first 10 amino acids sequenced was determined to be: Ala-Val-Ala-Pro-Ala-His-Asp-Thr-Pro-Pro. This sequence was perfectly homologous to amino acid residues starting at residue position 112 in ORF-2 (SEQ ID NO:13). Thus, the cleavage occurred between Thr and Ala which correspond to amino acids 111 and 112, respectively.

30 Thus, a c62K protein may be produced by transfecting insect cells with a baculovirus expression vector containing a nucleic acid sequence encoding the capsid protein of HEV. More generally, it will be appreciated that only the portion of the ORF2 nucleotide sequence, that encoding the c62K fragment (*e.g.*, sequences encoding amino acids 112-660 derived from the ORF2 73K sequence; exemplary of such sequences are represented by SEQ ID NO:3 and

SEQ ID NO:4), and homologous sequences therewith need be expressed as a protease will cleave the excess N-terminal amino acids to the c62K protein.

Other baculoviruses are known to those of skill in the art, for example, *Orygia pseudotsugata* is a commonly used vector. Baculoviruses have relatively narrow host ranges 5 are generally confined to replication in Lepidopteran insect cells. Suitable Lepidopteran cell lines other than *Spodoptera frugiperda* are known to those of skill in the art, for example, *Lamantria dispar*, and *Helicos zea*.

It will also be appreciated by those skilled in the art that while the preferable expression system is a baculovirus expression system, the ORF2 sequence containing the coding region 10 for the C-terminal 549 amino acids encoded by HEV ORF2 (relative to the Burma strain variant) may be expressed in other expression systems as well and may be cleaved by proteinases inherent in these systems, or they may be subsequently cleaved by a baculovirus infected cell extract *in vitro*. Further, the HEV capsid proteins may be obtained from HEV propagated in human or monkey liver *in vivo* or *in vitro* as described above, and that these 15 capsid proteins may be cleaved with baculovirus infected insect cell lysate to form the 62K antigens as well.

Additionally, the cleavage site contained in the capsid protein may be used as an artificially inserted cleavage site for use in recombinant protein products, expression systems and industrial processes for making said products. For example, it is beneficial to construct 20 recombinant proteins such that they are generated as fusion proteins. One benefit is that the fusion partner may be used as means for purifying the recombinant protein of interest. For example, one particularly useful fusion partner is a poly histidine fragment which is efficiently purified by means of a metal chelate affinity chromatography on NTA resin, described in U.S. Patent 5,310,663, herein incorporated by reference. It is useful to have a cleavage site 25 engineered in between the fusion partner and the recombinant protein such that the recombinant protein may be freed from the fusion partner after purification. Thus, the discovery of a novel baculovirus specific cleavage site provides an alternative to the conventional sites currently used for recombinant proteins produced in non-baculovirus systems.

The cleavage site may be advantageous for baculovirus systems as well. For example, 30 a fusion partner useful for directing the new polypeptide to the cytoplasm may be preferentially cleaved once in the cytoplasm.

The boundaries defining the amino acids which comprise the cleavage site may be determined by techniques known to those skilled in the art. One such technique employs the

use of site directed mutagenesis to alter individual amino acids flanking the cleavage site and subsequent testing of proteinase activity on the mutant peptides.

In addition, the identity of the baculovirus specific proteinase may be determined and its nucleic acid sequence cloned and expressed by techniques known to those skilled in the art.

5 This will enable use of the specific proteinase in a purified form rather than baculovirus infected cell lysate.

7. RECOMBINANT PRODUCTION AND PURIFICATION OF A RE-ENGINEERED R62K HEV ANTIGEN.

10 The question remained as to whether or not a "re-engineered" 62K protein species, referred to herein as r62K, would result in the formation of a stable protein with similar biochemical and structural properties to the processed form of c62K. Therefore, the DNA sequence from amino acid 112 to the last amino acid of the 3' end of ORF2 (Burma strain) was cloned into baculovirus expression vector pBluBacIII as shown in Fig. 5 and described in 15 Example 4. A methionine codon was incorporated at 5' end to ensure proper translation initiation.

After transfection and 4 rounds of plaque purifications, viral stocks and cell lysates were prepared from 10 individual plaque isolates. Western blot analysis was performed to screen for the viral isolates which produced soluble r62K protein at the highest level (Fig. 12). 20 Nearly all the viral isolates produced soluble r62K. The solubility of r62K ranged from approximately 60-70% of total extract. One isolate was chosen for amplification for further studies.

The r62K was found to be completely soluble in the lysis buffer with quantitative recovery of the molecule in the cell lysis supernatant. The lysis supernatant was subsequently processed through three chromatography steps to obtain purified r62K protein, according to 25 Example 6b. The initial chromatography step was performed on an E. Merck DEAE EMD 650(S) column. It was found that the use of the EMD DEAE derivative enhanced recovery of the r62K relative to other similar weak anion exchange resins (Toyopearl 650(S), DEAE Sepharose Fast Flow, etc.). The enhanced recovery was attributed to the "tentacle arm" 30 structure of the E. Merck derivatized resin.

Further purification was achieved using a Sephadryl S-100 column which was used primarily for buffer exchange with some minor purification. The final material was obtained from peak fractions purified on a Poros HQ/F strong anion exchange resin.

The final material obtained by this procedure was determined to be greater than 95% 35 pure and essentially endotoxin free by limulus amebocyte lysate assay. For purposes of

Western blotting, the corresponding gel samples were diluted 1:10 prior to SDS-PAGE and transfer to PVDF membrane. The r62K band appears as a doublet which suggests the existence of a modified form of the r62K. N-terminal sequence analysis, peptide mapping, and mass spectroscopy data support the existence of a single primary amino acid sequence for the 5 re-engineered 62K.

Further biochemical characterization of the purified 62-kDa protein was undertaken using a variety of methods (Example 9). Transfer of the recombinant 62-kDa sequence to PVDF and subsequent amino acid sequence analysis indicated that the amino terminus of the 62-kDa protein was intact with the exception that the N-terminal methionine introduced to 10 ensure correct initiation of translation, had been removed. The overall yields in each of the first five cycles during sequencing were low, indicating that a significant portion of the 62-kDa was probably blocked at the amino terminus.

Tryptic peptide analysis revealed as many as 143 peaks by reverse phase HPLC. Eight peaks were selected for LDMS to determine structural integrity and potential post translational 15 modifications (Example 9). Of these eight peaks, four gave rise to single species peptides. Three of these peptides matched various internal regions of the 62-kDa protein as determined by Edman degradation sequencing. One peak, peak 65, did not yield a sequence by Edman degradation. However, the molecular mass agreed very well with the predicted mass for the amino terminal tryptic peptide taking into account the removal of the N-terminal methionine 20 by a cellular aminopeptidase followed by the acylation of the adjacent alanine residue. The results suggest that the amino terminus of the 62K antigen polypeptides are blocked -- probably acetylated.

Post-source decay analysis by laser desorption mass spectrometry indicated that peak 25 65 was the amino terminal tryptic peptide (Example 9). The other four tryptic digest HPLC peaks which gave rise to multiple peptide species were also sequenced and provided further confirmation that the authentic HEV sequenced was preserved.

LC-MS data (Example 9) established the true molecular masses of the components of the 62-kDa doublet that was observed by Western blotting. With the elucidation of the amino terminus in previous experiments, it was possible from ES-MS data to predict the 30 putative carboxyl terminal processing steps that gave rise to the bimodally distributed '62-kDa' species.

The predicted molecular mass of the 62-kDa protein using the coding sequence of residue 112 to residue 660 of the ORF-2 region is 59.1-kDa. The protein was not found to be glycosylated both by periodate oxidation and GC-MS analysis. The data presented in Example

9 suggested that a deletion occurred in the molecule and that the deletion was likely at the amino or carboxyl terminus.

In combination with the confirmation of the amino terminus, the ES-MS data suggested that the carboxyl terminus may be clipped between residues 539-540 and residues 536-537 (relative to the predicted 62-kda protein sequence). Automated carboxyl terminal sequencing validated the carboxyl terminal processing of the protein and firmly established residues 539-540 (a 9 amino acid carboxy terminal deletion; *e.g.*, SEQ ID NO:25 and SEQ ID NO:26) and 524-525 (a 23 amino acid carboxy terminal deletion; *e.g.*, SEQ ID NO:27 and SEQ ID NO:28) as the carboxy termini of the 58.1-kDa and 56.5-kDa proteins respectively. Accordingly, the 10 original 62K antigen isolated from insect cells is composed of these two related polypeptide species.

Thus the intended protein was expressed at high levels and purified to greater than 95% purity, although the apparent carboxy terminal processing was not anticipated. This processing did not appear to interfere with the ability of the protein to serve as an effective antigen, for 15 example, the results presented in Table 1 (Example 9). In fact, the 62K antigen represents an improved antigen in comparison to bacterial expressed proteins in HEV diagnostic assays.

The excellent immunogenic properties of this antigen were also apparent from the ability of the 62K antigen preparation to elicit protective immune responses in primates after heterologous challenge with HEV (see Section IV below). These observations suggest that the 20 baculovirus expressed protein may contain an immunologic structure that closely resembles the native virus capsid protein.

8. SIZE DETERMINATION OF 62K SUBUNIT VLPs.

Gel filtration is an attractive technique for the purification and analytical characterization of viral particles as it is much less time consuming than density gradient ultracentrifugation and permits chromatographic resolution and removal of particles larger or smaller than the desired viral particle. Sephadryl S-1000 Superfine has very high porosity which makes the resin suitable for applications involving the separation of viral particles, subcellular particles, and microsomal vesicles such as Percoll. The exclusion limits of S-1000 Superfine correspond 30 to particles approximately 300-400 nm in diameter.

The absorbance profile of the Sephadryl S-1000 Superfine chromatography of the purified c62K and r62K virus particles is shown in Fig. 13. Elution of the c62K and r62K particles corresponded to the peaks having a retention times of 95-105 minutes. This corresponded to a particulate size of approximately 20-30 nm in diameter. The S-1000 column

was also calibrated with three standards; two particulate, and one monomeric in structure. Vaccinia virus (250 nm) was found to have a retention time of approximately 48 minutes. Hepatitis B plasma derived surface antigen (HBsAg) particles (22 nm) were found to have a retention time of 95 minutes while bovine serum albumin (monomeric protein standard) had 5 a retention time of 132 minutes.

The 62K antigens of the present invention (including the C-terminal 549 amino acids encoded by HEV ORF2 relative to the Burma strain variant and homologous sequences therewith) can similarly be prepared in other types of expression systems, preferably eucaryotic systems (e.g., mammalian and yeast), using the HEV genomic-insert plasmids above, with 10 amplification of the desired sequences and cloning into a suitable expression vector. The coding sequences used in producing the re-engineered peptides can be derived from the cloning vectors described above and detailed elsewhere (Tam 1991-a), or from synthetic nucleotide synthesis using PCR splicing methods to join oligonucleotide fragments, according to known methods, in building up nucleotide sequences. Such modifications can be easily made by those 15 of ordinary skill in the art.

62K antigens produced in this manner may be screened for antigenicity by the method described in Example 8. Briefly, the antigens are purified according to the method detailed in Example 6b, and plated onto wells of microtitre dishes. The polypeptides are washed with blocking solution and then reacted with sera known to contain anti-HEV antibodies. The 20 unbound antibodies are washed away and a second antibody conjugated to a reporter molecule is then reacted with the peptide-antibody complexes. Results may be obtained, after washing away unbound second antibody, by detection of the reporter molecule.

62K antigens produced in this manner in accordance with the invention, are those that show substantially similar immunoreactivity to HEV positive sera as does a 62K antigen having 25 the sequence of SEQ ID NO:15 produced in insect cells. Immunoreactivity is substantial similar when the percentage of sera samples that are reactive with both antigens is, preferably, greater than 80%, more preferably greater than 90%, and even more preferably greater than 95%.

30 F. PREPARATION OF ANTIGENIC POLYPEPTIDES AND ANTIBODIES.

As described herein, the 62K antigen comprises mixtures of proteins (e.g., the 58.1-kDa and 56.5-kDa species, Examples 6 and 9) or individual polypeptides (e.g., SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28) derived from the carboxy terminal 549 amino acids of ORF2 of HEV. One

embodiment of the present invention, includes production of a 62K antigen containing two polypeptides obtained by expression of a coding sequence in insect cells (Examples 4 and 6). These two polypeptides contain carboxy terminal deletions relative to the carboxy terminal 549 amino acids of ORF2. Other expression systems can be used to produce the individual 5 polypeptides or mixtures of polypeptides of the present invention.

For example, polynucleotide sequences encoding an antigen or antigens of the present invention can be cloned in the plasmid p-GEX or various derivatives thereof. The plasmid pGEX (Smith, *et al.*, 1988) and its derivatives express the polypeptide sequences of a cloned insert fused in-frame to the protein glutathione-S-transferase (sj26). In one vector construction, 10 plasmid pGEX-hisB, an amino acid sequence of 6 histidines is introduced at the carboxy terminus of the fusion protein.

The various recombinant pGEX plasmids can be transformed into appropriate strains of *E. coli* and fusion protein production can be induced by the addition of IPTG (isopropyl-thio galactopyranoside). Solubilized recombinant fusion protein may then be purified from cell 15 lysates of the induced cultures using glutathione agarose affinity chromatography.

In the case of β -galactosidase fusion proteins (such as those produced by lambda gt11 clones) the fused protein may be isolated readily by affinity chromatography or by passing cell lysis material over a solid support having surface-bound anti- β -galactosidase antibody.

Also included in the invention is an expression vector, such as the lambda gt11 or 20 pGEX vectors described above, containing sequences encoding the polypeptides of the present invention (e.g., SEQ ID NO:15 / SEQ ID NO:16, SEQ ID NO:25 / SEQ ID NO:26 and SEQ ID NO:27 / SEQ ID NO:28, or a homologous sequence therewith) and expression control elements which allow expression of the coding regions in a suitable host. The control elements generally include a promoter, translation initiation codon, and translation and transcription 25 termination sequences, and an insertion site for introducing the insert into the vector.

The DNA encoding the desired antigenic polypeptide can be cloned into any number of commercially available vectors to generate expression of the polypeptide in the appropriate host system. These systems include, but are not limited to, the following: baculovirus expression (Reilly, *et al.*; Beames, *et al.*; Pharmingen; Clontech, Palo Alto, CA), vaccinia 30 expression (Earl, 1991; Moss, *et al.*), expression in bacteria (Ausubel, *et al.*; Clontech), expression in yeast (Gellissen, 1992; Romanos, 1992; Goeddel; Guthrie and Fink), expression in mammalian cells (Clontech; Gibco-BRL, Ground Island, NY), e.g., Chinese hamster ovary (CHO) cell lines (Haynes, 1983, Lau, 1984, Kaufman, 1990). These recombinant polypeptide antigens can be expressed directly or as fusion proteins.

Expression in yeast systems has the advantage of commercial production. Recombinant protein production by vaccinia and CHO cell line have the advantage of being mammalian expression systems. Further, vaccinia virus expression has several advantages including the following: (i) its wide host range; (ii) faithful post-transcriptional modification, processing, 5 folding, transport, secretion, and assembly of recombinant proteins; (iii) high level expression of relatively soluble recombinant proteins; and (iv) a large capacity to accommodate foreign DNA.

The recombinant expressed polypeptide antigens are typically isolated from lysed cells or culture media. Purification can be carried out by methods described herein.

10 Antigens obtained by any of these methods can be used for antibody generation, diagnostic tests and vaccine development.

In another aspect, the invention includes specific antibodies (polyclonal or monoclonal) directed against the polypeptide antigens of the present invention. For example, purified antigen or fused antigen protein may be used for producing monoclonal antibodies. Here the 15 spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art (Harlow, *et al.*). To produce a human-derived hybridoma, a human lymphocyte donor is selected. A donor vaccinated with the polypeptides of the present invention may serve as a suitable lymphocyte donor. Lymphocytes can be isolated from a peripheral blood sample. Epstein-Barr virus (EBV) can be 20 used to immortalize human lymphocytes or a suitable fusion partner can be used to produce human-derived hybridomas. Primary *in vitro* sensitization with viral specific polypeptides can be used in the generation of human monoclonal antibodies.

Antibodies secreted by the immortalized cells are screened to determine the clones that secrete antibodies of the desired specificity, for example, by using the ELISA or Western blot 25 methods.

In another aspect, the present invention includes nucleic acid molecules (e.g., DNA or RNA) that encode the polypeptide antigens of the present invention.

G. SYNTHETIC PRODUCTION OF HEV PEPTIDES

30 In addition to the procedures for producing the peptides described above, peptides of up to about fifty amino acids in length may be produced by conventional solid phase synthesis methods. Such methods are known to those skilled in the art. Peptides produced in this manner may be covalently linked to other peptides or protein conjugates or moieties, as would be formed, for example, recombinantly in a fusion protein.

III. DIAGNOSTIC METHOD

In a related aspect, the invention is directed to a method of diagnosing individuals with HEV infections wherein HEV derived peptide antigens are used to examine an individual's serum for the presence of anti-HEV antibodies.

5

A. IMMUNOREACTIVITY OF HEV ANTIGENS

Following production of HEV antigens, in accordance with the invention, serum samples from individuals known to be infected with HEV are tested for their ability to bind to such antigens. Assays for antibody-antigen binding are well known in the art (Harlow, 1988).

10 Solid-phase assays, such as enzyme-linked immunosorbent assay (ELISA) binding assays are particularly suitable for measuring antibody-peptide antigen binding. Such assays may be carried out in direct or competitive binding assay format. In the direct method, the test peptide is adsorbed to a solid phase. Test anti-HEV antisera is added to the peptide, and binding of human antibody to the peptide is measured, for example, as in the method of Example 8.

15 Alternatively, when peptides are expressed as fusion proteins of sufficient size to be retained by an SDS-PAGE, western blots may be used to determine binding of the peptide portion of the fusion protein to a serum sample.

Clones 406.3-2(M) and 406.4-2(M) were shown to encode immunoreactive peptides (PCT International Application PCT/US93/00475, filed 15 Jan 1993; PCT International Application PCT/US93/00459, filed 15 Jan 1993; PCT International Application PCT/US91/02368, filed 5 April 1991, WO91/15603, published 17 October 1991). In continuing studies with these peptides and their analogs from the Burma strain, with HEV-positive human sera (from five different epidemics), peptide 406.3-2(M) was immunoreactive with eight of eleven samples tested, peptide 406.4-2(M) was immunoreactive with nine of 25 eleven samples tested, and peptides 406.3-2(B) and 406.4-2 were both immunoreactive with all six of six samples tested (Yarbough 1991, herein incorporated by reference). A description of experiments leading to the above results may be found in Example 1. Peptide antigen SG3 was shown to be highly immunoreactive with infected sera (PCT International Application PCT/US93/00475, filed 15 Jan 1993; PCT International Application PCT/US93/00459, filed 30 15 Jan 1993).

In the present invention, to evaluate the antigenicity of a purified c62K protein preparation, immunoassays were performed using a panel of human acute phase and convalescent phase sera taken during various hepatitis E epidemics. Sera were tested by ELISA for IgG and IgM antibodies to HEV according to the method of Example 8. Three antigens

derived from the putative capsid protein of HEV were used: (1) SG3, 327 amino acids of ORF2 (SEQ ID NO:17) expressed in *E. coli*; (2) 73K, 660 amino acids of ORF2 (SEQ ID NO:13) expressed in baculovirus; and (3) c62K, 549 amino acids of ORF2 (SEQ ID NO:15) processed by a baculovirus proteinase(s).

5 Serum samples were from confirmed and suspected hepatitis E cases in endemic regions. As shown in Table 1 below, the c62K protein expressed in baculovirus detected measurable antibody to HEV in several pedigreed specimens from acute hepatitis E cases that would have gone undetected when using SG3, the best HEV antigen expressed in *E. coli* (Yarbough 1994). Specimens that tested positive to only the c62K antigen are denoted by an
 10 asterisk. For IgG anti-HEV, 3/18 serum samples (17%) scored as antibody positive uniquely with the c62K protein. For IgM anti-HEV, 7/18 serum samples (39%) scored as antibody positive uniquely with the c62K protein. In most cases, the O.D. values suggested that the anti-HEV detected by the SG3 protein or the 73K protein were just below the threshold of credible detection.

15

Table 1 COMPARATIVE ANTIGENICITY STUDIES <i>E. coli</i> and Baculovirus Expressed Proteins				
ELISA FOR ANTI-HEV IgG				
	SG3	c62K	73K	
20				
	Borneo S89	0.895	2.579	1.077
	FVH 3	0.338	1.298	0.374
	FVH 11	1.237	2.416	1.247
	FVH 26	0.397	1.353	0.571
25				
	FVH 29	0.515	1.051	0.540
	FVH 31	0.401	2.474	0.494
	MB0283	2.602	2.771	2.558
	MB0288	2.088	2.506	2.311
30				
	Som 002	1.357	2.616	1.301
	Som 010	2.489	2.617	2.588
	Som 032	2.456	2.503	2.351
	Som 055	1.930	2.386	1.539
	*Som 428	0.284	1.687	0.312
	*Som 443	0.246	0.727	0.337

	*Som 458	0.206	2.441	0.257
	Som Pool #3	2.305	2.474	2.235
	Sudan 54	2.159	2.717	2.310
	Sudan 60	2.264	2.541	2.402
ELISA FOR ANTI-HEV IgM				
		SG3	c62K	73K
5	*Boreno S89	0.237	2.527	0.356
	FVH 3	0.064	0.164	0.061
	*FVH 11	0.091	0.405	0.115
10	*FVH 26	0.077	0.319	0.069
	*FVH 29	0.149	0.493	0.115
	FVH 31	0.080	0.223	0.061
	*MB0283	0.123	0.892	0.147
	*MB0288	0.083	0.335	0.090
15	Som 002	0.508	2.598	0.681
	Som 010	0.534	2.526	0.939
	Som 032	0.722	2.861	0.877
	Som 055	1.342	2.560	1.283
	Som 428	1.165	2.463	0.863
20	Som 443	0.411	1.106	0.392
	*Som 458	0.279	1.525	0.248
	Som Pool #3	0.942	2.397	1.428
	Sudan 54	0.532	2.652	0.754
25	Sudan 60	0.396	0.529	0.414

25

Altogether the results demonstrated that the sensitivity and specificity of the assay was significantly improved using c62K as an antigen source. This observation suggests that structural determinants present on c62K recognized by anti-HEV antibodies engendered during 30 a natural infection more closely resemble the native virion as opposed to the baculovirus 73K and *E. coli* expressed recombinant proteins. Taken collectively, the 62K antigen is a significant advancement for detecting low levels of antibody directed to the hepatitis E virus.

B. COMPARISON OF IMMUNOREACTIVITY BETWEEN C62K AND R62K

Comparative ELISA assays were performed to measure the antigenic similarities between these two proteins and further support the correspondence of the r62K and c62K protein preparations. In accordance with the method of Example 8, equivalent amounts of 5 c62K and r62K proteins were used to measure the antigenic similarities between these two protein preparations. IgG anti-HEV detection with miscellaneous serum samples showed that cleaved (c) and re-engineered (r) 62K protein species were comparable in their specificity and sensitivity to detect anti-HEV (Table 2, below).

10

15

20

25

30

35

Table 2 COMPARATIVE ANTIGENICITY STUDIES Endpoint Titrations for <i>E. coli</i> and Baculovirus Expressed Proteins			
ELISA FOR ANTI-HEV IgG			
	SG3	r62K	73K
Cyno 9004	1:1000	1:5000	1:500
Chimp Rusten	1:500	1:5000	1:200
K. Sa	1:1000	1:5000	1:500
A. Za	1:200	1:5000	nd
Mex 387	1:2500	1:10000	1:1000
Sudan 60	1:1000	1:5000	1:500
ABTD 80	1:1000	1:25000	1:200
Som Pool	1:1000	1:25000	1:200
ELISA FOR ANTI-HEV IgM			
	SG3	62K	73k
Cyno 9004	nd	nd	nd
Chimp Rusten	nd	1:1000	nd
K. Sa	nd	1:200	nd
A. Za	1:100	1:2000	nd
Mex 387	nd	1:200	nd
Sudan 60	nd	nd	nd
ABTD 80	1:200	1:5000	nd
Som Pool	1:100	1:5000	nd

C. SENSITIVITY OF THE R62K ANTIGEN

A small subset of human and non-human primate sera was diluted and assayed for anti-HEV IgG and IgM to define the sensitivity of the r62K protein preparation (Table 3, below). Diluted sera was tested with each of the *E. coli* and baculovirus expressed antigens. The

ELISA endpoint was defined as the greatest dilution of sera that still permitted a positive result in the assay. Endpoint titration data established that the r62K protein has a limit of detection for anti-HEV IgG that minimally exceeds 5-fold that of the currently used *E. coli* expressed SG3 antigen. The detection of anti-HEV IgM was consequentially increased 25-fold by using 5 the r62K protein preparation as the antigen of choice. The 62K antigen is a significant advancement for detecting low levels of antibody directed to the hepatitis E virus.

Table 3 COMPARATIVE ANTIGENICITY STUDIES Cleaved and Re-engineered Baculovirus Expressed Proteins ELISA for anti-HEV IgG			
	c62K	r62K	73K
Confirmed cases in endemic regions			
ABTD 80	2.212	2.229	0.344
ABTD 86	1.689	2.399	0.309
MB 2/88	2.083	1.961	0.724
Mex F387	2.664	2.635	1.069
Som Pool	1.679	2.264	0.342
Sudan 60	2.493	2.298	1.024
Travellers to endemic regions			
A. Za (1/100)	1.598	1.887	0.138
A. Za (1/500)	0.807	1.060	0.045
K. Sa (1/100)	1.983	1.905	0.800
K. Sa (1/500)	1.226	1.314	0.219
B. Ka (1/100)	0.097	0.080	0.105
B. Ka (1/500)	0.058	0.050	0.054
S. Ha (1/100)	0.116	0.122	0.122
S. Ha (1/500)	0.088	0.062	0.047
Sporadic cases-acute hepatitis			
HEP 31	0.071	0.075	0.078
HEP 35	0.541	0.542	0.157
HEP 69	0.085	0.090	0.086
HEP 28	0.087	0.083	0.090

35 **IV. THERAPEUTIC APPLICATIONS.**

The in vivo immunogenic efficacy of the ORF2 62K antigen to confer protection against a heterologous challenge was investigated (Example 11). The r62K antigen (Examples 4, 6 and 9) was used to inoculate cynomolgus macaques that were subsequently challenged with the heterologous HEV Mexico strain. The results indicate that this candidate antigen may

be useful in developing a vaccine to prevent acute hepatitis E in developing countries and to provide protection for travellers to disease-endemic regions.

Immunization of cynos with the ORF2 r62K protein protected against subsequent heterologous wildtype HEV infection and disease. Accepted criteria for evidence of HEV infection and virus replication include: (1) detection of HEV antigen in the liver, (2) detection of HEV RNA in the feces or serum, (3) seroconversion to HEV antibody positive. Hepatitis E disease is defined as HEV infection and (1) a rise in ALT levels greater than two standard deviations above baseline and (2) histopathology compatible with viral hepatitis.

Experiments performed in support of the present invention demonstrate that animals immunized with a recombinant capsid protein derived from the HEV Burma strain are protected from challenge with wild-type virus of the divergent HEV Mexico strain. There were no significant elevations in liver enzymes and no histopathologic evidence for hepatocellular damage in any of the three immunized animals. Vaccination thus conferred protection against disease in all the cynos immunized with r62K.

For two of the three vaccinated animals, full protection against HEV infection was substantiated by the absence of measurable viral antigen in the liver or viral RNA in the stool. Further, in these two animals neutralizing antibodies were demonstrated to be present (Example 11, Figure 15). The partial protection against infection in one cyno, as evidenced by the delayed and transient presence of viral RNA in the stool, may be related to the relatively low levels of measurable anti-HEV antibodies. Nevertheless, in the absence of necro-inflammatory changes, it appears that hepatitis was prevented by immunization with the r62K vaccine, although complete protection from infection was not achieved in this one animal.

When required, levels of neutralizing antibodies may be increased by use of higher doses of antigen and/or repeated inoculations prior to challenge with infectious virus. Such repeated inoculations are currently used for vaccination against, for example, hepatitis A virus (HAV) and hepatitis B virus (HBV).

Both the results, in the vaccinated animals and in the animals used to titrate the challenge inoculum virus, support that the development of HEV infection and associated disease are dependent on a threshold effect related to the amount of the inoculum and the presence and characteristics of a pre-existing specific immune response. In the titration study using HEV infected animals, the extent of hepatitis was related and the timing to onset of ALT elevations was inversely related to the amount of inoculum received.

In the vaccine portion of the study, the results with cyno 9330 suggest that although HEV infection was not prevented, the presence of HEV specific immunity at the time of

challenge resulted in a limited infection characterized by a delayed latency to onset of detectable virus replication, a shortened duration of detectable viral replication and the absence of characteristic features of HEV induced disease.

In a previous study (Purdy et. al., 1993), immunization with a truncated version of 5 HEV Burma ORF2, trpE-C2, expressed in *E. coli* afforded variable degrees of protection for HEV infection and disease. One cyno was reported to be fully protected against virus infection and hepatitis after homologous strain wild-type challenge. However, animals challenged with the heterologous HEV Mexico strain were only partially protected. Although one immunized cyno appeared to be protected from hepatitis, the animal had evidence of viral antigen in the 10 liver and viral RNA in the stool after heterologous wild-type challenge.

The data described in the present specification definitively establishes for the first time the feasibility of developing an effective vaccine for hepatitis E capable of providing cross-protection for the most divergent HEV strains isolated and characterized to date. Within the 549 amino acids expressed in a "62K" ORF2 vaccine candidate, there are 31 amino acids 15 changes between the Burma and Mexico strains (Tam, *et al.*, 1991; Huang, *et al.*, 1992) and no more than 4 amino acid changes between the more closely related Burma, China, and Pakistan strains (Tsarev, *et al.*, 1992).

V. HEV SPECIFIC PEPTIDE ANTIGENS FOR HEV ASSAYS

20 This section describes the peptide antigens which are employed in the assay kit and assay method described in Section VI below.

In accordance with the invention, HEV antigens, characterized as useful for diagnosis 25 of HEV herein, include the 62K (B) or (M) antigen consisting of, for example, an amino acid sequence selected from the group consisting of SEQ ID NO:15 / SEQ ID NO:16, SEQ ID NO:25 / SEQ ID NO:26 and SEQ ID NO:27 / SEQ ID NO:28, or a homologous sequence therewith. The 62K antigen may be produced by cleavage of either native or recombinant ORF2 derived proteins with a protease, preferably a baculovirus protease. Alternatively the 30 62K antigen may be re-engineered and expressed in a recombinant expression system. Re-engineered 62K antigen or "r62K" preferably contains a methionine at the N-terminus and is preferably produced by a baculovirus expression vector in an insect cell.

The 62K antigens are derived from the carboxyl-terminal 549 residues of the capsid protein which is encoded by open reading frame-2 (relative to Burma strain). These peptide antigens can be prepared as described in Section II above and in Example 4 which follows.

Studies conducted in support of the present invention, discussed above, demonstrate that the 62K antigen is specific for HEV; i.e., 62K immunoreacts with antibodies present in the serum of HEV infected individuals. The antigen may not detect all HEV positive sera, and may pick up some false positives; i.e., non-infected individuals. The 62K antigen derived from 5 the Mexico strain (or other variant strains) of HEV can be expected to be specifically immunoreactive with HEV positive sera.

Several HEV peptide antigens have been previously characterized (PCT International Application PCT/US93/00475, filed 15 Jan 1993; PCT International Application PCT/US93/00459, filed 15 Jan 1993; PCT International Application PCT/US91/02368, filed 10 5 April 1991, WO91/15603, published 17 October 1991). These peptides form part of the present invention when used in assays in combination with the 62K antigens.

A first antigen in the group of previously characterized HEV peptide antigens contains the epitope formed by the 406.4-2(B) peptide (SEQ ID NO:19), or the 406.4-2(M) peptide (SEQ ID NO:20). Also contemplated are peptide antigens containing the epitope formed by 15 an amino acid sequence homologous with or an internally consistent variation between SEQ ID NO:19 and SEQ ID NO:20. This first peptide antigen is derived from the carboxyl terminus of the protein encoded by open reading frame-3. A second peptide antigen contains the epitope formed by the 406.3-2(B) peptide (SEQ ID NO:23) or the 406.3-2(M) peptide (SEQ ID NO:24). Also contemplated as a second peptide antigen are peptide antigens containing the 20 epitope formed by an amino acid sequence homologous with or an internally consistent variation between SEQ ID NO:11 and SEQ ID NO:12. A third peptide antigen contains the epitope formed by the SG3(B) peptide (SEQ ID NO:17) or the SG3(M) peptide (SEQ ID NO:18). Also contemplated as a third peptide antigen are peptide antigens containing the 25 epitope formed by an amino acid sequence homologous with or an internally consistent variation between SEQ ID NO:17 and SEQ ID NO:18. These second and third peptide antigens are derived from the carboxyl terminus of the capsid protein encoded by open reading frame-2. Figure 3 shows the sequence of the 406.4-2(B) and (M) peptides and figure 4 shows the sequence of the 406.3-2(B) and (M) and SG3(B) and SG3(M) peptides. Methods for obtaining the confirmatory peptides are described above and detailed in the following 30 Examples.

In accordance with the present invention, reactivity of antibodies in a serum sample taken from an individual suspected of being infected with a causative agent of hepatitis to a 62K antigen is a reliable method for diagnosing the causative agent as HEV. Also forming part of

the present invention, reactivity to the known peptides used in conjunction with a 62K antigen may enhance the sensitivity and reliability of the diagnostic method described below.

VI. UTILITY

5 This section describes uses of the antigenic peptides and proteins of the invention as diagnostic reagents for diagnosing hepatitis E viral infection and in vaccine compositions for protecting an individual from infection with HEV.

A. DIAGNOSTIC METHODS AND KITS

10 Three basic types of diagnostic applications of the antigens will be described. The first is based on inhibition of complement-mediated, antibody-dependent cytolysis by the antigen. In this method, serum from a test individual is reacted with HEV-infected cultured human hepatocytes in the presence of complement. The presence of anti-HEV antibody is evidenced by cell lysis, as judged, for example, by trypan blue dye exclusion. Where cell lysis is 15 observed, the specificity of the anti-HEV antibody for the HEV antigen is demonstrated by first reacting the serum with excess antigen, then mixing the serum with the cells in the presence of complement. Antibody specificity is indicated by a substantial decrease in cell lysis. The method can also be used to quantitate the antibody titre in the analyte serum, by titrating the serum with increasing amounts of antigen concentration where a noticeable effect on the extent 20 of cell lysis is first observed.

The second general assay type is a solid-phase immunoassay. In this method, a solid phase reagent having surface-bound antigen is reacted with analyte serum, under conditions which allow antibody binding to the antigen on the reagent. After washing the reagent to remove unbound serum components, the reagent is reacted with reporter-labeled anti-human 25 antibody to bind reporter to the reagent in proportion to the amount of bound anti-HEV antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, as in the system described in Example 1, the reporter is an enzyme which is detected by incubating the solid reagent in the presence of a suitable fluorometric or colorimetric substrate. 30 However, radiolabel and other reporters may be used.

After reacting the analyte serum with the solid-phase bound antigen and washing to remove the unbound serum components, one may alternatively use the antigen itself bound to reporter as a detection reagent instead of using an anti-human antibody as a reporter mediator.

The competitive assay takes advantage of antibody bivalence. The same reporters may be used in this embodiment of the solid-phase assay as was described above.

Multiple antigens may be used in conjunction or in tandem in each of the assays described above. In addition, reaction to each antigen may be distinguished. For example, in 5 the solid-phase assay described above, two or more different antigens may be bound to solid phase in separate locations so that reaction to each antigen may be quantitated separately. Alternatively, antigens labeled with distinguishable reporters may be used to detect antigens which are interspersed on the solid support.

The solid surface reagent in the above assay is prepared by known techniques for 10 attaching protein material to solid support material, such as polymeric beads, dip sticks, or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

15 The third general assay type is a homogeneous assay, in which antibody binding to a solid support produces some change in the reaction medium. Known general types of homogeneous assays proposed heretofore include: (a) spin-labeled reporters, where antibody binding to the antigen is detected by a change in reporter mobility (broadening of the spin splitting peaks); (b) fluorescent reporters, where binding is detected by a change in fluorescence 20 efficiency; (c) enzyme reporters, where antibody binding effects enzyme/substrate interactions; and (d) liposome-bound reporters, where binding leads to liposome lysis and release of encapsulated reporter. The adaption of these methods to the antigens of the present invention follows conventional methods for preparation of homogeneous assay reagents.

In each of the three general assays described above, the assay method involves reacting 25 the serum from a test individual with the antigen, and examining the antigen for the presence of bound antibody. In the first assay, the examining is done by observing the decrease in antibody-mediated cytolysis, when the antibody is bound to the antigen. In the solid-phase assay, the examining involves attaching a labeled anti-human antibody (or labeled antigen) to the antibody being examined, and measuring the amount of reporter bound to the solid support. 30 And in the third assay type, the examining is done by observing the effect of antibody binding on a homogeneous assay reagent.

B. VACCINE COMPOSITIONS AND METHODS**1. PREPARATION OF VACCINE COMPOSITIONS.**

The recombinant or cleaved 62K antigens described above are incorporated into a vaccine composition, according to known procedures, to enhance the antigenicity of the injected 5 antigens.

In one composition, the HEV antigen is covalently coupled to a carrier protein, such as keyhole limpet hemocyanin, and injected either in solution form or in combination with an adjuvant. Alternatively, where the HEV antigen is prepared as part of a fusion protein, the non-HEV moiety of the protein may serve as the carrier protein.

10 The derivatized or fusion protein is carried in a pharmaceutically acceptable carrier, such as in solution or in an adjuvant, such as converted alum.

Alternatively, the free antigen itself, e.g., the HEV 62K antigen, may be formulated in alum or used without adjuvant. A suitable adjuvanted vaccine has a preferred antigen concentration of about 1 mg antigen/mg alum, and not to exceed 80 mg of alum per injection.

15

2. ANTIGEN VACCINE METHOD.

In a related aspect, the invention is directed to a method of inhibiting infection of an individual by hepatitis E virus, by administering to the subject, by parenteral injection, e.g., intramuscular or intravenous injection, the vaccine composition of the invention. *Preferred*

20 vaccine compositions, for use in the method are those in which the HEV antigen includes the sequence in the peptides identified by: SEQ ID NO:15; SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO:28 with or without an amino terminal methionine and homologous sequences therewith. The antigen vaccine composition is preferably administered intramuscularly in a series of inoculations, for example, two to three injections 25 each given at four week intervals.

Individual dosages of the vaccine composition are administered in a therapeutically effective amount. Such dosages are determined by physicians, for example, based on clinical trial data. Exemplary dosage ranges for the vaccine composition are about 0.05 μ g to 1 mg, preferably about 0.1 μ g to 30 μ g. Individual dosages may contain a single 62K antigen 30 polypeptide or multiple polypeptides derived from the 549 amino acid carboxy terminal region of HEV ORF2. In addition, such 62K antigens may be combined with other known HEV antigenic polypeptides for vaccine formulations.

The 62K antigen preparation of the present invention may be useful to (i) prevent epidemics and sporadic cases of hepatitis E in developing countries, (ii) protect pregnant women at risk in disease endemic regions, and (iii) provide protection to travellers to those regions. The *in vitro* and *in vivo* experiments described herein can be used to determine the 5 optimal immunization regime with the 62K antigen preparation.

As discussed above, the 62K antigens of the present invention can be used in vaccine preparation. Further, antibodies generated against the polypeptide antigens of the present invention can be used for passive immunotherapy or passive immunoprophylaxis. Antibodies directed against the antigens of the present invention can be administered in amounts similar 10 to those used for other therapeutic administrations of antibody. For example, pooled gamma globulin is administered at 0.02-0.1 ml/lb body weight during the early incubation of other viral diseases such as rabies, measles and hepatitis B to interfere with establishment of infection. Thus, antibodies reactive with the 62K antigens can be passively administered alone or 15 in conjunction with another anti-viral agent to a host infected with HEV to enhance the ability of the host to deal with the infection.

The usefulness and efficacy of the above described therapeutic methods can be evaluated *in vitro*, using the cell systems described above, and *in vivo*, using the animal model systems described above.

20 The following examples, which illustrate various methods and compositions in the invention, are intended to illustrate, but not limit the scope of the invention.

MATERIALS

Enzymes: DNase I and alkaline phosphatase were obtained from Boehringer Mannheim 25 Biochemicals (BMB, Indianapolis, IN); EcoRI, EcoRI methylase, DNA ligase, and DNA Polymerase I, from New England Biolabs (NEB, Beverly MA); and RNase A was obtained from Sigma (St. Louis, MO) .

Other reagents: EcoRI linkers were obtained from NEB; and nitro blue tetrazolium (NBT), 5-bromo-4-chloro-3-indolyl phosphate (BCIP), 5-bromo-4-chloro-3-indolyl-B-D-30 galactopyranoside (Xgal), p-Nitrophenyl phosphate, and isopropyl B-D-thiogalactopyranoside (IPTG) were obtained from Sigma. cDNA synthesis kit and random priming labeling kits are available from Boehringer-Mannheim Biochemical (BMB, Indianapolis, IN).

Cloning and Expression vectors such as pBluescript™ (pBS), can be obtained from Stratagene Cloning Systems (La Jolla, CA), the pGEX™ expression vector can be obtained from

Pharmacia (Piscataway, NJ), and the pBluBacIII can be obtained from Invitrogen (San Diego, CA).

Immunodiagnostic Test Kits for Hepatitis A Virus (HAV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), are available from Abbott Diagnostics (Abbott Park, IL, USA).

5 Immunodiagnostic Test Kits for Hepatitis E Virus (HEV) are available from Genelabs Diagnostics USA (Redwood City, CA).

DEAE EMD 650(S) was obtained from E. Merck Separations (Darmstadt, Germany). Sephadryl S-100 and S-1000 were obtained from Pharmacia Biotech (Piscataway, NJ). Poros Q/F and HQ/F chromatography columns were obtained from PerSeptive Biosystems 10 (Cambridge, MA). Buffer ingredients were obtained from AMRESCO (Solon, OH) and proteins were purified on a Waters 650E chromatography workstation (Milford, MA) with data management provided by Millennium 2010 software (Milford, MA).

EXAMPLE 1

15 Preparation of 406.3-2, 406.4-2, and SG3 Antigens

A. PRODUCTION OF RANDOM HEV DNA FRAGMENTS.

A pBET1 plasmid (Tam, *et al.*, 1991a) was digested with EcoRI to release the insert which was purified from the linearized plasmid by gel electrophoresis. The purified fragment was suspended in a standard digest buffer (0.5M Tris HCl, pH 7.5; 1 mg/ml BSA; 10mM 20 MnC12) to a concentration of about 1 mg/ml and digested with DNase I at room temperature for about 5 minutes. These reaction conditions were determined from a prior calibration study, in which the incubation time required to produce predominantly 100-300 basepair fragments was determined. The material was extracted with phenol/chloroform before ethanol precipitation.

25 The fragments in the digest mixture were blunt-ended and ligated with EcoRI linkers. The resultant fragments were analyzed by electrophoresis (5-10V/cm) on 1.2% agarose gel, using PhiX174/HaeIII and lambda/HindIII size markers. The 100-300 bp fraction was eluted onto NA45 strips (Schleicher and Schuell, Keene, NH), which were then placed into 1.5 ml microtubes with eluting solution (1 M NaCl, 50 mM arginine, pH 9.0), and incubated at 67°C 30 for 30-60 minutes. The eluted DNA was phenol/chloroform extracted and then precipitated with two volumes of ethanol. The pellet was resuspended in 20 ml TE (0.01 M Tris HCl, pH 7.5, 0.001 M EDTA).

B. CLONING IN AN EXPRESSION VECTOR.

Lambda gt11 phage vector (Huynh) was obtained from Promega Biotec (Madison, WI). This cloning vector has a unique EcoRI cloning site 53 base pairs upstream from the beta-galactosidase translation termination codon. The genomic fragments from above, provided 5 either directly from coding sequences or after amplification of cDNA, were introduced into the EcoRI site by mixing 0.5-1.0 ug EcoRI-cleaved gt11, 0.3-3 ul of the above sized fragments, 0.5 ul 1OX ligation buffer (above), 0.5 ul ligase (200 units), and distilled water to 5 ul. The mixture was incubated overnight at 14°C, followed by *in vitro* packaging, according to standard methods (Maniatis, 1982, pp. 256-268).

10 The packaged phage were used to infect *E. coli* strain KM392, obtained from Dr. Kevin Moore, DNAX (Palo Alto, CA). Alternatively, *E. Coli* strain Y1090, available from the American Type Culture Collection (ATCC #37197), can be used. The infected bacteria were plated and the resultant colonies were checked for loss of beta-galactosidase activity-(clear plaques) in the presence of X-gal using a standard X-gal substrate plaque assay method 15 (Maniatis). About 50% of the phage plaques showed loss of beta-galactosidase enzyme activity (recombinants).

C. SCREENING FOR HEV RECOMBINANT PROTEINS.

HEV convalescent antiserum was obtained from patients infected during documented 20 HEV outbreaks in Mexico, Borneo, Pakistan, Somalia, and Burma. The sera were immunoreactive with VLPs in stool specimens from each of several other patients with ETNANB hepatitis.

A lawn of *E. coli* KM392 cells infected with about 10⁴ pfu of the phage stock from above was prepared on a 150 mm plate and incubated, inverted, for 15-18 hours at 37°C. The lawn was overlaid with a nitrocellulose sheet, causing transfer of expressed HEV recombinant 25 protein from the plaques to the paper. The plate and filter were indexed for matching corresponding plate and filter positions.

The filter was washed twice in TBST buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween 20), blocked with AIB (TBST buffer with 1% gelatin), washed again in TBST, and incubated overnight after addition of antiserum (diluted to 1:50 in AIB, 12-15 ml/plate). 30 The sheet was washed twice in TBST and then contacted with enzyme-labeled anti-human antibody to attach the labeled antibody at filter sites containing peptides recognized by the antiserum. After a final washing, the filter was developed in a substrate medium containing 33 ml NBT (50 mg/ml stock solution maintained at 4°C) mixed with 16 ml BCIP (50 mg/ml stock solution maintained at 4°C) in 5 ml of alkaline phosphatase buffer (100 mM Tris, 9.5, 100 mM

NaCl, 5 mM MgCl₂). Purple color appeared at points of peptide production, as recognized by the antiserum.

D. SCREENING PLATING.

5 The areas of peptide production determined in the previous step were replated at about 100-200 pfu on an 82 mm plate. The above steps, beginning with a 15-18 hour incubation, through NBT-BCIP development, were repeated in order to plaque purify phage secreting an antigen capable of reacting with the HEV antibody. The identified plaques were picked and eluted in phage buffer (Maniatis, p. 443).

10 Two subclones which were selected are the 406.3-2 and 406.4-2 clones whose sequences are set forth above. These sequences were isolated from an amplified cDNA library derived from a human Mexico HEV stool specimen. Using the techniques described in this section, polypeptides expressed by these clones have been tested for immunoreactivity against a number of different human HEV-positive sera obtained from sources around the world.

15 As shown in Table 4 below, 9 sera immunoreacted with the polypeptide expressed by the 406.4-2, and 8 sera immunoreacted with polypeptide expressed by the 406.3-2 clone.

For comparison, the Table also shows reactivity of the various human sera with the non structural peptide Y2. Only one of the sera reacted with the polypeptide expressed by this clone. No immunoreactivity was seen for normal expression products of the gt11 vector.

20

Table 4									
Immunoreactivity of HEV Recombinant Proteins: Human Sera									
Sera	Source	Stage	406.4-2(M)	406.3-2(M)	406.4-2(B)	406.3-2(B)	Y2	gt11	
FVH-21	Burma	A	-	-	NT	NT	-	-	
FVH-8	Burma	A	+	-	NT	NT	+	-	
B-IgG	Burma	C	+	+	+	+	NT	-	
SOM-19	Somalia	A	+	+	+	+	-	-	
SOM-20	Somalia	A	+	+	+	+	-	-	
IM-35	Borneo	A	+	+	NT	NT	-	-	
IM-36	Borneo	A	-	-	NT	NT	-	-	
PAK-1	Pakistan	A	+	+	NT	NT	-	-	

Table 4									
Immunoreactivity of HEV Recombinant Proteins: Human Sera									
FFI-4	Mexico	A	+	+	+	+	+	-	-
FFI-125	Mexico	A	+	+	+	+	+	-	-
F387-C	Mexico	C	+	+	+	+	+	NT	-
Normal	U.S.		-	-	-	-	-	-	-

5

Y2 represents an amino acid sequence encoded by a 157 basepair nucleic acid sequence from the first open reading frame of the HEV genome.

Acute-phase sera are collected between 1 and 12 days after the onset of HEV-related symptoms.

10 Convalescent-phase sera are collected between 30 and 90 days after the onset of jaundice.

+, reaction; -, no reaction; NT, not tested; A, acute; C, convalescent.

E. PRODUCING THE 406.3-2(M) ANTIGEN.

15 The 406.3-2 gt11 plasmid from above was digested with EcoRI and the released HEV fragment was amplified by PCR in the presence of linkers which added an NcoI site at the 5' fragment end, and a BamHI site at the 3' fragment end. The amplified material was digested with NcoI and BamHI and inserted into the NcoI/BamHI site of the glutathione S-transferase vector pGEX™ expression vector, according to the manufacturer's instructions.

20 The pGEX™ plasmid was used to transform *E. coli* host cells, and cells which are successfully transformed with the pGEX™ vector are identified by immunofluorescence, using anti-HEV human antisera.

F. PRODUCING THE 406.4-2 ANTIGEN.

25 The 406.4-2 gt11 plasmid from above was digested with EcoRI and the released HEV fragment was amplified by PCR, and the amplified fragment was inserted into the NcoI/BamHI site of the pGEX™ expression vector, as above. Peptide expression of the 406.4-2 peptide was similar to that described for the 406.3-2 fusion peptide.

G. PRODUCING THE SG3 ANTIGEN.

The SG3 peptide was prepared by first amplifying the SEQ ID NO:7 sequence with 5' EcoRI-NcoI and 3' BamHI primer-linkers, using a gt10 phage BET1 clone plasmid containing the entire ORF2 and ORF3 regions of HEV (B). The amplified fragment was inserted into the 5 EcoRI/BamHI site of a pBluescript™ vector (Stratagene, La Jolla, CA), according to the manufacturer's instructions. After vector propagation and harvesting, the cloned insert was released by digestion with NcoI and BamHI, and gel purified. The purified fragment was inserted into the NcoI/BamHI site of a pGEX™ vector, and expressed in an *E. coli* expression system. Peptide expression of the SG3 peptide was similar to that described for the 406.3-2 10 fusion peptide.

H. PRODUCING THE CAPSID PROTEIN.

The capsid protein (B) was prepared substantially as described above by PCR amplification of the SEQ ID NO:1, from a pBET1 plasmid using a 5' primer containing an 15 NcoI site and a 3' primer containing a BamHI site. The amplified fragment was inserted into the NcoI/BamHI site of a pGEX™ vector, and expressed in an *E. coli* expression system. The capsid protein (M) was similarly prepared.

I. PEPTIDE PURIFICATION.

20 HEV peptide antigens which were soluble, such as 406.4-2 and 406.3-2, were purified by polyacrylamide gel electrophoresis of bacterially expressed whole cell lysates. Crude lysate preparations were loaded on 7.5% SDS-PAGE gels and run until size markers corresponding to the predicted size of each protein have nearly run off each gel. The gel running buffer was replaced with fresh buffer and the gel allowed to 25 continue to run for 5 minute intervals. The gel running buffer was collected after each interval and replaced with fresh buffer. The fractions were dialyzed and concentrated, and each fraction tested for immunoreactivity to a pGEX™ fusion partner, glutathione S-transferase, specific monoclonal antibody. Highly reactive fractions were pooled.

Alternatively, the peptides when expressed as GST fusions (pGEX™) were purified by 30 column chromatography using Gluathione Sepharose, 4B (Pharmacia, Piscataway, NJ). Briefly, non-GST fusion proteins were washed away from the column and bound protein was then eluted with 10mM glutathione in 50mM Tris HCl pH 8.0.

Insoluble HEV peptides, such as SG3, were purified as follows. Cells induced to express the pGEX™ fusion protein were lysed with two passes through a french-press. The

lysate was layered on a 40% solution of glycerol and spun at 3500 rpm in a J-20 rotor in a Beckman J221 centrifuge for 5 minutes. The pellet was resuspended in PBS then repelleted. The pellet was then resuspended in 6 M urea,

6 M guanadine in PBS pH 8.0 with homogenization for 5 minutes and repelleted. The 5 suspension was filtered through a 0.22um filter (Nalgene, Kent, U.K.) and loaded on an IMAC column (Pharmacia) containing Fast Flow Chelating Sepharose™ (Pharmacia) loaded with 3 column volumes of a CoCl₂ solution according to the manufacturer's instructions.

The bound protein was eluted with a 2 column gradient of 6 M urea, 6 M guanadine, and between 0-1 M imidazole in PBS with a pH range of 8.0 to 6.0. The column was stripped 10 with 0.1 M EDTA in PBS and the fractions analyzed; *e.g.*, by the ELISA protocol detailed in Examples 6, 8 or 10.

EXAMPLE 2

Human Primary Hepatocytes in Culture

15 A. ISOLATION OF HEPATOCYTES.

Hepatocytes were isolated from human liver obtained from Stanford University Medical Center. The liver was either perfused *in situ* or excised as a wedge for perfusion in laboratory. The initial perfusion was performed for 10 minutes at 60 ml/min using Ca⁺⁺-, Mg⁺⁺-free Hanks' balanced salt solution supplemented with 10 mM HEPES (pH7.4) and 0.5 mM 20 [ethylene bis(oxyethylenenitrillo]-tetraacetic acid. Perfusion was continued for additional 20 minutes using Williams' medium E (WME) supplemented with 10 mM HEPES (pH7.4) and 100 U/ml collagenase (type I, Sigma Chemical Co., St. Louis, MO).

After perfusion the liver capsule was removed using fine forceps, and hepatocytes were dislodged by gentle shaking in collagenase solution. The hepatocyte suspension was filtered 25 through several layers of gauze and mixed with an equal volume of WMW containing 10% fetal bovine serum (FBS). Hepatocytes were sedimented by centrifugation at 50 X g for 5 minutes and resuspended in WME containing 5% FBS. Hepatocytes were sedimented and resuspended in the manner for 2 additional times. The final cell preparation was further filtered through several layers of gauze before examining for viability using trypan blue. The cells 30 were plated at a density of 2 x 10⁶ cells per 60-mm Primaria plates (Falcon / Becton Dickinson, Franklin Lakes, NJ) pre-coated with collagen (Collaborative Research, Bedford, MA).

Cultures were incubated at 37°C in 5% CO₂ for 3 hours to allow attachment and the medium was changed to a serum-free formulation and every 48 hrs thereafter. The serum-free

formulation was a WME-based medium supplemented with growth factors, hormones, 10 mM HEPES (pH7.4), 100 ug/ml gentamicin, as has been described (Lanford, 1989).

B. DETECTION OF LIVER-SPECIFIC PROTEINS.

5 Human hepatocyte cultures were maintained in serum-free medium for various periods of time and labeled with [³⁵S]-methionine for 24 hrs. The medium was adjusted to contain 1 mM PMSF, 1 mM EDTA, and 1% NP40. Antibodies specific for the different plasma proteins were bound to protein A-agarose beads, the beads were washed with PBS, and aliquots of the labeled medium were incubated for 16 hrs at 4°C with the antibody-bead complexes. The 10 beads were washed 3 times with a buffer containing 1% NP40, and immunoprecipitated proteins were eluted with gel electrophoresis sample buffer containing 2% SDS and 2% 2-mercaptoethanol. Samples were analyzed by gradient SDS-PAGE (4 to 15%) and autoradiography.

15

EXAMPLE 3

In Vitro HEV Infection of Primary Human Hepatocytes

A. HEV INFECTION OF HUMAN HEPATOCYTES.

The HEV-infected cynomolgus monkey #73 stool pool (fourth passage) was used as an inoculum for infections of primary human hepatocytes. Various amounts of inoculum was 20 diluted in 1 ml of serum-free medium (SFM) and applied to the culture during a 3 hr incubation period. This solution was then supplemented with 2 ml of fresh SFM and the entire mixture was incubated overnight. The next day, cell monolayers were washed with WME (10 mM HEPES, pH7.4) for three times and changed to fresh SFM, which was changed at two day intervals thereafter.

25

B. IMMUNOFLUORESCENCE STAINING ASSAY.

Primary cynomolgus monkey hepatocytes were isolated and plated in tissue culture plates with collagen-coated coverslips as described. Cells on coverslips were infected with either the HEV-infected cynomolgus monkey #73 stool pool or an NIH normal human serum 30 three days after initial plating. The infections were allowed to proceed for 2 weeks.

Cells on coverslips were fixed in 90% acetone at room temperature for 1 minute. The coverslips were then air-dried. The coverslips were blocked in 1% goat serum in PBS for 1 hour, washed with PBS three times, and incubated with a mixture of rabbit antisera against HEV recombinant proteins 406.3-2(B), 406.4-2(M), and 406.4-2(B) at room temperature for

3 hours. The coverslips were again washed with PBS 3 times and reacted with fluorescein isothiocyanate-conjugated (FITC) goat anti-rabbit IgG(H+L) (Zymed) diluted in PBS-1% goat serum for 30 minutes. After the coverslips were washed with PBS for 3 times and air-dried, they were mounted with FITC glycerol solution and examined under a fluorescent microscope.

5

C. REVERSE TRANSCRIPTION/POLYMERASE CHAIN REACTION (RT/PCR).

HEV infection of primary cynomolgus macaque hepatocytes was evaluated by RT/PCR assays. The primers for cDNA synthesis and PCR were based on the nucleotide sequences of the full-length HEV cDNA (Tam, *et al.*, 1991a, 1991b). Primers HEV3.2SF1 (nt 6578-6597) and HEV3.2SF2 (nt 6650-6668) are of sense polarity from the ORF2 region of the viral genome and HEV3.2SR1 (nt 7108-7127) and HEV3.2SR2 (nt 7078-7097) are antisense primers within the region.

Following extraction of total cellular RNA from HEV-infected cells using one-step guanidinium procedure or HEV-infected supernatants according to the method of Chomczynski, *et al.* (Chomczynski, 1987), aliquots of RNA samples were heat-denatured at 95°C for 5 minutes and subjected to reverse transcription at room temperature for 5 minutes and 42°C for 60 minutes using 200 units per reaction of MMLV-reverse transcriptase (BRL) in a 20 ul reaction volume containing 20 units of RNasin (Promega), 1x PCR buffer (Perkin-Elmer Cetus, Norwalk, CT), with a concentration of 1 mM each deoxyribonucleotide (Perkin-Elmer Cetus), and 2.5 uM of HEV3.2SR1 primer. The reaction mixture was then heat-treated at 95°C for 5 minutes to denature the MMLV-reverse transcriptase.

Ten microliters of the cDNA synthesis product was used for PCR in a final volume of 50 ul with 0.5 uM HEV3.2SF1 primer, 1.25 units Taq DNA polymerase (AmpliTaq, Perkin-Elmer Cetus), and 1x PCR buffer, overlayed with 50 ul of mineral oil, and subjected to 40 cycles of PCR in a Perkin-Elmer thermocycler (95°C x 1 minute; 52°C x 2 minutes; 72°C x 30 seconds). Ten microliters of the first-round PCR product then underwent another 40 cycles of nested PCR (95°C x 1 minute; 55°C x 2 minutes; 72°C x 30 seconds) in a total volume of 50 ul containing the internal PCR primers HEV3.2SF2 and HEV3.2SR2.

First- and second-round PCR products were subjected to agarose electrophoresis, 30 ethidium bromide stained and photographed under UV light. Southern transfer was performed and filters were hybridized with [³²P-dCTP]-labeled internal probe HEVORF2-7 exclusive of the primers (nt 6782-6997), and autoradiography performed.

EXAMPLE 4Preparation of a 62 kDa HEV Antigen

The 62K antigens were produced by a baculovirus expression system in insect cells as follows.

5

A. CONSTRUCTION OF RECOMBINANT BACULOVIRUSES. Recombinant baculovirus ORF-2-rAcNPV expressing the entire ORF-2 of Burma strain of hepatitis E virus was constructed as described previously, He, J., et al., J. Clin. Microbiology, 31:2167 (1993), herein incorporated by reference.

10 Construction of recombinant baculovirus pBBIII-62K expressing the C-terminal 549 amino acids of ORF2 is described as follows below and summarized in Fig. 5. In brief, a 204 base-pair (bp) DNA fragment containing nucleotides 5480 to 5684 of ORF-2 from the Burma strain of HEV (Figure 2) was synthesized using polymerase chain reaction (PCR) and a HEV cDNA plasmid template pBBIII-ORF2, together with two primers (5' primer, SEQ ID NO:29 and 3' primer, SEQ ID NO:30). The 5' primer contained a BamHI site and the 3' primer has a HindIII site to facilitate plasmid construction. The PCR product was digested with BamHI/HindIII and ligated to a baculovirus expression vector pBluBacIII (Invitrogen, San Diego) which has been previously digested with the same restriction endonucleases to form plasmid pYZ1 (Fig. 1).

20 A 1.5 kilobase-pair (kbp) HindIII DNA fragment, corresponding to 3' portion of HEV ORF-2, is excised from a previously constructed plasmid pBBIII-OF2 and inserted into the plasmid pYZ1 at the HindIII site to form the final baculovirus transfer vector pBBIII-62K, which is subsequently used in recombinant virus construction. The nucleotide sequence derived from PCR is confirmed by DNA sequencing and the correct orientation of the HindIII/HindIII 25 insert in pBBIII-62K is verified by restriction digestion analysis. Transfection, plaque purification, and virus amplification of recombinant baculovirus BBIII-62K is carried out according to protocols described (Invitrogen, San Diego).

B. CELL CULTURE AND EXPRESSION CONDITIONS.

30 *Spodoptera frugiperda* (Sf9) Cells in suspension culture flasks were maintained at 27°C in Grace's insect medium supplemented with 5% fetal bovine serum (v/v), 50 ug/mL gentamycin, and 0.1% Pluronic F-68. All culture ingredients were obtained from Gibco/BRL (Gaithersburg, MD) and cells were cultured according to protocols described by the manufacturer (Invitrogen, La Jolla, CA). Viable cells with a density of 2 x 10⁶/mL were

pelleted by centrifugation. The cell pellet was resuspended in 1/10 of the original volume of medium containing the recombinant virus, BBIII-62K, at a multiplicity of infection of 2 plaque forming units (PFU) per cell. Infection was carried out for one hour without stirring. The infected cells were diluted to the original density with fresh medium and maintained at 27°C 5 for 2-7 days with agitation (75-95 rpm).

Procedures for infection of monolayer cells are described in protocols supplied by Invitrogen, Inc.

EXAMPLE 5

10 SDS PAGE and Immunoblot of ORF2 Produced in
Sf-9 Suspension Culture and Monolayer Cells

Infected cell lysates from Example 5, above, prepared after various times post infection were separated by centrifugation to generate both phosphate-buffered saline (PBS)-soluble and insoluble fractions. Proteins from both fractions were electrophoresed on SDS-polyacrylamide 15 gels, which were either stained with Coomassie-blue solution (Fig. 6a) or transferred to nitrocellulose paper followed by a Western blot analysis (Fig. 6b), as follows.

A. ANTI-HEV ANTISERUM.

Two rabbit polyclonal antisera, anti-SG3 and anti-1L6, were generated to the 3' portion 20 of ORF-2, 327 and 42 amino acids in length sharing the same C-terminus of ORF-2 from the Burma strain of HEV as described previously (Yarbough 1991, 1994), herein incorporated by reference.

B. SDS-PAGE AND IMMUNOBLOT.

25 To prepare protein samples for SDS-PAGE, approximately 2×10^6 baculovirus-infected Sf9 cells were pelleted in microcentrifuge and resuspended in 150 ul of phosphate-buffered saline. Cells are lysed by sonication. The lysate was subjected to centrifugation in a microcentrifuge at 4°C for 15 min. The supernatant and pellet were separated and denatured in protein denaturation buffer containing 20 mM Tris (pH 6.8), 10% 2-mercaptoethanol, 2% 30 SDS, 30% (vol/vol) glycerol, and 0.1 mg/ml bromophenol blue. Protein samples were electrophoresed on 4-20% polyacrylamide-SDS gels which were then transferred to a PVDF membrane. Immunoblot was carried out using rabbit polyclonal antisera described above and a chemiluminescence detection assay (ECL kit of Amersham).

EXAMPLE 6Purification of 73K, c62K and r62K ORF2 Products

A. PURIFICATION OF FULL-LENGTH ORF2 (73K).

Recombinant baculovirus ORF2-rAcNPV infected cell pellets were resuspended in phosphate buffered saline (PBS) containing 1 mM EDTA, 1 ug/mL aprotinin, 10 ug/mL leupeptin, 0.5 mg/mL Pefabloc SC, and 10 ug/mL pepstatin at a cell density of 20% (w/v). The suspension was lysed by three passages through a Microfluidics microfluidizer M-110S at a liquid pressure of 14,000 PSI followed by centrifugation of the lysate at 10,000 X g for 30 minutes at 5°C.

10 The supernatant was decanted and the insoluble pellet resuspended in 25 mM BICINE at pH 8.5. The suspension was re-centrifuged under the same conditions and the washed pellet extracted in 25 mM BICINE containing 0.5% SDS (w/v) for 30 minutes at ambient temperature. The extracted material was centrifuged for 30 minutes at 10,000 x g at ambient temperature with the resultant supernatant separated and diluted 1:5 in 25 mM BICINE pH 8.5
15 in 8M urea.

This material was chromatographed on a Hyper-D-S (BioSeptra, Framingham, MA) strong cation exchange column in the same buffer at a superficial linear velocity of 3000 cm/hr. Following loading and washing of the column, the 73K protein was eluted in a linear gradient of 0 to 400 mM NaCl in the same buffer.

20 The 73K protein containing fractions from the Hyper-D-S column were dialyzed against a 500 volume excess of water overnight followed by centrifugation of the dialyzate at 10,000 x g at 4°C. The supernatant was discarded and the pellet extracted with 0.5% SDS in 25 mM Tris pH 8.5. Solid Cleland's Reagent (DTT) was added to a concentration of 50 mM and the solution heated to 100°C for three minutes followed by immediate dilution into a 100 fold
25 volumetric excess solution containing 50 mM glycine pH 10.5, 10% glycerol, 5 mM glutathione (reduced), 0.5 mM glutathione (oxidized), and 1 g/L PEG 3500. The solution was allowed to air oxidize overnight. Following oxidation, the solution was concentrated and diafiltered by tangential cross flow filtration to 25 mM Tris pH 8.5. The material was further concentrated by centrifical ultrafiltration.

30

B. PREPARATION OF CELL LYSATE AND PURIFICATION OF RECOMBINANT 62K ANTIGEN.

Frozen Sf9 cells infected with recombinant baculovirus BBIII-62K were resuspended in phosphate buffered saline (PBS) containing 1ug/mL aprotinin, 1 mM EDTA, 10 ug/mL
35 leupeptin (Boehringer Mannheim, Indianapolis, IN), 0.5 mg/mL Pefabloc SC (Boehringer

Mannheim), 10 ug/mL pestatin (Boehringer Mannheim) at a concentration of 20% (w/v). The cellular suspension was lysed in a Microfluidics microfluidizer M110S (Newton, MA) by two passages at 14,000 PSI. Lysed cells were centrifuged (15,000 X g, 4°C, 30 minutes). The cellular supernatant was then pre-treated by addition of solid dithiothreitol (DTT) (Cleland, 5 1964) to a concentration of 50 mM and dialyzed initially against 100 volumes of 10 mM Tris pH 8.5, 50 mM NaCl, and 0.5 mM DTT for 8 hours at 4°C.

Dialysis was continued for another 8 hours against fresh buffer minus DTT. Using this two step dialysis procedure aggregation of the 62-kDa protein with contaminating cellular proteins was virtually eliminated. The r62-kDa protein was found to be completely soluble in 10 the lysis buffer with quantitative recovery of the molecule in the cell lysis supernatant.

The dialysate was prefiltered through a Millipore 0.22 micron filter and then loaded directly onto a DEAE EMD 650(S) column (E. Merck) equilibrated in 10 mM Tris pH 8.6 50 mM NaCl. The r62-kDa protein was eluted in a linear gradient of 50-500 mM NaCl over 15 column volumes at a superficial linear velocity of 100 cm/hr. The 62-kDa protein eluted early 15 in the gradient.

The presence of ORF-2 related 62-kDa was confirmed by Western blotting of column fractions with rabbit polyclonal antibody, 1L6 (Yarbough, *et al.*, 1991), an antibody raised against the carboxyl terminal region of the parent ORF-2 protein.

The r62K containing fractions from the DEAE column were pooled, concentrated by 20 centrifugal ultrafiltration (Amicon, Beverly, MA). The r62-kDa protein was further purified and buffer exchanged on a 60 cm Sephadryl S-100 column (Pharmacia, Piscataway, NJ) equilibrated in 25 mM Tris, pH 7.2, (5 X 100 cm) at a superficial linear velocity of 30 cm/hr. Fractions containing 62-kDa were pooled and concentrated by centrifugal ultrafiltration. This step in the procedure was utilized primarily as a buffer exchange step.

25 The 62-kDa containing pool from the S-100 column was applied to the strong anion exchange column Poros Q/F column (4.6 X 10 mm) (Perseptive Biosystems, Cambridge MA) equilibrated with buffer B (25 mM Tris, pH 7.2) at a superficial linear velocity of 3000 cm/hr. The column was washed with 5 column volumes of buffer B. The 62-kDa was eluted with a linear gradient of 0 to 1 M NaCl (total 10 column volumes) in buffer B. The 62-kDa protein 30 eluted at approximately 300 mM NaCl. If necessary, the r62-kDa was buffer exchanged by tangential cross flow diafiltration using a spiral wound cartridge (Millipore Prep TFF; Millipore, Bedford, MA). At this stage, the 62-kDa protein was nearly homogeneous based upon SDS-PAGE and Western blotting.

In the purification steps described above, buffer conductivities and pH's were monitored with a Radiometer Copenhagen CDM 83 conductivity meter (Westlake, OH) and a PHM reference standard pH meter, respectively. All buffer constituents were either biotechnology or USP grade and determined to be essentially pyrogen free by limulus 5 amebocyte lysate assay.

Further, for the quantitation of recovery of 62K antigen from insect cell lysates the following double antibody sandwich (ELISA) technique was utilized. Anti-1L6 antibody, a polyclonal rabbit antibody directed against the carboxyl terminal portion of the ORF-2 protein, was purified by Protein G Sepharose affinity chromatography and coated onto microtiter plates 10 at a concentration of 1.6 ug/mL per well in carbonate/bicarbonate buffer. After washing and blocking, purified 62-kDa antigen (quantitated by amino acid analysis) or process samples were added to the plate and diluted in series of two fold dilutions. After incubation of the antigen and washing, a second antibody, anti-SG3 conjugated to biotin was added to the plate and 15 incubated. The SG3 antigen corresponds to the carboxyl terminal 328 amino acids of the 62-kDa protein (Yarbough, *et al.*, 1994). This incubation was followed by a final incubation with streptavidin conjugated horse radish peroxidase. After final washing, substrate was added and the plates were read at an absorbance of 490 nm.

Protein concentrations of samples were established using the Bradford assay (Pierce, Rockford, IL).

20

EXAMPLE 7

Electron Microscopy

Protein samples were applied to Formvar-coated carbon grids and stained with 2% uranyl acetate or 2% phosphotungstic acid, pH 6.5, before they were viewed on a electron 25 microscope. When fixation was required, protein samples were fixed in PBS containing 2% glutaraldehyde for 30 min. Buffer exchange was then carried out by centrifugation in Centricon-30 (Amicon, Beverly MA) to change the sample buffer to PBS.

30

EXAMPLE 8

ELISA Assays

ELISA was used to compare the antigenicity of HEV protein products expressed in *E. coli* and baculovirus. Small scale paneling of coded sera was used to define the sensitivity and specificity of a diagnostic incorporating baculovirus expressed proteins.

A. HUMAN SERA.

Human sera were from stored panels previously collected during various epidemics of hepatitis E at various geographical locations. Sera from non-human primates were from cynos and chimps experimentally infected with the hepatitis E virus at the Center for Disease Control,

5 Atlanta, GA.

B. ELISA.

The proteins used for immunodiagnosis include: (1) SG3 encoding 327 amino acids of ORF2 expressed as a fusion protein in *E. coli* (SEQ ID NO:17), (2) 73K encoding 660 amino acids of ORF2 expressed in baculovirus, and (3) 62K encoding 549 amino acids of ORF2 expressed in baculovirus. Antigens were coated individually onto the wells of polystyrene microtiter plates (Yarbough, *et al.*, 1994). Each well was incubated overnight at 4°C with 200 ng of each protein in 100ul 0.05 M sodium carbonate pH 9.5 (1.59 g Na₂CO₃, 2.93 g NaHCO₃, 0.02% sodium azide, pH 9.5, bring to 1000ul) buffer. After washing in PBS-0.05% 10 polyoxyethylene (20) monolaurate "Tween 20 TM" (Sigma) and blocking with 200 ul of 1% bovine serum albumin (BSA) in PBS for 1.5 hours at room temperature, serum samples were 15 diluted 1:100 in antibody diluent (1000 ml Tris buffered saline (40 mM Tris pH 7.5, 1 M NaCl), 30 ml goat serum, 10 g bovine serum albumin, fraction V, 10 g non fat milk (Carnation), 1 g gelatin (EIA) grade, and 0.2 g thimersol (preservative), see Antibody Diluent 20 Production, following) and incubated for 30 minutes at 37°C. After removal of the primary antibody and washing to remove any unbound 1st antibody, the wells were incubated for 30 minutes at 37°C with secondary antibody, HRP conjugated goat anti-human IgG (gamma chain specific) or goat anti-human IgM (mu chain specific).

After final washing, substrate was added and the plates were read at an absorbance of 25 490 nm. Sera producing an O.D. value of 0.300 or greater were scored positive for HEV antibodies. This concurs with a P/N ration of greater than 3.0 and a minimum of 5 standard deviations above the mean of the normal sera.

C. ANTIBODY DILUENT PRODUCTION.

30 Antibody Diluent was made as follows: 200 ml of TBS was heated to 60°C and 1g gelatin melted therein. The volume was brought to 1000 ml with TBS. 10g BSA was added when the temperature had cooled to 40°C. The mixture was stirred at room temperature until the BSA was in solution. 30 ul of goat serum was then added followed by the addition of

thimeresol to 0.02%. The reagent could be stored for two weeks at 4°C. Prior to use, milk was stirred in to 1% at room temperature for 30 minutes.

EXAMPLE 9

5

Further Characterization of the 62K Antigen

A. CHARACTERIZATION OF RECOMBINANT 62-kDA PROTEIN BY SDS-POLYACRYL-AMIDE GEL ELECTROPHORESIS AND WESTERN BLOTTING

Processed fractions of the 62-kDa protein (Examples 4 and 6B) were denatured and analyzed by SDS-polyacrylamide gel electrophoresis. Briefly, sodium dodecyl sulfate 10 polyacrylamide gel electrophoresis was performed according to the tricine SDS-PAGE procedure (Schagger and von Jagow, 1987). Western blotting was performed as previously described (Yarbough, *et al.*, 1994). A rabbit polyclonal antibody directed to the carboxyl-terminal regions of ORF-2, 1L6, was used to evaluate purified protein (Example 5). The tricine buffer system was used in order to obtain higher resolution and minimize interference 15 with Edman reagents in solid phase sequencing from PVDF (polyvinylidene difluoride) membranes.

The results of an analysis of the r62-K purification process using 4-20% SDS-polyacrylamide gel electrophoresis and corresponding western blot are presented in Figures 14A and 14B. In Figure 14A: lane 1, Molecular weight markers; lane 2, cell lysate; lane 3, 20 cell lysate supernatant; lane 4 DEAE peak pool; lane 5, Sephadryl s-100 peak pool; lane 6, Poros HQ/F peak pool. Molecular mass markers are Novex SeeBlue Pre-Stained Standards (San Diego, CA) and range as follows (from top to bottom): Myosin, 250-kDa; BSA, 98-kDa; Glutamic dehydrogenase, 64-kDa; Alcohol dehydrogenase, 50-kDa; Carbonic anhydrase, 36-kDa; Myoglobin, 30-kDa; Lysozyme, 16-kDa; Aprotinin, 6-kDa; Insulin B chain, 4-kDa. 25 Figure 14B presents a Western blot of lanes 1-6 from above. Samples were diluted 15 fold prior to SDS-PAGE and transfer. 1L6 antibody was used as the initial antibody.

Analysis of the initial cell lysate (Fig. 14A, lane 2) indicated that the 62-kDa protein was adequately expressed in the baculovirus expression system and suitable for further processing. The cell lysis supernatant (Fig. 14A, lane 3) appeared to yield essentially 30 quantitative recovery of the 62-kDa protein as a soluble product. The DEAE pool (Fig. 14A, lane 4) yielded a significant purification of the 62-kDa from the previous lysate supernatant pool with the Sephadryl S-100 and Poros HQ/F chromatography steps resulting in further purification of the 62-kDa protein (Fig. 14A, lanes 5 and 6).

One curious aspect of the gel electrophoresis profiles was the apparent purification of 35 the 62-kDa band as a doublet. The Western blot illustrated in Figure 14B contains a 15 fold

dilution of the samples run on SDS-PAGE in parallel. In the Western blot, the protein was visualized as a doublet with the lower band appearing to accumulate over the course of purification. However, proteolysis appeared to be minimal. This result suggested that the protein may exists as a heterogenous species through potential side chain modifications such 5 as glycosylation, N-terminal, or C-terminal modification. The following experiments were carried out to determine the source of the heterogeneity.

B. AMINO TERMINAL SEQUENCE AND AMINO ACID COMPOSITION.

The 62-kDa protein was resolved by SDS-polyacrylamide gels and transferred to PVDF 10 (Biorad, Richmond, CA) membranes. The amino acid composition and amino-terminal sequences were determined for the protein.

Amino acid composition analysis was carried out on a Beckman Model 6300 (Fullerton, CA) ion-exchange instrument following a 16 hour hydrolysis at 115°C in 100 ul of 6N HCl, 0.02% phenol plus 2 nmol norleucine. Following hydrolysis, the samples were dried on a 15 Speedvac and the resulting amino acids dissolved in 100 ul of sample buffer (Beckman, Fullerton, CA) containing 2 nmol homoserine with the homoserine acting as a second internal standard to independently monitor transfer of the sample onto the analyzer (Rosenfeld, *et al.*, 1992). The instrument was calibrated with a 2 nmol mixture of amino acids and was operated according to the manufacturers specifications. Amino acid composition analysis was used to 20 accurately quantitate protein concentrations in samples.

Amino-terminal sequencing was carried out on either an Applied Biosystem 470A or 477 (Foster City, CA) that was equipped with on-line HPLC's for the identification of the resulting phenylthiohydantoin (Pth) amino acid derivatives. Prior to sample application 25 pmol of a 16 residue internal sequencing standard peptide with the formula: [norleucine-25 (succinyl-lysine)₄]₃-norleucine was first spotted onto the sequencing filter (Elliott, *et al.*, 1993). The 470A and 477 instruments were operated based upon manufacturer's recommendations and 3 pmol Pth standards were routinely used. All sequences were searched via the BLAST Network Service operated by the National Center for Biotechnology Information.

The levels of amino acids present in the first five cycles were approximately 10-fold 30 lower than expected suggesting that a major portion of the 62-kDa molecule was blocked at the N-terminus. The sequence obtained appeared to be identical to the processed form of the 62-kDa originally produced in Sf9 cells expressing the full length ORF-2. Presumably a methionine aminopeptidase present in baculovirus infected Sf9 cells cleaved the N-terminal

methionine introduced into the coding sequence of the recombinant protein to ensure correct initiation of translation.

C. TRYPTIC PEPTIDE ANALYSIS.

5 One hundred and two pmoles of the 62-kDa protein were digested *in situ* with trypsin in an excised polyacrylamide gel slice. A blank gel slice and a gel slice containing 50 pmoles of transferrin were also digested and analyzed in parallel as controls. The resulting peptides were resolved by reverse phase HPLC.

10 In gel enzymatic digestion was carried out according to Williams and Stone (Williams and Stone, 1995), using perfusion in an approximately 1:5 (enzyme weight:substrate weight) ratio of modified trypsin (Promega, Madison, WI) and digestion for 24 hours at 37°C. The resulting peptides were reduced/carboxymethylated, extracted with 0.1% TFA, 60% CH₃CN and then subjected to hydrolysis/amino acid analysis so that the amount and density (ug protein/mm³) could be determined, with both of the parameters serving as valuable criteria to 15 judge the probability of success of the impending digest. Amino acid composition analysis was carried out as described above.

20 Reverse phase HPLC was carried out on a Hewlett Packard 1090 HPLC system (Palo Alto, CA) equipped with an ISCO Model 2150 Peak Separator and a 25 cm Vydac C-18 (5 micron, 300 Angstrom) column (Hesperin, CA) equilibrated with 98% buffer A (0.06% Trifluoroacetic acid; TFA) and 2% buffer B (0.052% TFA, 80% acetonitrile) as described in Williams and Stone (1995). Peptides were then eluted with the following gradient program: 0-60 min (2-37% buffer B), 60-90 min (37-75% buffer B) and 90-105 min (75-98% buffer B) and were detected by their absorbance at 210 nm. Aliquots of digests in the 25-250 pmol range were fractionated on 2.1 mm internal diameter (ID) column eluted at 0.15 ml/min. Fractions 25 were collected in capless Eppendorf tubes.

30 Out of a possible total of 38 tryptic peptides and 143 potential peaks detected by reverse phase HPLC analysis of the digested 62-kDa protein, 8 peaks were selected for laser desorption mass spectroscopy since the HPLC profile suggested that these peaks appeared to contain only one major species.

30

D. LASER DESORPTION MASS SPECTROSCOPY (LDMS).

Peaks 45, 50, 62, 65, 73, 82, 101, and 116 were further evaluated by LDMS. LDMS was used to resolve several issues:

(i) whether the peak was an artifact peak or was in fact a peptide? The analysis confirmed that none of the peaks were artifactual;

(ii) whether the peak contained more than one peptide? The analysis demonstrated that, in a few cases the peaks represented mixtures of peptides; and

5 (iii) whether the LDMS calculated mass was comparable to the predicted mass which was derived from the predicted amino acid sequence encoded by the viral RNA? In all cases the mass of the peptide was equivalent to the predicted mass, with the exception of peak 65 which appeared to be blocked.

10 Also, this analysis allows the ready determination of any post translational modifications.

To perform LDMS, 3 μ l aliquots of peptides isolated via reverse phase HPLC were added on top of 1 μ l of an alpha cyano-4-hydroxy cinnamic acid (alpha CHCA) matrix solution that was spotted onto a new target. Mixing of the matrix was accomplished by repeatedly pulling the sample into and expelling it from a micropipette. The samples were then allowed 15 to air dry at room temperature. To avoid cross contamination, all targets were used only once. The alpha CHCA matrix solution was prepared at a concentration of 10-20 mg/mL in 40% $\text{CH}_3\text{CN}/0.1\%$ TFA (trifluoroacetic acid) and was used after vortexing and standing for a few minutes. Matrix solutions were stored for a maximum of 2 days at -20°C. The calibrants used 20 for external calibration of peptides were gramicidin S ($m/z = 1142.5$) and insulin ($m/z = 5734.5$). Both calibrants were stored at -20°C as 10 pmol/ μ l stocks in either 50% CH_3CN , 0.1% TFA, or 0.1% TFA. LDMS was carried out on a VG/Fisons TofSpec mass spectrometer (VG Organics, Manchester, U.K.) that was operated in the +ve linear ion mode at an accelerating voltage of 25kV and was equipped with a nitrogen laser (337 nm) and a 0.65 m linear flight tube.

25 Routinely, 30 shots were averaged for each spectrum with 3-6 spectra acquired for each sample. The predicted masses were based upon the average isotopic, singly protonated mass and the expected mass accuracy was about $\pm 0.25\%$.

Post-source decay sequencing was done in the reflectron mode with the ladder sequencing calibrated to a 2 pmole sequence of adrenocorticotrophic hormone fragment ACTH 30 clip fragment 18-39.

Peaks 65, 73, 101, and 116 appeared to be suitable for direct sequencing as the LDMS results indicated the presence of only one major species. Peaks 45, 50, 62, and 82 were also sequenced. Although the peaks appeared to be mixtures that would optimally require HPLC

repurification prior to individual sequencing, it was decided to directly sequence these mixtures in view of the known mass information and predicted amino acid sequence.

E. SEQUENCE ANALYSIS OF LDMS PEPTIDES.

5 Peptide 65 did not yield an interpretable sequence. Upon further examination, the mass observed by LDMS was consistent with the N-terminal residues of the 62-kDa protein with addition of an N-terminal acetyl group (predicted 1786.9 Daltons versus 1785.5 Daltons observed; corresponding to a 0.03% error). Evaluation of a tryptic peptide data base using the predicted sequence of the 62-kDa protein revealed only one other peptide that was similar in
10 molecular weight (residues 408-423). Post source decay analysis revealed that Peak 65 was indeed the predicted amino terminal tryptic peptide.

Sequence analysis of the peptides corresponding to peaks Peaks 45, 50, 62, 73, 82, 101, and 116 confirmed that the internal sequence of the predicted 62K protein was intact. Briefly, Peak 73 matched residues 327-355 of the known sequence. Peak 101 matched residues
15 123-139 of the known sequence. Peak 116 matched residues 424-431 of the known sequence. Peak 45 matched residues 412-423 of the ORF-2 sequence with a predicted mass of 1396.49 Daltons. Peak 50 matched residues 334-348 of the ORF-2 sequence. Peak 62 contained a short 6 peptide residue with a predicted mass of 749.84 Daltons which matched residues 513-518 of the ORF-2 sequence. Peak 82 was a mixture of three peptides that were matched to
20 residues 424-437 (primary sequence), residues 438-466 (secondary sequence), and residues 555-578 (tertiary sequence). Taken together these results indicate that the internal sequences of the predicted 62K polypeptide appeared to be intact and colinear with the predicted sequence.

F. LC-MS AND CARBOXYL TERMINAL SEQUENCE ANALYSIS

25 In order to evaluate the nature of the 62-kDa protein doublet observed by SDS-PAGE, the purified 62-kDa protein was chromatographed on a Vydac C18 reverse phase capillary column (Hesperin, CA) with the eluting peak being evaluated by electrospray mass spectrometry (ES-MS). Purified 62-kDa protein was chromatographed on a fused capillary Vydac C18 reverse phase column using ABI Model 410 syringe pumps at a flow rate of 50 ml
30 per minute. The protein was chromatographed in a solvent system of 0.1% TFA in water (v/v) to 0.1% TFA in acetonitrile. An in line flow splitter was used to divert peaks at a flow rate of 10 ml per minute to a VG BioQ triple quadrupole mass spectrometer (VG Organics, Manchester, U.K.) operating in the positive ion electrospray ionization mode. The 62-kDa protein resolved into two primary peaks by ES-MS corresponding to 56.1 and 58.6-kDa.

The predicted molecular mass of the 62-kDa protein using the coding sequence of residue 112 to residue 660 of the ORF-2 region is 59.1-kDa. These data suggested that a deletion occurred in the molecule and that the deletion was most likely at the amino or carboxyl terminus. The protein was not found to be glycosylated both by periodate oxidation and GC-MS analysis.

Molecular mass determination by ES-MS is typically 0.01% (Scoble, *et al.*, 1993). With the confirmation of the amino terminus, the ES-MS data suggests that the carboxyl terminus may be clipped between residues 551-552 and residues 536-537. Automated carboxyl terminal sequencing was performed using intact 62-kDa to confirm the putative carboxyl terminal processing.

For automated C-terminal sequence analysis, protein samples were applied to Zitex membranes (Norton Performance Plastics, Wayne NJ) pre-treated with isopropanol and inserted into inert Kel-F columns (Norton Performance Plastics, Wayne NJ). The sequencer column was installed into a Hewlett Packard G1009A sequencer (Palo Alto, CA) for chemical coupling and cyclization. The coupled peptidylthiohydantoin and cyclized product was cleaved to the C-terminal thiohydantoin-amino acid residue and the shortened peptide using an alkali salt of trimethylsilanolate (KOTMS). The derivatized sample was analyzed by an Hewlett Packard 1090 liquid chromatograph (Palo Alto, CA) with filter photometric detection at 269 nm using a Hewlett Packard specialty (2.1 mm x 25 cm) reversed phase PTH analytical HPLC column.

A 39 minute binary gradient (Solvent A: phosphate buffers pH 2.9; Solvent B: acetonitrile) utilizing alkyl sulfonate as an ion pairing agent was developed. Thiohydantoin-amino acid standards at 100 pmole were used to standardize the analysis. The initial sequencing cycle gave rise to two very strong peaks corresponding to glutamine and lysine neither of which are located at the predicted carboxyl terminus of the 62-kDa protein.

The second cycle revealed a very strong (> 200 pmole) leucine peak indicating the presence of more than one leucine in the polypeptide mixture. The third cycle was somewhat ambiguous due to increasing background. However, arginine was clearly present in the third cycle along with either a glutamic acid or glycine residue. The carboxyl sequencing data supports the existence of a heterogenous, truncated protein.

EXAMPLE 1062 kDa HEV Antigen Vaccine Confers Full Protection
Against Heterologous Wild-Type HEV in Animals

A. TITRATION OF THE CHALLENGE STOCK

5 A 10% stool suspension (Mex #14) from a person infected during an HEV epidemic in Telixtac, Mexico (Velazquez, *et al.*, 1990) has previously been reported to cause hepatitis E in experimentally infected cynos (Purdy, *et al.*, 1993). For titration of the challenge stock, four pairs of cynos were injected I.V. with dilutions of a Mexico 14 10% stool suspension prepared in phosphate buffered saline (PBS). Each group of two received 1 ml of either 10⁻²,
10 10⁻⁵, 10⁻⁶, or 10⁻⁷ dilutions.

Animals were monitored for evidence of infection by: 1) serum levels of ALT and SICD, 2) development of antibody to HEV, 3) shedding of HEV in the feces, 4) detection of HEV antigen in the liver, and 5) histopathologic changes (Table 5).

15 The data in Table 5 demonstrate titration of the Mexico 14 HEV inoculum. Anti-HEV was assayed by ELISA. HEV antigen in liver was detected by immunofluorescent assay of liver biopsy specimens. Liver biopsies were examined under code for necroinflammatory changes. ALT levels were assayed by standard methods (Purdy, *et al.*, 1993).

Table 5

20

TITRATION OF HEV INOCULUM - MEXICO STRAIN

Cyno No.	Inoculum Dilution	ALT Elevation (days) Range Peak (value) ¹	Histo-path.	HEV Ag in liver	Anti-HEV (day of sero-conversion)
9218	10 ⁻²	23-65 37(5.4)	+	+ days 13-28	+ day 20
9219	10 ⁻²	16-58 30(7.8)	+	+ days 13-27	+ day 20
25	9214	10 ⁻⁵	no ALT elevation	-	-
9220	10 ⁻⁵	30-37 34(4.6)	+	+ days 20,27	+ day 35
9213	10 ⁻⁶	37-52 52(1.1)	-/+	-	+ day 35
9215	10 ⁻⁶	49-52 49(1.3)	-	-	+ day 49
9212	10 ⁻⁷	elevated values from day 3	-	-	-
30	9217	10 ⁻⁷	no ALT elevation	-	-

1 = peak value/negative cutoff (99% confidence level)

Weekly serum specimens were tested for alanine aminotransferase (ALT) and for anti-HEV antibodies by ELISA. Both animals (cynos #9218, 9219) inoculated with a 10^{-2} dilution had elevated ALTs and seroconverted for anti-HEV within three weeks post infection. Only 5 one of the two (50%) cynos inoculated with the 10^{-5} dilution had elevated ALTs. This animal, cyno #9220 seroconverted on day 35 post infection. While both animals inoculated with 10^{-6} dilution displayed only transient and minimal ALT elevations, these monkeys (cynos #9213 and 10 9215) did however seroconvert at day 35 and 49. There were no ALT rises or antibody seroconversion in either of the animals inoculated with 10^{-7} dilution. Weekly liver biopsy specimens were evaluated histopathologically and by immunofluorescent analysis for the presence of HEV antigen. Findings of HEV antigen in the liver and histopathologic changes were concordant with the elevation of ALT and observed only in cynos #9218, 9219, and 9220. HEV RNA in cyno stools was assayed by RT-PCR.

The titer of the stock (CID_{50}) was defined as the concentration of HEV shown to be 15 infectious in 50% of the cynos tested. The CID_{50} titer of the Mex #14 inoculum was estimated at $10^{-5}/\text{ml}$ based on biochemical and histologic evidence of hepatitis in one of two cynos inoculated with a 10^{-5} dilution of the 10% w/v human stool suspension. A suspension diluted to contain 1000 cynomolgus infectious doses (CID_{50}) was used for I.V. challenge of the vaccinated and control cynos.

20

B. INFECTION OF CONTROL AND VACCINATED TEST ANIMALS.

1. IMMUNIZATION AND CHALLENGE OF ANIMALS.

Fourteen cynomolgus macaques (cynos) were used in the present study. Eight cynos 25 were injected I.V. with dilutions of a 10% stool suspension of the Mexico 14 suspension of HEV for titration of the challenge stock (see above). Six cynos, three vaccinated and three not vaccinated, were used to test for *in vivo* efficacy of the r62K antigen (Examples 4 and 6B). The monkeys were housed under BSL-2 biohazard containment at the Center for Disease Control and Prevention (Atlanta, GA) for the duration of the study.

Animals were quarantined for six weeks and serum specimens were collected weekly 30 for the following six weeks to establish baseline volumes for ALT and SICD. Prior to virus inoculation and vaccination all cyno sera were tested for the presence of antibodies reactive with HEV ORF2 and ORF3 proteins by ELISA (Examples 1 and 8). All animals were HEV antibody negative prior to inoculation.

The r62K (purified as described above, Examples 4 and 6) was precipitated with alum following standard protocols. The protein-alum complex was stored at 4°C prior to the immunization. Three cynomolgus monkeys (Cynos #9338, 9339, 9340) served as control animals. Each of the animals received I.M. injections of alum on day 0 and day 31. Three 5 cynomolgus monkeys (Cynos #9327, 9330, 9331) were immunized by I.M. injection with 20 ug alum-precipitated r62K protein in 0.5 ml of buffer on day 0 and day 31.

All six of the animals were challenged with a 10⁻² dilution of a 10% human stool suspension containing 1000 CID₅₀ of wild-type Mexico HEV (Mex #14) at day 74, 6 weeks after the final immunization.

10

2. SPECIMEN COLLECTION

For the eight animals used for titration of the Mexico 14 challenge stock, 1.5 ml blood samples were taken twice weekly. For the six animals used for the vaccine phase of the study, 1.5 ml blood samples were taken weekly. Blood collections continued for at least 120 days. 15 Each specimen was tested for alanine aminotransferase (ALT), serum isocitrate dehydrogenase (SICD), and anti-HEV IgG antibody. A baseline and 99% confidence limit for ALT and SICD activity was established for each animal using pre-inoculation values.

Needle biopsy specimens of liver were collected weekly. Specimens were divided for histopathology and identification of antigen. Biopsies were taken for at least 30 days after liver 20 enzymes return to baseline.

Stool specimens were collected daily, for at least 90 days after challenge, and stored at -70°C until analysis of viral RNA content.

C. EVALUATION OF COLLECTED SPECIMENS.

25 1. ELISA FOR ANTI-HEV.

The anti-HEV ELISA was a modification of a previously described EIA protocol (Example 8). Proteins coated to polystyrene ELISA plates as antigens included: ORF2 SG3 (Yarbough, et. al., 1994), ORF3 4-2M (Yarbough, et. al., 1991), and ORF2 r62K. Test sera were incubated in antigen coated wells, followed by gamma chain specific HRP-conjugated goat 30 anti-human IgG (Zymed, South San Francisco, CA). The signal to noise value (S/N) for each post-inoculation specimen was calculated as the absorbance at 490 nm divided by the absorbance at 490 nm for the pre-inoculation sera for the same animal. Baseline anti-HEV values were established for each of the monkeys with their five weekly pre-inoculation serum specimens.

The cutoff for anti-HEV reactivity was defined as 0.200 OD₄₉₀ which correlated with a S/N value of 3.39 and greater than 30 standard deviations above the mean of the pre-inoculation O.D. value. Antibody titers were determined by serial 2-fold dilutions with endpoint titers calculated as the greatest serum dilution in a 2-fold dilution sample that still 5 yielded an O.D. of at least 0.200 OD₄₉₀.

2. POLYMERASE CHAIN REACTION (PCR).

A reverse transcriptase-polymerase chain reaction (RT-PCR) method (Kawasaki, *et al.*; Wang, *et al.*, 1990) was used to assay for HEV RNA in cyno stools. Assays were performed 10 using HEV specific primers derived from published HEV sequences (Tam, *et al.*, 1991a, 1991b; McCaustland, *et al.*, 1991).

3. IMMUNOFLUORESCENT ASSAY.

Immunofluorescent assays for hepatitis E virus antigen in liver biopsy tissue were 15 performed according to Krawczynski and Bradley (1989).

D. HEPATITIS E IN NON-IMMUNIZED ANIMALS.

Biochemical and histologic evidence of hepatitis was observed in two cynos (cynos #9218, 9219) inoculated with a 10⁻² dilution of the challenge stock in the titration study. ALT 20 elevations were observed at two to three weeks post inoculation. Necroinflammatory changes coincided with biochemical evidence of hepatocellular damage. HEV antigen was detected in the livers of the monkeys at two to three weeks post-inoculation. Virus shedding in the stool was observed by RT-PCR.

Antibody to ORF2 of HEV was measurable by day 20. By day 65 ALT levels had 25 began to decline followed by clearing of the virus and resolution of disease.

Biochemical and histologic evidence of hepatitis was observed in three control animals (cynos 9338, 9339, 9340) inoculated with a 10⁻² dilution of the challenge stock in the in vivo efficacy study with r62K (Table 6).

The data presented in Table 6 show the course of Hepatitis E in non-immunized and 30 immunized cynos. Three cynos were immunized by I.M. injection with 0.5 ml of 20 ug alum-precipitated r62K protein on day 0 and day 31. Six cynos were challenged with 1000 CID₅₀ of wild-type Mexico HEV (Mex #14) at day 74. Anti-HEV was assayed by ELISA. HEV antigen in liver was detected by immunofluorescent assay of liver biopsy specimens. Liver biopsies were examined under code for necroinflammatory changes. ALT levels were assayed

by standard methods. HEV RNA was detected by RT-PCR (Purdy, *et al.*, 1993; Kawasaki, *et al.*; Wang, *et al.*, 1990).

Table 6

5 HEV VACCINE EXPERIMENT: CHALLENGE WITH HEV MEXICO

	Animal No.	Immunization (62K antigen)	Anti-HEV at Challenge	Elevated Alt (u/l) Range (days)	Elevated Alt (u/l) Peak Day S/CO	
					Day	S/CO
10	CY9327	2 X 20 ug	positive	24-87 ¹	83	1.3
	CY9330	2 X 20 ug	positive	14-104 ¹	41	1.5
	CY9331	2 X 20 ug	positive	single	97	1.5
	CY9338	Alum (X 2)	negative	11-14	20	4.5
	CY9339	Alum (X 2)	negative	20-34	27	4.7
	CY9340	Alum (X 2)	negative	27-31	27	2.5
15	Animal No.	Histopathology (necro-inflammatory changes)		HEV Ag in liver (day)	HEV RNA in stools (day)	
	CY9327	0		negative	negative	
	CY9330	0		negative	30,34	
	CY9331	0		negative	negative	
	CY9338	positive		14	nd ²	
	CY9339	positive		14,20	8-20	
20	CY9340	positive		14,20	nd	

1 = single day, isolated elevations

2 = not determined

25 ALT elevations with peaks in excess of 2.5 signal/cutoff ratios were exhibited at two to three weeks post challenge for each of the control monkeys. Necroinflammatory changes coincided with biochemical evidence of hepatocellular damage.

HEV antigen was detected in the livers of the three animals within two weeks post challenge. Virus shedding in the stool was observed by RT-PCR as early as one week after 30 challenge in the three control animals. Viral shedding was sustained for as long as three weeks. ALT levels returned to baseline by day 38 post challenge for each of the unvaccinated animals. Antibody to ORF2 of HEV was measurable within three weeks post wild-type

challenge for each of the control animals. One animal, cyno #9340, also mounted a coincident ORF3 antibody response.

Concomitant with resolution of disease, antibody to ORF2 of HEV peaked by day 36-41 and persisted for at least 12 weeks after challenge. Antibody to ORF3 was short lived with 5 antibody levels declining by week 12 post challenge. One control animal, cyno #9340, expired between weeks 15-16 post-challenge. The cause of death was essentially unrelated to the HEV infection. The remaining two animals, cyno #9338 and 9339, had declining but still measurable anti-HEV antibody after 21 weeks post-challenge.

10 E. COMPLETE PROTECTION AGAINST HEPATITIS E IN VACCINATED CYNOS

Three cynos (# 9327, 9331, and 9330) were immunized twice with 20 ug doses of alum-precipitated r62K ORF2 (Table 6). Anti-HEV antibody directed to ORF2 was initially detected 1-2 weeks following the initial immunization. An anti-HEV ORF2 antibody titer as high as 1:2000 was achieved in all the immunized cynos. Anti-HEV titers continued to rise 15 after the boost immunization for cyno 9327 and 9331. Anti-HEV was still measurable in cyno #9330 but the antibody levels had dropped during the 6 week period between the final boost and the wild-type challenge. Cyno 9327 and 9331 had estimated titers of 1:5000; cyno 9330 had a lower titer of 1:2500 (Table 7).

20

Table 7

SERUM ANTI-HEV INVERSE TITERS: VACCINATED ANIMALS

Cyno Specimen	Antigen Reactivity		
	anti-62K	anti-SG3	anti-4-2
day of challenge	5,000	1,000	< 100
	2,500	500	< 100
six weeks post-challenge	2,500	400	< 100
	20,000	2,500	1,000
day of challenge	5,000	1,000	< 100
	2,500	500	< 100

After challenge with 1000 CID₅₀ of the heterologous wild-type HEV, the levels of measurable antibody directed to ORF2 were stable in cyno 9327 and 9331. However, for cyno 9330, there was an apparent anamnestic response observed at six weeks post challenge; endpoint titers rose nearly 10-fold to 1:20,000 (Table 7). Concomitant with the rise in anti-
5 HEV ORF2, cyno 9330 showed an antibody response directed to ORF3.

Although antibody levels continued to rise for the next four weeks, this was abruptly followed by a continuous decrease in antibody to HEV. By 12 weeks after challenge the anti-HEV titers had dropped significantly in cyno 9330; anti-HEV titers remained constant for cyno 9327 and 9331. One vaccinated animal, cyno #9331, died between weeks 16-21 post-
10 challenge. The cause of death was essentially unrelated to the HEV infection. At 21 weeks post challenge, cyno #9327 showed slowly declining antibody directed to ORF2; endpoint titers have only varied 2-fold. At 21 weeks post challenge, #9330 had no measurable antibody to ORF3 and the the antibody titer to ORF2 had dropped more than 20-fold.

For all of the vaccinated animals, ALT levels were near baseline for the duration of
15 the study. There was no detection of antigen in the liver, nor were there any observed necroinflammatory changes (Table 6). In two of the immunized cynos, virus was not detected by RT-PCR in the feces; in one of the immunized cynos, viral shedding was delayed and in short duration. As there was no biochemical or histopathologic evidence for hepatocellular damage in any of the three immunized animals, vaccination seems to have conferred protection
20 against disease in all the cynos immunized with r62K.

F. EVIDENCE FOR "BREAKTHROUGH" HEPATITIS E INFECTION WITHOUT DISEASE.

The appearance of antibody directed to the ORF3 of HEV in cyno #9330, at six weeks post challenge, suggested that the animal was indeed infected with the challenge virus. This
25 observation was substantiated by the amnestic antibody response to ORF2. Viral shedding in the stool of cyno 9330 was detected by RT-PCR but was delayed in appearance and was of shorter duration relative to control animals (Table 6). Overall, these findings are consistent with breakthrough infection: limited and delayed viral replication in the absence of disease.

The partial protection against infection in cyno 9330 may be accounted for by the fact
30 that the animal had lower levels of anti-HEV prior to challenge. Nevertheless, in the absence of necro-inflammatory changes or biochemical evidence of hepatitis, it appears that hepatocellular damage and hepatitis were prevented by immunization.

EXAMPLE 11*In Vitro* HEV Infection and Neutralization

A. CELL CULTURE AND ANTIBODY PREPARATION.

Sera from unvaccinated and vaccinated cynos (described in Example 10) were tested 5 for potential neutralizing antibody using *in vitro* neutralization assays (see below). Weekly sera samples collected for 5 weeks prior to vaccination were combined to make a pre-bleed sera pool. Sera samples were collected on the day of challenge prior to inoculation of the animals with HEV.

Sera from the control group of three animals (cyno #9338, 9339, 9340) were pooled 10 prior to affinity purification of total immunoglobins (Igs) by protein G column chromatography (Perseptive Biosystems, Cambridge MA). Sera from vaccinated animals #9327 and 9330 were individually purified for Igs.

Purified IgG samples were concentrated by speed-vac centrifugation prior to use in the 15 *in vitro* neutralization assay. Equivalent amounts of ORF2 reactive antibody from each Ig pool were approximated by normalizing according to ELISA end-point titer against the ORF2 SG3 protein.

Normal primary cyno hepatocytes were isolated from liver wedge biopsy. Hepatocytes were plated at a density of 1×10^6 cells per ml in each well of collagen-coated 6-well plates. 20 *In vitro* culture of hepatocytes in a serum free medium (SFM) formulation supplemented with growth factors and hormones was as described (Example 2). Plated liver cells were inoculated six days post isolation with either a known infectious HEV inoculum or a pre-incubated mixture of test antibodies and virus stock.

The inoculum used for HEV challenge of the hepatocytes was infectious bile obtained from cyno 11708. This animal had been experimentally infected with a 10% stool suspension 25 from third passage stool, cyno #73 (HEV Burma strain, Bradley, *et al.*, 1987, Purdy, *et al.*, 1993).

Igs from each pre-bleed pool and challenge pool were incubated separately with the virus inoculum for 1 hr at 37°C with gentle shaking. Warm serum free media (SFM) was added to the antibody-virus mixture and used to inoculate the cultured hepatocytes. Complete 30 medium changes were performed after 24 hours and at 48 hour intervals. Duplicate wells of hepatocyte cultures were used to examine the potential neutralizing activity of each antibody preparation throughout the experiment.

RNA prepared from media and tissue culture cells was analyzed for the presence of positive and negative strand HEV RNA by the use of a strand-specific RT-PCR assay.

B. IN VITRO NEUTRALIZATION OF HEPATITIS E VIRUS BY SERUM ANTIBODIES FROM VACCINATED ANIMALS.

Total IgGs purified from unvaccinated and vaccinated cynos were examined for the presence of potentially neutralizing antibodies to HEV as just described. The data presented 5 in Figure 15 show the *in vitro* neutralization of Hepatitis E Virus by serum antibodies from vaccinated animals.

Sera from the control group of unvaccinated animals were pooled. RNA prepared from media and tissue culture cells harvested on day 14 post infection was analyzed for the presence of positive and negative strand HEV RNA by the use of a strand-specific RT-PCR assay.

10 IgGs (pre-bleed) obtained prior to vaccination for all cynos were incapable of blocking *in vitro* HEV infection (Figure 15, "pre-NV (non-vaccinated) cynos", "pre-CY9327" and "pre-CY-9330") as determined by positive strand PCR assay. The observed PCR product correlated with the amount of product observed for infected culture controls that were carried out in the absence of any IgGs.

15 Pooled IgGs from unvaccinated cynos (9338, 9339, 9340) at the time of challenge did not block the *in vitro* infection of the cultured hepatocytes (Figure 15, "challenge NV cynos"). Once again, the observed PCR products correlated with the amount of product observed for infected culture controls that were carried out in the absence of any IgGs.

IgGs taken at the time of challenge from two of the vaccinated cynos (cyno 9327, 9330) 20 appeared to have mounted a neutralizing immune response capable of completely blocking virus infection *in vitro* (Figure 15, "challenge CY9327" and "challenge CY9330"). By the positive strand RT-PCR readout, there were no detectable products thereby verifying the absence of HEV viral RNA and validating the neutralizing activity of these cyno antibodies.

In Figure 15: lanes designated "N" contained no sample; two hepatocyte control lanes 25 are shown, one from an "uninfected control" cell culture and the other from an "infected control" cell culture; the lane designated "spike" is a positive control to show the maximum possible signal that could be obtained from the inoculum itself; and the "RNA control" lanes were used for quantitation and evaluation of the RT-PCR reactions -- 1 fg positive strand RNA, 10 fg positive strand RNA and 100 fg negative strand RNA.

30 These observations strengthen the biochemical and histopathologic evidence that antibodies mounted in response to vaccination with the 62K antigen preparation neutralize the HEV virus and confers protection against infection and subsequent disease.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT:
 - (A) NAME: Genelabs Technologies, Inc.
 - (B) ADDRESS: 505 Penobscot Drive
 - (C) CITY: Redwood City
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) POSTAL CODE: 94063-4738
- (ii) TITLE OF INVENTION: HEPATITIS E VIRUS ANTIGENS AND USES THEREFOR
- (iii) NUMBER OF SEQUENCES: 31
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Dehlinger & Associates
 - (B) STREET: P.O. Box 60850
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 94306-0850
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Fabian, Gary R.
 - (B) REGISTRATION NUMBER: 33,875
 - (C) REFERENCE/DOCKET NUMBER: 4600-0293.41
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 324-0880
 - (B) TELEFAX: (415) 324-0960

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2049 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)
ORF-2
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATGCGCCCTC GGCCTATTTT GTTGCTGCTC CTCATGTTTT TGCCTATGCT GCCCGCGCCA	60
---	----

CCGGCCCGGTC AGCCGTCTGG CCGCCGTCGT GGGCGCGCA GCGGCGGTTTC CGGCGGTGGT	120
--	-----

TTCTGGGTG ACCGGGTTGA TTCTCAGCCC TTGCAATCC CCTATATTCA TCCAACCAAC	180
CCCTTCGCCC CCGATGTCAC CGCTGCGGCC GGGGCTGGAC CTCGTGTTCG CCAACCCGCC	240
CGACCACTCG GCTCCGCTTG GCGTGACCAAG GCCCAGCGCC CCGCCGTTGC CTCACGTCGT	300
AGACCTACCA CAGCTGGGGC CGCGCCGCTA ACCGCGGTGCTCCTCGGCTTCA TGACACCCCG	360
CCAGTGCCTG ATGTCGACTC CCGCGGCACCC ATCTTGCACCC GGCAGTATAA CCTATCAACA	420
TCTCCCTTA CCTCTTCCGT GGCCACCGGC ACTAACCTGG TTCTTATGC CGCCCTCTT	480
AGTCCGCTTT TACCCCTTA GGACGGCACC AATACCCATA TAATGCCAC GGAAGCTTCT	540
AATTATGCCCGTACGACCGGGT TGCCCGTGCACCAATCCGTT ACCGCCGCT GGTCCCCAAT	600
GCTGTGGCGC GTTACGCCAT CTCCATCTCA TTCTGCCAC AGACCACAC CACCCCGACG	660
TCCGTTGATA TGAATTCAAT AACCTCGACG GATGTTCGTA TTTTAGTCCA GCCCGGCATA	720
GCCTCTGAGC TTGTGATCCC AAGTGAGCGC CTACACTATC GTAACCAAGG CTGGCGCTCC	780
GTCGAGACCT CTGGGGTGGC TGAGGAGGAG GCTACCTCTG GTCTTGTAT GCTTTGCATA	840
CATGGCTCAC TCGTAAATTCTCTACTAAT ACACCCCTATA CCGGTGCCCT CGGGCTGTTG	900
GACTTTGCCCTTGAGCTTGA GTTTCGCAAC CTTACCCCCG GTAACACCAA TACGCCGGTC	960
TCCCCTTATT CCAGCACTGC TCGCCACCGC CTTCGTCGCG GTGCGGACGG GACTGCCGAG	1020
CTCACCAACCA CGGCTGCTAC CCGCTTATG AAGGACCTCT ATTTACTAG TACTAATGGT	1080
GTCGGTGAGA TCGGCCGCGG GATAGCCCTC ACCCTGTTCA ACCTTGCTGA CACTCTGCTT	1140
GGCGGCCTGC CGACAGAATT GATTCGTCG GCTGGTGGCC AGCTGTTCTA CTCCCGTCCC	1200
GTTGTCTCAG CCAATGGCGA GCCGACTGTT AAGTTGTATA CATCTGTAGA GAATGCTCAG	1260
CAGGATAAGG GTATTGCAAT CCCGCATGAC ATTGACCTCG GAGAATCTCG TGTGGTTATT	1320
CAGGATTATG ATAACCAACA TGAACAAGAT CGGCCGACGC CTTCTCCAGC CCCATCGCGC	1380
CCTTTCTCTG TCCTTCGAGC TAATGATGTG CTTTGGCTCT CTCTCACCGC TGCCGAGTAT	1440
GACCAGTCCA CTTATGGCTC TTCGACTGGC CCAGTTATG TTTCTGACTC TGTGACCTTG	1500
GTAAATGTTG CGACCGCGC GCAGGGCGTT GCCCGGTGCG TCGATTGGAC CAAGGTCACA	1560
CTTGACGGTC GCCCCCTCTC CACCATCCAG CAGTACTCGA AGACCTTCTT TGTCCCTGCCG	1620
CTCCGGGTA AGCTCTCTT CTGGGAGGCA GGCACAACTA AAGCCGGTA CCCTTATAAT	1680
TATAACACCA CTGCTAGCGA CCAACTGCTT GTCGAGAATG CGGCCGGCA CGGGTCGCT	1740
ATTTCCACTT ACACCACTAG CCTGGGTGCT GGTCCCGTCT CCATTCTGC GGTTGCCGTT	1800
TTAGCCCCCC ACTCTGCGCT AGCATTGCTT GAGGATACCT TGGACTACCC TGCCCGCGCC	1860
CATACTTTG ATGATTTCTG CCCAGAGTGC CGCCCCCTTG GCCTTCAGGG CTGCGCTTTC	1920
CAGTCTACTG TCGCTGAGCT TCAGCGCCTT AAGATGAAGG TGGTAAAAC TCGGGAGTTG	1980
TAGTTTATTT GCTTGTGCCCG CCCTTCTTTC TGTTGCTTAT TTCTCATTTC TGCGTTCCGC	2040
GCTCCCTGA	2049

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2058 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
 (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico Strain)
 ORF-2 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGCGCCCTA	GGCCTCTTT	GCTGTTGTT	CTCTTGTTC	TGCCTATGTT	GCCCCGCCA	60
CCGACCGGTC	AGCCGCTCTGG	CCGCCGTCGT	GGGCGGCGCA	GCGCGGGTAC	CGGCGGTGGT	120
TTCTGGGTG	ACCGGGTTGA	TTCTCAGCCC	TTCGCAATCC	CCTATATTCA	TCCAACCAAC	180
CCCTTTGCC	CAGACGTTGC	CGCTGCGTCC	GGGTCTGGAC	CTCGCCTTCG	CCAACCAGCC	240
CGGCCACTTG	GCTCCACTTG	GCGAGATCAG	GCCCAGCGCC	CCTCCGCTGC	CTCCCGTCGC	300
CGACCTGCCA	CAGCCGGGGC	TGCGGCGCTG	ACGGCTGTGG	CGCCTGCCA	TGACACCTCA	360
CCCGTCCC	ACGTTGATT	TCGGCGTGA	ATTCTACGCC	CCCAGTATAA	TTTGTCTACT	420
TCACCCCTGA	CATCCTCTGT	GGCCTCTGGC	ACTAATTAG	TCCTGTATGC	AGCCCCCCTT	480
AATCCGCCTC	TGCCGCTGCA	GGACGGTACT	AATACTCACA	TTATGGCCAC	AGAGGCCTCC	540
AATTATGCAC	AGTACCGGGT	TGCCCGCGCT	ACTATCCGTT	ACCGGCCCC	AGTGCCTAAT	600
GCAGTTGGAG	GCTATGCTAT	ATCCATTCT	TTCTGGCCTC	AAACAACCAC	AACCCCTACA	660
TCTGTTGACA	TGAATTCCAT	TACTTCCACT	GATGTCAGGA	TTCTTGTCA	ACCTGGCATA	720
GCATCTGAAT	TGGTCATCCC	AAGCGAGCGC	CTTCACTACC	GCAATCAAGG	TTGGCGCTCG	780
GTTGAGACAT	CTGGTGGTGC	TGAGGAGGAA	GCCACCTCCG	GTCTTGTCA	GTTATGCATA	840
CATGGCTCTC	CAGTTAACTC	CTATACCAAT	ACCCCTTATA	CCGGTGCCCT	TGGCTTACTG	900
GACTTTGCCT	TAGAGCTTGA	GTTCGCAAT	CTCACCCACCT	GTAACACCAA	TACACGTGTG	960
TCCCGTTACT	CCAGCACCGC	CCGTCACCGG	CTCCGCCGAG	GGGCGACGG	GACTGCGGAG	1020
CTGACCACAA	CTGCAGCCAC	CAGGTTCATG	AAAGATCTCC	ACTTTACCGG	CCTTAATGGG	1080
GTAGGTGAAG	TCGGCCGCGG	GATAGCTCTA	ACATTACTTA	ACCTTGCTGA	CACGCTCCTC	1140
GGCGGGCTCC	CGACAGAATT	AATTCGTCC	GCTGGCGGGC	AACTGTTTA	TTCCCGCCCG	1200
GTTGTCTCAG	CCAATGGCGA	GCCAACCGTG	AAGCTCTATA	CATCAGTGGA	GAATGCTCAG	1260
CAGGATAAGG	GTGTTGCTAT	CCCCCACGAT	ATCGATCTTG	GTGATTGCGG	TGTGGTCATT	1320
CAGGATTATG	ACAACCAGCA	TGAGCAGGAT	CGGCCACCC	CGTCGCCTGC	GCCATCTCGG	1380
CCTTTTCTG	TTCTCCGAGC	AAATGATGTA	CTTGGCTGT	CCCTCACTGC	AGCCGAGTAT	1440
GACCAGTCCA	CTTACGGGTC	GTCAACTGGC	CCGGTTATA	TCTCGGACAG	CGTGACTTTG	1500
GTGAATGTTG	CGACTGGCGC	GCAGGCCGTA	GCCCCATCGC	TTGACTGGTC	CAAAGTCACC	1560

CTCGACGGGC GGCCCCCTCCC GACTGTTGAG CAATATTCCA AGACATTCTT TGTGCTCCCC	1620
CTTCGTTGGCA AGCTCTCCTT TTGGGAGGCC GGCACAACAA AAGCAGGTTA TCCTTATAAT	1680
TATAATACTA CTGCTAGTGA CCAGATTCTG ATTGAAAATG CTGCCGGCCA TCGGGTGC	1740
ATTTCAACCT ATACCACCAAG GCTTGGGCC GGTCCGGTCG CCATTCTGC GGCGCGGTT	1800
TTGGCTCCAC GCTCCGCCCT GGCTCTGCTG GAGGATACTT TTGATTATCC GGGCGGGCG	1860
CACACATTTG ATGACTTCTG CCCTGAATGC CGCGCTTTAG GCCTCCAGGG TTGTGCTTC	1920
CAGTCAACTG TCGCTGAGCT CCAGGCCTT AAAGTTAAGG TGGGTAAAAC TCGGGAGTTG	1980
TAGTTTATTT GGCTGTGCC ACCTACTTAT ATCTGCTGAT TTCCCTTATT TCCTTTTCT	2040
CGGTCCCGCG CTCCCTGA	2058

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1647 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Hepatitis E virus (Burma) r62kDa,
FIGURE 2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCGGTGCTC CGGCCATGA CACCCGCCA GTGCCTGATG TCGACTCCCG CGGGGCCATC	60
TTGCGCCGGC AGTATAACCT ATCAACATCT CCCCTTACCT CTTCCGTGGC CACCGGCACT	120
AACCTGGTTC TTTATGCCGC CCCTCTTAGT CCGCTTTAC CCCTTCAGGA CGGCACCAAT	180
ACCCATATAA TGGCCACGGA AGCTTCTAAT TATGCCAGT ACCGGGTTGC CCGTGCCACA	240
ATCCGTTACC GCCCGCTGGT CCCCAATGCT GTCGGCGGTT ACGCCATCTC CATCTCATTC	300
TGGCCACAGA CCACCAACCAC CCCGACGTCC GTTGATATGA ATTCAATAAC CTCGACGGAT	360
GTTCGTATTT TAGTCCAGCC CGGCATAGCC TCTGAGCTTG TGATCCAAG TGAGCGCCTA	420
CACTATCGTA ACCAAGGCTG GCGCTCCGTC GAGACCTCTG GGGTGGCTGA GGAGGAGGCT	480
ACCTCTGGTC TTGTTATGCT TTGCATACAT GGCTCACTCG TAAATTCTA TACTAATACA	540
CCCTATACCG GTGCCCTCGG GCTGTTGGAC TTTGCCCTTG AGCTTGAGTT TCGAACCTT	600
ACCCCCGGTA ACACCAATAC GCGGGCTCC CGTTATTCCA GCACTGCTCG CCACCGCCTT	660
CGTCGCGGTG CGGACGGGAC TGCCGAGCTC ACCACCACGG CTGCTACCCG CTTTATGAAG	720
GACCTCTATT TTACTAGTAC TAATGGTGTGTC GGTGAGATCG GCCGGGGAT AGCCCTCACC	780
CTGTTCAACC TTGCTGACAC TCTGCTTGGC GCCCTGCCGA CAGAATTGAT TTCGTCGGCT	840
GGTGGCCAGC TGTTCTACTC CCGTCCCGTT GTCTCAGCCA ATGGCGAGCC GACTGTTAAG	900

TTGTATACAT CTGTAGAGAA TGCTCAGCAG GATAAGGGTA TTGCAATCCC GCATGACATT	960
GACCTCGGAG AATCTCGTGT GGTATTACAG GATTATGATA ACCAACATGA ACAAGATCGG	1020
CCGACGCCCT CTCCAGCCCC ATCGCGCCCT TTCTCTGTCC TTGAGCTAA TGATGTGCTT	1080
TGGCTCTCTC TCACCGCTGC CGAGTATGAC CAGTCCACTT ATGGCTCTTC GACTGGCCCA	1140
GTTTATGTTT CTGACTCTGT GACCTTGGTT AATGTTGCGA CCGGCGCGCA GCCCGTTGCC	1200
CGGTCGCTCG ATTGGACCAA GGTCACACTT GACGGTCGCC CCCTCTCCAC CATCCAGCAG	1260
TACTCGAAGA CCTTCTTGT CCTGCCGCTC CGCGGTAAGC TCTCTTCTG GGAGGCAGGC	1320
ACAACAAAG CCGGGTACCC TTATAATTAT AACACCACTG CTAGCGACCA ACTGCTTGTC	1380
GAGAATGCCG CCGGGCACCG GGTCGCTATT TCCACTTACA CCACTAGCCT GGGTGCTGGT	1440
CCCGTCTCCA TTTCTGCGGT TGCGTTTTA GCCCCCCACT CTGCGCTAGC ATTGCTTGAG	1500
GATACCTTGG ACTACCCCTGC CCGCGCCCAT ACTTTGATG ATTTCTGCC AGAGTGCCGC	1560
CCCCTTGGCC TTCAGGGCTG CGCTTCCAG TCTACTGTG CTGAGCTTCA GCGCCTTAAG	1620
ATGAAGGTGG GTAAAACCTCG GGAGTTG	1647

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1647 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E virus (Mexico strain)
 r62kDa, FIGURE 2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: GCTGTGGCGC CTGCCATGA CACCTCACCC GTCCGGACG TTGATTCTCG CGGTGCAATT	60
CTACGCCGCC AGTATAATTT GTCTACTTCA CCCCTGACAT CCTCTGTGGC CTCTGGCACT	120
AATTTAGTCC TGTATGCAGC CCCCCTTAAC CCGCCTCTGC CGCTGCAGGA CGGTACTAAT	180
ACTCACATTA TGGCCACAGA GGCCCTAAC TATGCACAGT ACCGGGTTGC CCGCGCTACT	240
ATCCGTTACC GGCCCCTAGT GCCTAATGCA GTTGGAGGCT ATGCTATATC CATTCTTTC	300
TGGCCTAAA CAACCACAAAC CCCTACATCT GTTGACATGA ATTCCATTAC TTCCACTGAT	360
GTCAGGATTC TTGTTCAACC TGGCATAGCA TCTGAATTGG TCATCCCAAG CGAGGCCTT	420
CACTACCGCA ATCAAGGTTG GCGCTCGGTT GAGACATCTG GTGTTGCTGA GGAGGAAGCC	480
ACCTCCGGTC TTGTCATGTT ATGCATACAT GGCTCTCCAG TTAACCTCTA TACCAATACC	540
CCTTATACCG GTGCCCTTGG CTTACTGGAC TTTGCCTTAG AGCTTGAGTT TCGCAATCTC	600
ACCACCTGTA ACACCAATAC ACGTGTGTCC CGTTACTCCA GCACGGCCCG TCACCGGCTC	660
CGCCGAGGGGG CCGACGGGAC TGGGAGCTG ACCACAACTG CAGCCACCAAG GTTCATGAAA	720

GATCTCCACT TTACCGGCCT TAATGGGTA GGTGAAGTCG GCCGCGGAT AGCTCTAAC	780
TTACTTAACC TTGCTGACAC GCTCCTCGGC GGGCTCCCGA CAGAATTAAT TTGCTCGGCT	840
GGCGGGCAAC TGTTTATTC CGGCCGGTT GTCTCAGCCA ATGGCGAGCC AACCGTGAAG	900
CTCTATACAT CAGTGGAGAA TGCTCAGCAG GATAAGGGTG TTGCTATCCC CCACGATATC	960
GATCTTGGTG ATTGCGGTGT GGTCATTAG GATTATGACA ACCAGCATGA GCAGGATCGG	1020
CCCACCCCGT CGCCTGCGCC ATCTCGGCCT TTTTCTGTTG TCCGAGCAA TGATGTACTT	1080
TGGCTGTCCC TCACTGCAGC CGAGTATGAC CAGTCCACTT ACGGGTCGTC AACTGGCCCG	1140
GTTTATATCT CGGACAGCGT GACTTGGTG AATGTTGCGA CTGGCGCGCA GGCGTAGCC	1200
CGATCGCTTG ACTGGTCCAA AGTCACCCCTC GACGGGCGGC CCCTCCCGAC TGTTGAGCAA	1260
TATTCCAAGA CATTCTTTGT GCTCCCCCTT CGTGGCAAGC TCTCCTTTG GGAGGCCGGC	1320
ACAACAAAAG CAGGTTATCC TTATAATTAT AATACTACTG CTAGTGACCA GATTCTGATT	1380
GAAAATGCTG CCGGCCATCG GGTCGCCATT TCAACCTATA CCACCAGGCT TGGGGCCGGT	1440
CCGGTCGCCA TTTCTGCGGC CGCGGTTTG GCTCCACGCT CCGCCCTGGC TCTGCTGGAG	1500
GATACTTTG ATTATCCGGG GCGGGCGCAC ACATTGATG ACTTCTGCC C TGAATGCCGC	1560
GCTTTAGGCC TCCAGGGTTG TGCTTCCAG TCAACTGTGCTG CTGAGCTCCA GCGCCTTAAA	1620
GTAAAGGTGG GTAAAACCTCG GGAGTTG	1647

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 984 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain) SG3 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GGTGC GGACG GGACTGCCGA GCTCACCA ACCGGCTGCTA CCCGCTTTAT GAAGGACCTC	60
TATTTTACTA GTACTAATGG TGTCGGTGAG ATCGGCCGCG GGATAGCCCT CACCCCTGTT	120
AACCTTGCTG ACACTCTGCT TGGCGGCCTG CCGACAGAAAT TGATTCGTC GGCTGGTGGC	180
CAGCTTTCT ACTCCCGTCC CGTTGTCTCA GCCAATGGCG AGCCGACTGT TAAGTTGTAT	240
ACATCTGTAG AGAATGCTCA GCAGGATAAG GGTATTGCAA TCCCGCATGA CATTGACCTC	300
GGAGAACTC GTGTGGTTAT TCAGGATTAT GATAACCAAC ATGAACAAAGA TCGGCCGACG	360
CCTCTCCAG CCCCATCGCG CCCTTCTCT GTCTTCTCGAG CTAATGATGT GCTTTGGCTC	420
TCTCTCACCG CTGCCGAGTA TGACCAGTCC ACTTATGGCT CTTCGACTGG CCCAGTTAT	480

GTTCCTGACT CTGTGACCTT GGTTAATGTT GCGACCGCG CGCAGGCCGT TGCCCGTCTG	540
CTCGATTGGA CCAAGGTCAC ACTTGACGGT CGCCCCCTCT CCACCATCCA GCAGTACTCG	600
AAGACCTTCT TTGTCCTGCC GCTCCGCGGT AAGCTCTCTT TCTGGGAGGC AGGCACAACT	660
AAAGCCGGGT ACCCTTATAA TTATAACACC ACTGCTAGCG ACCAACTGCT TGTCGAGAAT	720
GCCGCCGGGC ACCGGGTCGC TATTTCACACT TACACCACTA GCCTGGGTGC TGGTCCCGTC	780
TCCATTTCTG CGGTTGCCGT TTTAGCCCC CACTCTGCGC TAGCATTGCT TGAGGATACC	840
TTGGACTACC CTGCCCGCGC CCATACTTTT GATGATTCT GCCCAGAGTG CCGCCCCCTT	900
GGCCTTCAGG GCTGCGCTTT CCAGTCTACT GTCGCTGAGC TTCAGCGCCT TAAGATGAAG	960
GTTGGTAAAAA CTCGGGAGTT GTAG	984

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 984 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
 (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico strain) SG3
 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

GGGGCCGACG GGACTGCGGA GCTGACCACA ACTGCAGCCA CCAGGTTCAT GAAAGATCTC	60
CACTTTACCG GCCTTAATGG GGTAGGTGAA GTCGGCCGCG GGATAGCTCT AACATTACTT	120
AACCTTGCTG ACACGCTCCT CGGCGGGCTC CCGACAGAAAT TAATTTGTC GGCTGGCGGG	180
CAACTGTTT ATTCCCGCCC GGTTGTCTCA GCCAATGGCG AGCCAACCGT GAAGCTCTAT	240
ACATCAGTGG AGAATGCTCA GCAGGATAAG GGTGTTGCTA TCCCCCACGA TATCGATCTT	300
GGTGATTGCGC GTGTGGTCAT TCAGGATTAT GACAACCAGC ATGAGCAGGA TCGGCCACC	360
CCGTCGCTG CGCCATCTCG GCCTTTTCT GTTCTCCGAG CAAATGATGT ACTTTGGCTG	420
TCCCTCACTG CAGCCGAGTA TGACCAGTCC ACTTACGGGT CGTCAACTGG CCCGGTTTAT	480
ATCTCGGACA GCGTGACTTT GGTGAATGTT GCGACTGGCG CGCAGGCCGT AGCCCGATCG	540
CTTGACTGGT CCAAAGTCAC CCTCGACGGG CGGCCCTCC CGACTGTTGA GCAATATTCC	600
AAGACATTCT TTGTGCTCCC CCTTCGTGGC AAGCTCTCCT TTTGGGAGGC CGGCACAAACA	660
AAAGCAGGTT ATCCTTATAA TTATAATACT ACTGCTAGTG ACCAGATTCT GATTGAAAAT	720
GCTGCCGGCC ATCGGGTCGC CATTCAACC TATACCACCA GGCTGGGGC CGGTCCGGTC	780
GCCATTCTG CGGCGCGGGT TTGGCTCCA CGCTCCGCC TGGCTCTGCT GGAGGATACT	840
TTTGATTATC CGGGCGGGC GCACACATT GATGACTTCT GCCCTGAATG CCGCGCTTTA	900

GGCCTCCAGG GTTGTGCTTT CCAGTCAACT GTCGCTGAGC TCCAGGCCT TAAAGTTAAG 960
 GTGGGTAAAAA CTCGGGAGTT GTAG 984

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 147 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)
406.3-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ACCTTGGACT ACCCTGCCCG CGCCCATACT TTTGATGATT TCTGCCAGA GTGCCGCC 60
 CTTGGCCTTC AGGGCTGCGC TTTCCAGTCT ACTGTCGCTG AGCTTCAGCG CCTTAAGATG 120
 AAGGTGGGTA AAACTCGGGA GTTGTAG 147

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 147 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico strain)
406.3-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ACTTTTGATT ATCCGGGGCG GGCGCACACA TTTGATGACT TCTGCCCTGA ATGCCCGC 60
 TTAGGCCTCC AGGGTTGTGC TTTCCAGTCA ACTGTCGCTG AGCTCCAGCG CCTTAAAGTT 120
 AAGGTGGGTA AAACTCGGGA GTTGTAG 147

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 372 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma Strain)
ORF-3 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATGAATAACA TGTCTTTGC TGCGCCCATG GGTCGCGAC CATGCGCCCT CGGCCTATTT	60
TGTTGCTGCT CCTCATGTTT TTGCCTATGC TGCCCGCGCC ACCGCCCCGT CAGCCGTCTG	120
GCCGCCGTGCG TGGGCGGCAGC AGCGGCGGTT CCGGCGGTGG TTTCTGGGGT GACCGGGTTG	180
ATTCTCAGCC CTTCGCAATC CCCTATATTC ATCCAACCAA CCCCTTCGCC CCCGATGTCA	240
CCGCTGCGGC CGGGGCTGGA CCTCGTGTTC GCCAACCGC CCGACCACTC GGCTCCGCTT	300
GGCGTGACCA GGCCCAGCGC CCCGCCGTTG CCTCACGTCG TAGACCTACC ACAGCTGGGG	360
CCGCGCCGCT AA	372

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 372 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico Strain)
ORF-3 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

ATGAATAACA TGTGGTTTGC TGCGCCCATG GGTCGCCAC CATGCGCCCT AGGCCTCTTT	60
TGCTGTTGTT CCTCTTGTGTT CTGCCTATGT TGCCCGCGCC ACCGACCGGT CAGCCGTCTG	120
GCCGCCGTGCG TGGGCGGCAGC AGCGGCGGTA CCGGCGGTGG TTTCTGGGGT GACCGGGTTG	180
ATTCTCAGCC CTTCGCAATC CCCTATATTC ATCCAACCAA CCCCTTGCC CCAGACGTTG	240
CCGCTGCGTC CGGGTCTGGA CCTCGCCTTC GCCAACCAAGC CCGGCCACTT GGCTCCACTT	300
GGCGAGATCA GGCCCAGCGC CCCCTCGCTG CCTCCCGTCG CCGACCTGCC ACAGCCGGGG	360
CTGCGCGCT GA	372

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 99 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)

406.4-2 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GCCAACCCGC CCGACCACTC GGCTCCGCTT GGC GTGACCA GGCCCAGCGC CCCGCCGTG	60
CCTCACGTCG TAGACCTACC ACAGCTGGGG CCGCGCCGC	99

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 99 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico strain)
406.4-2 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

GCCAACCAGC CGGGCCACTT GGCTCCACTT GGC GAGATCA GGCCCAGCGC CCCTCCGCTG	60
CCTCCCGTCG CCGACCTGCC ACAGCCGGGG CTGCGGCC	99

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 660 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)
ORF-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Arg Pro Arg Pro Ile Leu Leu Leu Leu Met Phe Leu Pro Met			
1	5	10	15

Leu Pro Ala Pro Pro Pro Gly Gln Pro Ser Gly Arg Arg Gly Arg		
20	25	30

Arg Ser Gly Gly Ser Gly Gly Phe Trp Gly Asp Arg Val Asp Ser		
35	40	45

Gln Pro Phe Ala Ile Pro Tyr Ile His Pro Thr Asn Pro Phe Ala Pro		
50	55	60

Asp Val Thr Ala Ala Ala Gly Ala Gly Pro Arg Val Arg Gln Pro Ala		
65	70	80

Arg Pro Leu Gly Ser Ala Trp Arg Asp Gln Ala Gln Arg Pro Ala Val		
85	90	95

Ala Ser Arg Arg Arg Pro Thr Thr Ala Gly Ala Ala Pro Leu Thr Ala
 100 105 110
 Val Ala Pro Ala His Asp Thr Pro Pro Val Pro Asp Val Asp Ser Arg
 115 120 125
 Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu Thr
 130 135 140
 Ser Ser Val Ala Thr Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro Leu
 145 150 155 160
 Ser Pro Leu Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met Ala
 165 170 175
 Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr Ile
 180 185 190
 Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile Ser
 195 200 205
 Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp Met
 210 215 220
 Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly Ile
 225 230 235 240
 Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn Gln
 245 250 255
 Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Glu Ala Thr
 260 265 270
 Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Leu Val Asn Ser Tyr
 275 280 285
 Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala Leu
 290 295 300
 Glu Leu Glu Phe Arg Asn Leu Thr Pro Gly Asn Thr Asn Thr Arg Val
 305 310 315 320
 Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala Asp
 325 330 335
 Gly Thr Ala Glu Leu Thr Thr Ala Ala Thr Arg Phe Met Lys Asp
 340 345 350
 Leu Tyr Phe Thr Ser Thr Asn Gly Val Gly Glu Ile Gly Arg Gly Ile
 355 360 365
 Ala Leu Thr Leu Phe Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu Pro
 370 375 380
 Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg Pro
 385 390 395 400
 Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser Val
 405 410 415
 Glu Asn Ala Gln Gln Asp Lys Gly Ile Ala Ile Pro His Asp Ile Asp
 420 425 430
 Leu Gly Glu Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His Glu
 435 440 445
 Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser Val

80

450	455	460	
Leu Arg Ala Asn Asp Val	Leu Trp Leu Ser	Leu Thr Ala Ala Glu Tyr	
465	470	475	480
Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly	Pro Val Tyr Val Ser Asp		
485	490	495	
Ser Val Thr Leu Val Asn Val Ala Thr Gly	Ala Gln Ala Val Ala Arg		
500	505	510	
Ser Leu Asp Trp Thr Lys Val Thr Leu Asp Gly Arg	Pro Leu Ser Thr		
515	520	525	
Ile Gln Gln Tyr Ser Lys Thr Phe Phe Val Leu	Pro Leu Arg Gly Lys		
530	535	540	
Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys	Ala Gly Tyr Pro Tyr Asn		
545	550	555	560
Tyr Asn Thr Thr Ala Ser Asp Gln Leu	Leu Val Glu Asn Ala Ala Gly		
565	570	575	
His Arg Val Ala Ile Ser Thr Tyr Thr Ser Leu	Gly Ala Gly Pro		
580	585	590	
Val Ser Ile Ser Ala Val Ala Val	Leu Ala Pro His Ser Ala Leu Ala		
595	600	605	
Leu Leu Glu Asp Thr Leu Asp Tyr Pro Ala Arg	Ala His Thr Phe Asp		
610	615	620	
Asp Phe Cys Pro Glu Cys Arg Pro Leu Gly	Leu Gln Gly Cys Ala Phe		
625	630	635	640
Gln Ser Thr Val Ala Glu Leu Gln Arg	Leu Lys Met Lys Val Gly Lys		
645	650	655	
Thr Arg Glu Leu			
660			

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 660 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico Strain)
ORF-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Arg Pro Arg Pro Leu	Leu Leu Leu Phe Leu	Leu Pro Met	
1	5	10	15

Leu Pro Ala Pro Pro Thr Gly	Gln Pro Ser Gly Arg Arg	Gly Arg
20	25	30

Arg Ser Gly Gly Thr Gly	Gly Phe Trp Gly Asp Arg	Val Asp Ser
35	40	45

Gln Pro Phe Ala Ile Pro Tyr Ile His Pro Thr Asn Pro Phe Ala Pro
 50 55 60
 Asp Val Ala Ala Ala Ser Gly Ser Gly Pro Arg Leu Arg Gln Pro Ala
 65 70 75 80
 Arg Pro Leu Gly Ser Thr Trp Arg Asp Gln Ala Gln Arg Pro Ser Ala
 85 90 95
 Ala Ser Arg Arg Arg Pro Ala Thr Ala Gly Ala Ala Ala Leu Thr Ala
 100 105 110
 Val Ala Pro Ala His Asp Thr Ser Pro Val Pro Asp Val Asp Ser Arg
 115 120 125
 Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu Thr
 130 135 140
 Ser Ser Val Ala Ser Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro Leu
 145 150 155 160
 Asn Pro Pro Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met Ala
 165 170 175
 Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr Ile
 180 185 190
 Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile Ser
 195 200 205
 Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp Met
 210 215 220
 Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly Ile
 225 230 235 240
 Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn Gln
 245 250 255
 Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Ala Thr
 260 265 270
 Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Pro Val Asn Ser Tyr
 275 280 285
 Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala Leu
 290 295 300
 Glu Leu Glu Phe Arg Asn Leu Thr Thr Cys Asn Thr Asn Thr Arg Val
 305 310 315 320
 Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala Asp
 325 330 335
 Gly Thr Ala Glu Leu Thr Thr Ala Ala Thr Arg Phe Met Lys Asp
 340 345 350
 Leu His Phe Thr Gly Leu Asn Gly Val Gly Glu Val Gly Arg Gly Ile
 355 360 365
 Ala Leu Thr Leu Leu Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu Pro
 370 375 380
 Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg Pro
 385 390 395 400
 Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser Val

405	410	415
Glu Asn Ala Gln Gln Asp Lys Gly Val Ala Ile Pro His Asp Ile Asp		
420	425	430
Leu Gly Asp Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His Glu		
435	440	445
Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser Val		
450	455	460
Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu Tyr		
465	470	475
Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Ile Ser Asp		
485	490	495
Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala Val Ala Arg		
500	505	510
Ser Leu Asp Trp Ser Lys Val Thr Leu Asp Gly Arg Pro Leu Pro Thr		
515	520	525
Val Glu Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu Arg Gly Lys		
530	535	540
Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr Pro Tyr Asn		
545	550	555
Tyr Asn Thr Thr Ala Ser Asp Gln Ile Leu Ile Glu Asn Ala Ala Gly		
565	570	575
His Arg Val Ala Ile Ser Thr Tyr Thr Arg Leu Gly Ala Gly Pro		
580	585	590
Val Ala Ile Ser Ala Ala Ala Val Leu Ala Pro Arg Ser Ala Leu Ala		
595	600	605
Leu Leu Glu Asp Thr Phe Asp Tyr Pro Gly Arg Ala His Thr Phe Asp		
610	615	620
Asp Phe Cys Pro Glu Cys Arg Ala Leu Gly Leu Gln Gly Cys Ala Phe		
625	630	635
Gln Ser Thr Val Ala Glu Leu Gln Arg Leu Lys Val Lys Val Gly Lys		
645	650	655
Thr Arg Glu Leu		
660		

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 549 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL ISOLATE: Hepatitis E virus (Burma strain)
r62kDa, FIGURE 4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Ala Val Ala Pro Ala His Asp Thr Pro Pro Val Pro Asp Val Asp Ser
 1 5 10 15

Arg Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu
 20 25 30

Thr Ser Ser Val Ala Thr Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro
 35 40 45

Leu Ser Pro Leu Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met
 50 55 60

Ala Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr
 65 70 75 80

Ile Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile
 85 90 95

Ser Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp
 100 105 110

Met Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly
 115 120 125

Ile Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn
 130 135 140

Gln Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Glu Ala
 145 150 155 160

Thr Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Leu Val Asn Ser
 165 170 175

Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala
 180 185 190

Leu Glu Leu Glu Phe Arg Asn Leu Thr Pro Gly Asn Thr Asn Thr Arg
 195 200 205

Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala
 210 215 220

Asp Gly Thr Ala Glu Leu Thr Thr Thr Ala Ala Thr Arg Phe Met Lys
 225 230 235 240

Asp Leu Tyr Phe Thr Ser Thr Asn Gly Val Gly Glu Ile Gly Arg Gly
 245 250 255

Ile Ala Leu Thr Leu Phe Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu
 260 265 270

Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg
 275 280 285

Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser
 290 295 300

Val Glu Asn Ala Gln Gln Asp Lys Gly Ile Ala Ile Pro His Asp Ile
 305 310 315 320

Asp Leu Gly Glu Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His
 325 330 335

Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser
 340 345 350

Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu
 355 360 365

Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Val Ser
 370 375 380

Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala Val Ala
 385 390 395 400

Arg Ser Leu Asp Trp Thr Lys Val Thr Leu Asp Gly Arg Pro Leu Ser
 405 410 415

Thr Ile Gln Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu Arg Gly
 420 425 430

Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr Pro Tyr
 435 440 445

Asn Tyr Asn Thr Thr Ala Ser Asp Gln Leu Leu Val Glu Asn Ala Ala
 450 455 460

Gly His Arg Val Ala Ile Ser Thr Tyr Thr Thr Ser Leu Gly Ala Gly
 465 470 475 480

Pro Val Ser Ile Ser Ala Val Ala Val Leu Ala Pro His Ser Ala Leu
 485 490 495

Ala Leu Leu Glu Asp Thr Leu Asp Tyr Pro Ala Arg Ala His Thr Phe
 500 505 510

Asp Asp Phe Cys Pro Glu Cys Arg Pro Leu Gly Leu Gln Gly Cys Ala
 515 520 525

Phe Gln Ser Thr Val Ala Glu Leu Gln Arg Leu Lys Met Lys Val Gly
 530 535 540

Lys Thr Arg Glu Leu
 545

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 549 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E virus (Mexico strain)
 r62kDa, FIGURE 4

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Ala Val Ala Pro Ala His Asp Thr Ser Pro Val Pro Asp Val Asp Ser
 1 5 10 15

Arg Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu
 20 25 30

Thr Ser Ser Val Ala Ser Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro
 35 40 45

Leu Asn Pro Pro Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met
 50 55 60

Ala Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr
 65 70 75 80

Ile Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile
 85 90 95

Ser Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp
 100 105 110

Met Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly
 115 120 125

Ile Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn
 130 135 140

Gln Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Glu Ala
 145 150 155 160

Thr Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Pro Val Asn Ser
 165 170 175

Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala
 180 185 190

Leu Glu Leu Glu Phe Arg Asn Leu Thr Thr Cys Asn Thr Asn Thr Arg
 195 200 205

Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala
 210 215 220

Asp Gly Thr Ala Glu Leu Thr Thr Ala Ala Thr Arg Phe Met Lys
 225 230 235 240

Asp Leu His Phe Thr Gly Leu Asn Gly Val Gly Glu Val Gly Arg Gly
 245 250 255

Ile Ala Leu Thr Leu Leu Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu
 260 265 270

Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg
 275 280 285

Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser
 290 295 300

Val Glu Asn Ala Gln Gln Asp Lys Gly Val Ala Ile Pro His Asp Ile
 305 310 315 320

Asp Leu Gly Asp Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His
 325 330 335

Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser
 340 345 350

Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu
 355 360 365

Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Ile Ser
 370 375 380

Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala Val Ala
 385 390 395 400

Arg Ser Leu Asp Trp Ser Lys Val Thr Leu Asp Gly Arg Pro Leu Pro

405	410	415
Thr Val Glu Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu Arg Gly		
420	425	430
Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr Pro Tyr		
435	440	445
Asn Tyr Asn Thr Thr Ala Ser Asp Gln Ile Leu Ile Glu Asn Ala Ala		
450	455	460
Gly His Arg Val Ala Ile Ser Thr Tyr Thr Thr Arg Leu Gly Ala Gly		
465	470	475
Pro Val Ala Ile Ser Ala Ala Ala Val Leu Ala Pro Arg Ser Ala Leu		
485	490	495
Ala Leu Leu Glu Asp Thr Phe Asp Tyr Pro Gly Arg Ala His Thr Phe		
500	505	510
Asp Asp Phe Cys Pro Glu Cys Arg Ala Leu Gly Leu Gln Gly Cys Ala		
515	520	525
Phe Gln Ser Thr Val Ala Glu Leu Gln Arg Leu Lys Val Lys Val Gly		
530	535	540
Lys Thr Arg Glu Leu		
545		

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 327 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain) SG3 region

(N1) SEQUENCE DESCRIPTION: SEQ ID NO:17.

1	5	10	15
Met Lys Asp Leu Tyr Phe Thr Ser Thr Asn Gly Val Gly Glu Ile Gly			
20	25	30	
Arg Gly Ile Ala Leu Thr Leu Phe Asn Leu Ala Asp Thr Leu Leu Gly			
35	40	45	
Gly Leu Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr			
50	55	60	
Ser Arg Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr			
65	70	75	80
Thr Ser Val Glu Asn Ala Gln Gln Asp Lys Gly Ile Ala Ile Pro His			
85	90	95	
Asp Ile Asp Leu Gly Glu Ser Arg Val Val Ile Gln Asp Tyr Asp Asn			
100	105	110	

Gln His Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro
 115 120 125
 Phe Ser Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala
 130 135 140
 Ala Glu Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr
 145 150 155 160
 Val Ser Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala
 165 170 175
 Val Ala Arg Ser Leu Asp Trp Thr Lys Val Thr Leu Asp Gly Arg Pro
 180 185 190
 Leu Ser Thr Ile Gln Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu
 195 200 205
 Arg Gly Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr
 210 215 220
 Pro Tyr Asn Tyr Asn Thr Thr Ala Ser Asp Gln Leu Leu Val Glu Asn
 225 230 235 240
 Ala Ala Gly His Arg Val Ala Ile Ser Thr Tyr Thr Ser Leu Gly
 245 250 255
 Ala Gly Pro Val Ser Ile Ser Ala Val Ala Val Leu Ala Pro His Ser
 260 265 270
 Ala Leu Ala Leu Leu Glu Asp Thr Leu Asp Tyr Pro Ala Arg Ala His
 275 280 285
 Thr Phe Asp Asp Phe Cys Pro Glu Cys Arg Pro Leu Gly Leu Gln Gly
 290 295 300
 Cys Ala Phe Gln Ser Thr Val Ala Glu Leu Gln Arg Leu Lys Met Lys
 305 310 315 320
 Val Gly Lys Thr Arg Glu Leu
 325

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 327 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
 (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico strain)
 SG3 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Gly Ala Asp Gly Thr Ala Glu Leu Thr Thr Thr Ala Ala Thr Arg Phe
 1 5 10 15

Met Lys Asp Leu His Phe Thr Gly Leu Asn Gly Val Gly Glu Val Gly
 20 25 30

Arg Gly Ile Ala Leu Thr Leu Leu Asn Leu Ala Asp Thr Leu Leu Gly

35

40

45

Gly Leu Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr
 50 55 60

Ser Arg Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr
 65 70 75 80

Thr Ser Val Glu Asn Ala Gln Gln Asp Lys Gly Val Ala Ile Pro His
 85 90 95

Asp Ile Asp Leu Gly Asp Ser Arg Val Val Ile Gln Asp Tyr Asp Asn
 100 105 110

Gln His Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro
 115 120 125

Phe Ser Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala
 130 135 140

Ala Glu Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr
 145 150 155 160

Ile Ser Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala
 165 170 175

Val Ala Arg Ser Leu Asp Trp Ser Lys Val Thr Leu Asp Gly Arg Pro
 180 185 190

Leu Pro Thr Val Glu Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu
 195 200 205

Arg Gly Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr
 210 215 220

Pro Tyr Asn Tyr Asn Thr Thr Ala Ser Asp Gln Ile Leu Ile Glu Asn
 225 230 235 240

Ala Ala Gly His Arg Val Ala Ile Ser Thr Tyr Thr Thr Arg Leu Gly
 245 250 255

Ala Gly Pro Val Ala Ile Ser Ala Ala Ala Val Leu Ala Pro Arg Ser
 260 265 270

Ala Leu Ala Leu Leu Glu Asp Thr Phe Asp Tyr Pro Gly Arg Ala His
 275 280 285

Thr Phe Asp Asp Phe Cys Pro Glu Cys Arg Ala Leu Gly Leu Gln Gly
 290 295 300

Cys Ala Phe Gln Ser Thr Val Ala Glu Leu Gln Arg Leu Lys Val Lys
 305 310 315 320

Val Gly Lys Thr Arg Glu Leu
 325

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)
406.4-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ala Asn Pro Pro Asp His Ser Ala Pro Leu Gly Val Thr Arg Pro Ser
1 5 10 15

Ala Pro Pro Leu Pro His Val Val Asp Leu Pro Gln Leu Gly Pro Arg
20 25 30

Arg

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 33 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico strain)
406.4-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Ala Asn Gln Pro Gly His Leu Ala Pro Leu Gly Glu Ile Arg Pro Ser
1 5 10 15

Ala Pro Pro Leu Pro Pro Val Ala Asp Leu Pro Gln Pro Gly Leu Arg
20 25 30

Arg

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 124 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma Strain)
ORF-3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Met Asn Asn Met Ser Phe Ala Ala Pro Met Gly Ser Arg Pro Cys Ala
1 5 10 15

Leu Gly Leu Phe Cys Cys Cys Ser Ser Cys Phe Cys Leu Cys Cys Pro
20 25 30

90

Arg	His	Arg	Pro	Val	Ser	Arg	Leu	Ala	Ala	Val	Val	Gly	Gly	Ala	Ala
35							40							45	
Ala	Val	Pro	Ala	Val	Val	Ser	Gly	Val	Thr	Gly	Leu	Ile	Leu	Ser	Pro
50							55				60				
Ser	Gln	Ser	Pro	Ile	Phe	Ile	Gln	Pro	Thr	Pro	Ser	Pro	Pro	Met	Ser
65							70				75			80	
Pro	Leu	Arg	Pro	Gly	Leu	Asp	Leu	Val	Phe	Ala	Asn	Pro	Pro	Asp	His
							85			90				95	
Ser	Ala	Pro	Leu	Gly	Val	Thr	Arg	Pro	Ser	Ala	Pro	Pro	Leu	Pro	His
							100			105			110		
Val	Val	Asp	Leu	Pro	Gln	Leu	Gly	Pro	Arg	Arg	Glx				
							115			120					

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 124 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico Strain)
ORF-3

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Met	Asn	Asn	Met	Trp	Phe	Ala	Ala	Pro	Met	Gly	Ser	Pro	Pro	Cys	Ala
1					5				10					15	
Leu	Gly	Leu	Phe	Cys	Cys	Cys	Ser	Ser	Cys	Phe	Cys	Leu	Cys	Cys	Pro
					20				25				30		
Arg	His	Arg	Pro	Val	Ser	Arg	Leu	Ala	Ala	Val	Val	Gly	Gly	Ala	Ala
							35			40			45		
Ala	Val	Pro	Ala	Val	Val	Ser	Gly	Val	Thr	Gly	Leu	Ile	Leu	Ser	Pro
							50			55			60		
Ser	Gln	Ser	Pro	Ile	Phe	Ile	Gln	Pro	Thr	Pro	Leu	Pro	Gln	Thr	Leu
							65			70			75		80
Pro	Leu	Arg	Pro	Gly	Leu	Asp	Leu	Ala	Phe	Ala	Asn	Gln	Pro	Gly	His
							85			90			95		
Leu	Ala	Pro	Leu	Gly	Glu	Ile	Arg	Pro	Ser	Ala	Pro	Pro	Leu	Pro	Pro
							100			105			110		
Val	Ala	Asp	Leu	Pro	Gln	Pro	Gly	Leu	Arg	Arg	Glx				
							115			120					

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 48 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Burma strain)
406.3-2

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Thr Leu Asp Tyr Pro Ala Arg Ala His Thr Phe Asp Asp Phe Cys Pro
1 5 10 15

Glu Cys Arg Pro Leu Gly Leu Gln Gly Cys Ala Phe Gln Ser Thr Val
20 25 30

Ala Glu Leu Gln Arg Leu Lys Met Lys Val Gly Lys Thr Arg Glu Leu
35 40 45

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E Virus (Mexico strain)
406.3-2 region

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Thr Phe Asp Tyr Pro Gly Arg Ala His Thr Phe Asp Asp Phe Cys Pro
1 5 10 15

Glu Cys Arg Ala Leu Gly Leu Gln Gly Cys Ala Phe Gln Ser Thr Val
20 25 30

Ala Glu Leu Gln Arg Leu Lys Val Lys Val Gly Lys Thr Arg Glu Leu
35 40 45

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 540 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

(C) INDIVIDUAL ISOLATE: Hepatitis E virus (Burma strain)
r62kDa, 58.1 kDa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Ala Val Ala Pro Ala His Asp Thr Pro Pro Val Pro Asp Val Asp Ser
 1 5 10 15
 Arg Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu
 20 25 30
 Thr Ser Ser Val Ala Thr Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro
 35 40 45
 Leu Ser Pro Leu Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met
 50 55 60
 Ala Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr
 65 70 75 80
 Ile Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile
 85 90 95
 Ser Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp
 100 105 110
 Met Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly
 115 120 125
 Ile Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn
 130 135 140
 Gln Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Ala
 145 150 155 160
 Thr Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Leu Val Asn Ser
 165 170 175
 Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala
 180 185 190
 Leu Glu Leu Glu Phe Arg Asn Leu Thr Pro Gly Asn Thr Asn Thr Arg
 195 200 205
 Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala
 210 215 220
 Asp Gly Thr Ala Glu Leu Thr Thr Ala Ala Thr Arg Phe Met Lys
 225 230 235 240
 Asp Leu Tyr Phe Thr Ser Thr Asn Gly Val Gly Glu Ile Gly Arg Gly
 245 250 255
 Ile Ala Leu Thr Leu Phe Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu
 260 265 270
 Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg
 275 280 285
 Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser
 290 295 300
 Val Glu Asn Ala Gln Gln Asp Lys Gly Ile Ala Ile Pro His Asp Ile
 305 310 315 320
 Asp Leu Gly Glu Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His
 325 330 335
 Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser
 340 345 350
 Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu

355	360	365	
Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Val Ser			
370	375	380	
Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala Val Ala			
385	390	395	400
Arg Ser Leu Asp Trp Thr Lys Val Thr Leu Asp Gly Arg Pro Leu Ser			
405	410	415	
Thr Ile Gln Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu Arg Gly			
420	425	430	
Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr Pro Tyr			
435	440	445	
Asn Tyr Asn Thr Thr Ala Ser Asp Gln Leu Leu Val Glu Asn Ala Ala			
450	455	460	
Gly His Arg Val Ala Ile Ser Thr Tyr Thr Thr Ser Leu Gly Ala Gly			
465	470	475	480
Pro Val Ser Ile Ser Ala Val Ala Val Leu Ala Pro His Ser Ala Leu			
485	490	495	
Ala Leu Leu Glu Asp Thr Leu Asp Tyr Pro Ala Arg Ala His Thr Phe			
500	505	510	
Asp Asp Phe Cys Pro Glu Cys Arg Pro Leu Gly Leu Gln Gly Cys Ala			
515	520	525	
Phe Gln Ser Thr Val Ala Glu Leu Gln Arg Leu Lys			
530	535	540	

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 540 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (iii) HYPOTHETICAL: NO
- (vi) ORIGINAL SOURCE:
 - (C) INDIVIDUAL ISOLATE: Hepatitis E virus (Mexico strain)
r62kDa, 58.1 kDa
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

Ala Val Ala Pro Ala His Asp Thr Ser Pro Val Pro Asp Val Asp Ser			
1	5	10	15
Arg Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu			
20	25	30	
Thr Ser Ser Val Ala Ser Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro			
35	40	45	
Leu Asn Pro Pro Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met			
50	55	60	
Ala Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr			
65	70	75	80

Ile Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile
 85 90 95
 Ser Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp
 100 105 110
 Met Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly
 115 120 125
 Ile Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn
 130 135 140
 Gln Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Glu Ala
 145 150 155 160
 Thr Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Pro Val Asn Ser
 165 170 175
 Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala
 180 185 190
 Leu Glu Leu Glu Phe Arg Asn Leu Thr Thr Cys Asn Thr Asn Thr Arg
 195 200 205
 Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala
 210 215 220
 Asp Gly Thr Ala Glu Leu Thr Thr Ala Ala Thr Arg Phe Met Lys
 225 230 235 240
 Asp Leu His Phe Thr Gly Leu Asn Gly Val Gly Glu Val Gly Arg Gly
 245 250 255
 Ile Ala Leu Thr Leu Leu Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu
 260 265 270
 Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg
 275 280 285
 Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser
 290 295 300
 Val Glu Asn Ala Gln Gln Asp Lys Gly Val Ala Ile Pro His Asp Ile
 305 310 315 320
 Asp Leu Gly Asp Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His
 325 330 335
 Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser
 340 345 350
 Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu
 355 360 365
 Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Ile Ser
 370 375 380
 Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala Val Ala
 385 390 395 400
 Arg Ser Leu Asp Trp Ser Lys Val Thr Leu Asp Gly Arg Pro Leu Pro
 405 410 415
 Thr Val Glu Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu Arg Gly
 420 425 430
 Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr Pro Tyr

95

435

440

445

Asn Tyr Asn Thr Thr Ala Ser Asp Gln Ile Leu Ile Glu Asn Ala Ala
 450 455 460

Gly His Arg Val Ala Ile Ser Thr Tyr Thr Arg Leu Gly Ala Gly
 465 470 475 480

Pro Val Ala Ile Ser Ala Ala Ala Val Leu Ala Pro Arg Ser Ala Leu
 485 490 495

Ala Leu Leu Glu Asp Thr Phe Asp Tyr Pro Gly Arg Ala His Thr Phe
 500 505 510

Asp Asp Phe Cys Pro Glu Cys Arg Ala Leu Gly Leu Gln Gly Cys Ala
 515 520 525

Phe Gln Ser Thr Val Ala Glu Leu Gln Arg Leu Lys
 530 535 540

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 525 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: Hepatitis E virus (Burma strain)
 r62kDa, 56.5 kDa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Ala Val Ala Pro Ala His Asp Thr Pro Pro Val Pro Asp Val Asp Ser
 1 5 10 15

Arg Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu
 20 25 30

Thr Ser Ser Val Ala Thr Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro
 35 40 45

Leu Ser Pro Leu Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met
 50 55 60

Ala Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr
 65 70 75 80

Ile Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile
 85 90 95

Ser Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp
 100 105 110

Met Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly
 115 120 125

Ile Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn
 130 135 140

Gln Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Ala

145	150	155	160
Thr Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Leu Val Asn Ser			
165	170	175	
Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala			
180	185	190	
Leu Glu Leu Glu Phe Arg Asn Leu Thr Pro Gly Asn Thr Asn Thr Arg			
195	200	205	
Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala			
210	215	220	
Asp Gly Thr Ala Glu Leu Thr Thr Ala Ala Thr Arg Phe Met Lys			
225	230	235	240
Asp Leu Tyr Phe Thr Ser Thr Asn Gly Val Gly Glu Ile Gly Arg Gly			
245	250	255	
Ile Ala Leu Thr Leu Phe Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu			
260	265	270	
Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg			
275	280	285	
Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser			
290	295	300	
Val Glu Asn Ala Gln Gln Asp Lys Gly Ile Ala Ile Pro His Asp Ile			
305	310	315	320
Asp Leu Gly Glu Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His			
325	330	335	
Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser			
340	345	350	
Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu			
355	360	365	
Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Val Ser			
370	375	380	
Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala Val Ala			
385	390	395	400
Arg Ser Leu Asp Trp Thr Lys Val Thr Leu Asp Gly Arg Pro Leu Ser			
405	410	415	
Thr Ile Gln Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu Arg Gly			
420	425	430	
Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr Pro Tyr			
435	440	445	
Asn Tyr Asn Thr Thr Ala Ser Asp Gln Leu Leu Val Glu Asn Ala Ala			
450	455	460	
Gly His Arg Val Ala Ile Ser Thr Tyr Thr Ser Leu Gly Ala Gly			
465	470	475	480
Pro Val Ser Ile Ser Ala Val Ala Val Leu Ala Pro His Ser Ala Leu			
485	490	495	
Ala Leu Leu Glu Asp Thr Leu Asp Tyr Pro Ala Arg Ala His Thr Phe			
500	505	510	

Asp Asp Phe Cys Pro Glu Cys Arg Pro Leu Gly Leu Gln
 515 520 525

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 525 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
 (C) INDIVIDUAL ISOLATE: Hepatitis E virus (Mexico strain)
 r62kDa, 56.5 kDa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Ala Val Ala Pro Ala His Asp Thr Ser Pro Val Pro Asp Val Asp Ser
 1 5 10 15

Arg Gly Ala Ile Leu Arg Arg Gln Tyr Asn Leu Ser Thr Ser Pro Leu
 20 25 30

Thr Ser Ser Val Ala Ser Gly Thr Asn Leu Val Leu Tyr Ala Ala Pro
 35 40 45

Leu Asn Pro Pro Leu Pro Leu Gln Asp Gly Thr Asn Thr His Ile Met
 50 55 60

Ala Thr Glu Ala Ser Asn Tyr Ala Gln Tyr Arg Val Ala Arg Ala Thr
 65 70 75 80

Ile Arg Tyr Arg Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala Ile
 85 90 95

Ser Ile Ser Phe Trp Pro Gln Thr Thr Thr Pro Thr Ser Val Asp
 100 105 110

Met Asn Ser Ile Thr Ser Thr Asp Val Arg Ile Leu Val Gln Pro Gly
 115 120 125

Ile Ala Ser Glu Leu Val Ile Pro Ser Glu Arg Leu His Tyr Arg Asn
 130 135 140

Gln Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Ala
 145 150 155 160

Thr Ser Gly Leu Val Met Leu Cys Ile His Gly Ser Pro Val Asn Ser
 165 170 175

Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu Asp Phe Ala
 180 185 190

Leu Glu Leu Glu Phe Arg Asn Leu Thr Thr Cys Asn Thr Asn Thr Arg
 195 200 205

Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg Leu Arg Arg Gly Ala
 210 215 220

Asp Gly Thr Ala Glu Leu Thr Thr Ala Ala Thr Arg Phe Met Lys
 225 230 235 240

Asp Leu His Phe Thr Gly Leu Asn Gly Val Gly Glu Val Gly Arg Gly

245	250	255
Ile Ala Leu Thr Leu Leu Asn Leu Ala Asp Thr Leu Leu Gly Gly Leu		
260	265	270
Pro Thr Glu Leu Ile Ser Ser Ala Gly Gly Gln Leu Phe Tyr Ser Arg		
275	280	285
Pro Val Val Ser Ala Asn Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser		
290	295	300
Val Glu Asn Ala Gln Gln Asp Lys Gly Val Ala Ile Pro His Asp Ile		
305	310	315
Asp Leu Gly Asp Ser Arg Val Val Ile Gln Asp Tyr Asp Asn Gln His		
325	330	335
Glu Gln Asp Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser		
340	345	350
Val Leu Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu		
355	360	365
Tyr Asp Gln Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Ile Ser		
370	375	380
Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gln Ala Val Ala		
385	390	395
Arg Ser Leu Asp Trp Ser Lys Val Thr Leu Asp Gly Arg Pro Leu Pro		
405	410	415
Thr Val Glu Gln Tyr Ser Lys Thr Phe Phe Val Leu Pro Leu Arg Gly		
420	425	430
Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala Gly Tyr Pro Tyr		
435	440	445
Asn Tyr Asn Thr Thr Ala Ser Asp Gln Ile Leu Ile Glu Asn Ala Ala		
450	455	460
Gly His Arg Val Ala Ile Ser Thr Tyr Thr Arg Leu Gly Ala Gly		
465	470	475
480		
Pro Val Ala Ile Ser Ala Ala Val Leu Ala Pro Arg Ser Ala Leu		
485	490	495
Ala Leu Leu Glu Asp Thr Phe Asp Tyr Pro Gly Arg Ala His Thr Phe		
500	505	510
Asp Asp Phe Cys Pro Glu Cys Arg Ala Leu Gly Leu Gln		
515	520	525

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 43 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:

- (C) INDIVIDUAL ISOLATE: HEV 5' primer

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGGGGGGATC CATATGGCGG TCGCTCCGGC CCATGACACC CCG

43

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(iii) HYPOTHETICAL: NO

(vi) ORIGINAL SOURCE:
(C) INDIVIDUAL ISOLATE: HEV 3' primer

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

ATTAGAACCT TCCGTGGCCA TTATATG

27

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 33 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(iii) HYPOTHETICAL: YES

(iv) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(C) INDIVIDUAL ISOLATE: internally consistent sequence of
two HEV 406.4-2 antigens

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 3
(D) OTHER INFORMATION: /note= "where Xaa is Q or P"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 5
(D) OTHER INFORMATION: /note= "where Xaa is G or D"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 7
(D) OTHER INFORMATION: /note= "where Xaa is L or S"

(ix) FEATURE:

(A) NAME/KEY: Modified-site
(B) LOCATION: 12
(D) OTHER INFORMATION: /note= "where Xaa is E or V"

(ix) FEATURE:

(A) NAME/KEY: Modified-site

100

(B) LOCATION: 13
(D) OTHER INFORMATION: /note= "where Xaa is I or T"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 22
(D) OTHER INFORMATION: /note= "where Xaa is P or H"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 24
(D) OTHER INFORMATION: /note= "where Xaa is A or V"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 29
(D) OTHER INFORMATION: /note= "where Xaa is P or L"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION: 31
(D) OTHER INFORMATION: /note= "where Xaa is L or P"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Ala Asn Xaa Pro Xaa His Xaa Ala Pro Leu Gly Xaa Xaa Arg Pro Ser
1 5 10 15

Ala Pro Pro Leu Pro Xaa Val Xaa Asp Leu Pro Gln Xaa Gly Xaa Arg
20 25 30
Arg

IT IS CLAIMED:

1. A Hepatitis E Virus (HEV) polypeptide composition, comprising at least one polypeptide derived from the carboxy-terminal 549 amino acids of HEV open reading frame 5 (ORF) 2.
2. A polypeptide composition of claim 1, where at least one polypeptide contains a carboxy terminal deletion of up to about 24 carboxy terminal amino acids of said 549 amino acid HEV ORF2 polypeptide.
3. A polypeptide composition of claim 1, where said composition contains a polypeptide having the sequence presented as SEQ ID NO:15 or a homologous sequence thereto.
- 15 4. A polypeptide composition of claim 1, where said composition contains a polypeptide having the sequence presented as SEQ ID NO:16 or a homologous sequence thereto.
5. A polypeptide composition of claim 1, where said composition contains a 20 polypeptide having the sequence presented as SEQ ID NO:25 or a homologous sequence thereto.
- 25 6. A polypeptide composition of claim 1, where said composition contains a polypeptide having the sequence presented as SEQ ID NO:26 or a homologous sequence thereto.
7. A polypeptide composition of claim 1, where said composition contains a 30 polypeptide having the sequence presented as SEQ ID NO:27 or a homologous sequence thereto.
8. A polypeptide composition of claim 1, where said composition contains a polypeptide having the sequence presented as SEQ ID NO:28 or a homologous sequence thereto.

9. A polypeptide composition of claim 1, where said composition contains two polypeptides having the sequences presented as SEQ ID NO:25 and SEQ ID NO:27, or homologous sequences thereto.

5 10. A polypeptide composition of claim 1, where said composition contains two polypeptides having the sequences presented as SEQ ID NO:26 and SEQ ID NO:28, or homologous sequences thereto.

10 11. A substantially isolated nucleic acid sequence encoding a polypeptide of any of claims 1-10.

12. An expression vector for producing a Hepatitis E Virus polypeptide antigen composition, comprising,
a nucleic acid sequence encoding a polypeptide of any of claims 1-10, said nucleic acid sequence inserted into an expression vector, where said nucleic acid sequence is operably linked to a promoter able to initiate transcription in a selected host cell.

15 13. An expression system for producing a Hepatitis E Virus polypeptide antigen composition, comprising,
a nucleic acid sequence encoding a polypeptide of any of claims 1-10, said nucleic acid sequence inserted into an expression vector, wherein said nucleic acid sequence is operably linked to a promoter able to initiate transcription in a selected host cell, and
said expression vector is carried within the host cell.

20 14. An expression system of claim 13, where said expression vector is a baculovirus expression vector and said host cell is an insect cell.

25 15. A Hepatitis E Virus (HEV) polypeptide composition produced by a process comprising,
culturing an insect cell containing an expression vector of claim 12 under conditions sufficient to express a polypeptide encoded by said nucleic acid.

30 16. A composition of claim 15, wherein at least one polypeptide of the composition has an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID

NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and homologous sequences therewith.

17. A Hepatitis E Virus (HEV) polypeptide composition produced by a process
5 comprising,

- a) obtaining an HEV capsid derived antigen having at least 549 carboxy terminal amino acids of an HEV capsid protein; and
- b) incubating the antigen with a baculoviral infected lysate under conditions sufficient to cleave carboxy terminal sequences of the HEV capsid derived antigen.

10

18. A method of producing a Hepatitis E Virus (HEV) polypeptide composition, comprising the steps of:

culturing a cell containing the expression vector of claim 12 under conditions sufficient to express a polypeptide sequence encoded by said nucleic acid.

15

19. A method of detecting hepatitis E virus infection in an individual, comprising:

- a) reacting a serum sample taken from the individual with the Hepatitis E Virus (HEV) polypeptide composition of any of claims 1 to 10; and
- b) examining a polypeptide of the composition for the presence of bound antibody.

20

20. The method of claim 19, wherein polypeptides of the HEV polypeptide composition are attached to a solid support, said reacting includes contacting such serum with the support and said examining includes reacting the support and bound antibody with a reporter-labeled anti-human antibody.

25

21. A kit for ascertaining the presence of antibodies to HEV in a serum sample taken from an individual, comprising:

a solid support with surface-bound antigens wherein the surface-bound antigens are polypeptides of the HEV polypeptide composition of any of claims 1 to 10.

30

22. A vaccine composition used in immunizing an individual against Hepatitis E Virus (HEV) comprising,

an HEV polypeptide composition of any of claims 1 to 10 in a pharmacologically acceptable carrier.

23. A vaccine composition of claim 22, where at least one polypeptide of the composition has an amino acid sequence selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, and homologous sequences therewith.

5

24. A method of inhibiting infection of an individual by HEV, comprising: administering to the subject a vaccine composition of any of claims 21 to 22 in a therapeutically effective amount.

1/19




Fig. 1

2/19

Fig. 2A

I-ORF3-->
 5110v 5120v 5130v 5140v 5150v 5160v
 TGGAATGAATAACATGTCTTTGCTGCGCCCATGGGTTCGCGACCATGCGCCCTCGGCCT
 GAATGAATAACATGT TTTGCTGCGCCCATGGGTTCGC ACCATGCGCCCT GGCCT
 CTGAATGAATAACATGTGGTTGCTGCGCCCATGGGTTGCCACCATGCGCCCTAGGCCT

I-ORF2-->
 5170v 5180v 5190v 5200v 5210v 5220v
 ATTTTGGTGTGCTCCTCATGTTTTGCCTATGCTGCCCCGCCACCGCCGGTCAGCCG
 TTTTG TG TG TCCTC TGTG TGCCTATG TGCCCCGCCACCG CCGGTCAAGCCG
 CTTTGCTGTTGTTCTGCCTATGTTGCCCGGCCACCGACCGGTCAAGCCG

 5230v 5240v 5250v 5260v 5270v 5280v
 TCTGGCCGCCGTCGTGGCGGCCAGCGGGCGGTCCGGCGGTGGTTCTGGGGTGACCGG
 TCTGGCCGCCGTCGTGGCGGCCAGCGGGCGGT CGGGCGGTGGTTCTGGGGTGACCGG
 TCTGGCCGCCGTCGTGGCGGCCAGCGGGCGGTACCGGGCGGTGGTTCTGGGGTGACCGG

 5290v 5300v 5310v 5320v 5330v 5340v
 GTTGATTCTCAGCCCTTCGCAATCCCCTATATTCAACCAACCCCTCGCCCCCGAT
 GTTGATTCTCAGCCCTTCGCAATCCCCTATATTCAACCAACCCCTT GCCCC GA
 GTTGATTCTCAGCCCTTCGCAATCCCCTATATTCAACCAACCCCTTGCCCCAGAC

I-406.4-2-->
 5350v 5360v 5370v 5380v 5390v 5400v
 GTCACCGCTGCGGCCGGGGCTGGACCTCGTGGTCTCGCAACCCGCCGACCACTCGGCTCC
 GT CCGCTGCG CGGGG CTGGACCTCG TTCGCCAACCGCCCG CCACT GGCTCC
 GTTGCCGCTGCGTCCGGGTCTGGACCTCGCCTCGCAACAGCCCGGCACTTGGCTCC

 5410v 5420v 5430v 5440v 5450v 5460v
 GCTTGGCGTGACCAGGCCAGCGCCCCGCCGTTGCCTCACGTGCTAGACCTACCAAGCT
 CTTGGCG GA CAGGCCAGCGCCCC CCG TGCCTC CGTCG GACCT CCACAGC
 ACTTGGCGAGATCAGGCCAGCGCCCCCTCCGCTGCCCTCGCCACCTGCCACAGCC

<-406.4-2-I
<-ORF3--I
 5470v 5480v 5490v 5500v 5510v 5520v
 GGGGCCGCGCCGCTAACCGCGGTGCTCCGGCCATGACACCCGCCAGTGCCTGATGTC
 GGGGC GCG CGCT AC GC GT GC CC GCCCATGACACC C CC GT CC GA GT
 GGGGCTGCGCGCTGACGGCTGTGGCGCCTGCCATGACACCTCACCCGTCCCAGCGTT

3/19

Fig. 2B

5530v 5540v 5550v 5560v 5570v 5580v
 GACTCCCGCGGCCATCTGCGCCGGCAGTATAACCTATCAACATCTCCCTTACCTCT
 GA TC CGCGG GC AT T CGCCG CAGTATAA T TC AC TC CCCCT AC TC
 GATTCTCGCGGTGCAATTCTACGCCAGTATAATTGTCTACTTCACCCCTGACATCC

5590v 5600v 5610v 5620v 5630v 5640v
 TCCGTGGCCACCGGCACTAACCTGGTTCTTATGCCGCCCTCTTAGTCGCTTTACCC
 TC GTGGCC C GGCACCAA T GT CT TATGC GCCCC CTTA TCCGC T T CC
 TCTGTGGCCTCTGGCACTAATTAGTCCTGTATGCAGCCCCCTTAATCCGCCTCTGCCG

5650v 5660v 5670v 5680v 5690v 5700v
 CTTCAGGACGGCACCAATACCCATATAATGGCACCGGAAGCTCTAATTATGCCAGTAC
 CT CAGGACGG AC AATAC CA AT ATGGCAC GA GC TC AATTATGC CAGTAC
 CTGCAGGACGGTACTAATACTCACATTATGGCACAGAGGCCTCCAATTATGCACAGTAC

5710v 5720v 5730v 5740v 5750v 5760v
 CGGGTTGCCCGTGCCACAATCCGTTACCGCCCGCTGGTCCCCAATGCTGTCGGCGGTTAC
 CGGGTTGCCCG GC AC ATCCGTTACCG CC CT GT CC AATGC GT GG GG TA
 CGGGTTGCCCGCGCTACTATCCGTTACCGCCCTAGTCCTAATGCAGTTGGAGGCTAT

trpE-C2 I->

5770v 5780v 5790v 5800v 5810v 5820v
 GCCATCTCCATCTCATTCTGGCCACAGACCACCACCCGACGTCCGTTGATATGAAT
 GC AT TCCAT TC TTCTGGCC CA AC ACCAC ACCCC AC TC GTTGA ATGAAT
 GCTATATCCATTCTTTCTGGCCTCAAACAACCACAACCCCTACATCTGTTGACATGAAT

5830v 5840v 5850v 5860v 5870v 5880v
 TCAATAACCTCGACGGATGTTCGTATTTAGTCCAGCCGGCATAGCCTCTGAGCTTGTG
 TC AT AC TC AC GATGT G ATT T GT CA CC GGCATAGC TCTGA T GT
 TCCATTACTCCACTGATGTCAGGATTCTGTTCAACCTGGCATAGCATCTGAATTGGTC

5890v 5900v 5910v 5920v 5930v 5940v
 ATCCAAGTGAGCGCCTACACTATCGTAACCAAGGCTGGCGCTCCGTCGAGACCTCTGGG
 ATCCAAG GAGCGCCT CACTA CG AA CAAGG TGGCGCTC GT GAGAC TCTGG
 ATCCAAGCGAGCGCCTCACTACCGCAATCAAGGTTGGCGCTGGTTGAGACATCTGGT

5950v 5960v 5970v 5980v 5990v 6000v
 GTGGCTGAGGAGGAGGCTACCTCTGGCTTGTTATGCTTGCATACATGGCTCACTCGTA
 GT GCTGAGGAGGA GC ACCTC GGTCTTGT ATG T TGCATACATGGCTC C GT
 GTTGCTGAGGAGGAAGCCACCTCCGGTCTTGTATGCATACATGGCTCTCCAGTT

6010v 6020v 6030v 6040v 6050v 6060v
 AATTCCCTATACTAATACACCCCTATACCGGTGCCCTCGGGCTGTTGGACTTGCCTTGAG
 AA TCCTATAC AATAC CC TATACCGGTGCCCT GG T TGGACTTGGCTACTGGACTTGCCTTAGAG
 AACTCCTATACCAATACCCCTTATACCGGTGCCCTGGCTACTGGACTTGCCTTAGAG

Fig. 2C

6070v 6080v 6090v 6100v 6110v 6120v
 CTTGAGTTTCGCAACCTTACCCCCGGTAACACCAATACGCGGGTCTCCGTTATTCCAGC
 CTTGAGTTTCGCAA CT ACC CC GTAACACCAATAC CG GT TCCC GTTA TCCAGC
 CTTGAGTTTCGCAATCTCACCAACCTGTAACACCAATACACGTGTCCC GTTACTCCAGC

 6130v 6140v 6150v 6160v 6170v 6180v
 I-SG3-->
 ACTGCTGCCACCGCCTCGTCGCGGTGCGGACTGCCGAGCTCACCAACCGGCT
 ACTGCTCG CAC C CG G GACGGGACTGC GAGCT ACCAC AC GC
 ACTGCTCGTCACTCCGCCCAGGGGCC---GACGGGACTGCGGAGCTGACCAACTGCA

 6190v 6200v 6210v 6220v 6230v 6240v
 GCTACCCGCTTTATGAAGGACCTCTATTTACTAGTACTAATGGTGTGGTGAGATCGGC
 GC ACC G TT ATGAA GA CTC A TTAC G TAATGG GT GGTGA TCGGC
 GCCACCAGGTTCATGAAAGATCTCCACTTACCGGCCTTAATGGGTAGGTGAAGTCGGC

 6250v 6260v 6270v 6280v 6290v 6300v
 CGCGGGATAGCCCTCACCTGTTAACCTTGCTGACACTCTGCTTGGCGGCCGACA
 CGCGGGATAGC CT AC T T AACCTTGCTGACAC CT CT GGCGG CT CCGACA
 CGCGGGATAGCTAACATTACTAACCTTGCTGACACGCTCTCGCGGGCTCCGACA

 6310v 6320v 6330v 6340v 6350v 6360v
 GAATTGATTTCGTCGGCTGGTGGCCAGCTGTTCTACTCCCGTCCCGTTGTCTCAGCCAAT
 GAATT ATTCGTCGGCTGG GG CA CTGTT TA TCCCG CC GTTGTCTCAGCCAAT
 GAATTAAATTTCGTCGGCTGGCGGGCAACTGTTTATTCCCGCCGGTTGTCTCAGCCAAT

 6370v 6380v 6390v 6400v 6410v 6420v
 GGCGAGCCGACTGTTAAGTTGTATACATCTGTAGAGAATGCTCAGCAGGATAAGGGTATT
 GGCGAGCC AC GT AAG T TATACATC GT GAGAATGCTCAGCAGGATAAGGGT TT
 GGCGAGCCAACCGTGAAGCTCTATACATCAGTGGAGAATGCTCAGCAGGATAAGGGTGT

 6430v 6440v 6450v 6460v 6470v 6480v
 GCAATCCCGCATGACATTGACCTCGGAGAATCTCGTGTGGTTATTCAAGGATTATGATAAC
 GC ATCCC CA GA AT GA CT GG GA TC CGTGTGGT ATTCAAGGATTATGA AAC
 GCTATCCCCACGATATCGATCTGGTGATTCGCGTGTGGTCACTCAGGATTATGACAAC

 6490v 6500v 6510v 6520v 6530v 6540v
 CAACATGAACAAGATCGGCCGACGCCCTCTCCAGCCCCATCGGCCCTTCTGTCCCT
 CA CATGA CA GATCGGCC AC CC TC CC GC CCATC CG CCTTT TCTGT CT
 CAGCATGAGCAGGATCGGCCACCCCGTCGCCTCGGCCATCTGGCCTTTCTGTCTC

 6550v 6560v 6570v 6580v 6590v 6600v
 CGAGCTAATGATGTGCTTGGCTCTCTCACCGCTGCCAGTATGACCAGTCCACTTAT
 CGAGC AATGATGT CTTGGCT TC CTCAC GC GCCGAGTATGACCAGTCCACTTA
 CGAGCAAATGATGTACTTGGCTGTCCCTCACTGCAGCCAGTATGACCAGTCCACTAC

5/19

Fig. 2D

6610v 6620v 6630v 6640v 6650v 6660v
 GGCTCTCGACTGGCCCAGTTATGTTCTGACTCTGTGACCTGGTTAATGTTGCGACC
 GG TC TC ACTGGCCC GTTTAT T TC GAC GTGAC TTGGT AATGTTGCGAC
 GGGCGTCAACTGGCCCGGTTATATCTGGACAGCGTACTTGGTGAATGTTGCGACT

6670v 6680v 6690v 6700v 6710v 6720v
 GGCGCGCAGGCCGTTGCCCGGTCGCTCGATTGGACCAAGGTACACACTGACGGTCGCCCC
 GGCGCGCAGGCCGT GCCCG TCGCT GA TGG CCAA GTCAC CT GACGG CG CCC
 GGCGCGCAGGCCGTAGCCGATCGCTGACTGGTCCAAAGTCACCCCTCGACGGCGGGCCC

6730v 6740v 6750v 6760v 6770v 6780v
 CTCTCCACCATCCAGCAGTACTCGAAGACCTTCTTGTCTGCCGCTCCGCGGTAAAGCTC
 CTC C AC T AGCA TA TC AAGAC TTCTTGT CT CC CT CG GG AAGCTC
 CTCCCAGTGTGAGCAATATTCCAAGACATTCTTGTGCTCCCCCTCGTGGCAAGCTC

6790v 6800v 6810v 6820v 6830v 6840v
 TCTTCTGGGAGGCAGGCACAACCTAAAGCCGGTACCCCTATAATTATAACACCACTGCT
 TC TT TGGGAGGC GGCACAAC AAAGC GG TA CCTTATAATTATAAA AC ACTGCT
 TCCTTTGGGAGGCCGGCACAAACAAAAGCAGGTTATCCTTATAATTATAACTACTGCT

6850v 6860v 6870v 6880v 6890v 6900v
 AGCGACCAACTGCTTGTGAGAATGCCGCCGGCACCGGGTCGCTATTCCACTTACACC
 AG GACCA T CT T GA AATGC GCCGG CA CGGGTCGC ATTTC AC TA ACC
 AGTGACCAAGATTCTGATTGAAAATGCTGCCGGCATCGGGTCGCCATTCAACCTATAACC

6910v 6920v 6930v 6940v 6950v 6960v
 ACTAGCCTGGGTGCTGGTCCCCTCCTCCATTCTGCCGGTTGCCGTTTAGCCCCCACTCT
 AC AG CT GG GC GGTCC GTC CCATTCTGCCGG GC GTTTT GC CC C CTC
 ACCAGGCTGGGGCCGGTCCGGTCGCCATTCTGCCGGCGGGTTGGCTCACGCTCC

I-406.3-2-->

6970v 6980v 6990v 7000v 7010v 7020v
 GCGCTAGCATTGCTTGAGGATACTTGGACTACCCCTGCCCGCCCATACTTTGATGAT
 GC CT GC TGCT GAGGATACTTGTGATTATCCGGGGCGGGCGCACACATTGATGAC
 GCCCTGGCTCTGCTGGAGGATACTTTGATTATCCGGGGCGGGCGCACACATTGATGAC

7030v 7040v 7050v 7060v 7070v 7080v
 TTCTGCCAGAGTGCCGCCCTTGGCTTCAGGGCTGCGCTTCCAGTCTACTGTCGCT
 TTCTGCC GA TGCCGC C T GGCCT CAGGG TG GCTTTCCAGTC ACTGTCGCT
 TTCTGCCCTGAATGCCCGCTTAGGCCTCCAGGGTTGTGCTTCCAGTCAACTGTCGCT

<- SG3 - I

<- 406.3-2 - I

7090v 7100v 7110v 7120v 7130v 7140v
 GAGCTTCAGCGCCTTAAGATGAAGGTGGGAAAAACTCAGGGAGTTGTAGTTATTGCTTG
 GAGCT CAGCGCCTTAA T AAGGTGGGAAAAACTCAGGGAGTTGTAGTTATTG TG
 GAGCTCCAGCGCCTTAAAGTTAAGGTGGGAAAAACTCAGGGAGTTGTAGTTATTGCTG

6/19

7150v 7160v 7170v 7180v 7190v
TGCCCCCCTTCTTCTGTTGC-----TTATTTCTCATTTCTGCCTCCGCGCTCCC
TGCCC CCT CTT TGC TTATTC TTTCT GT CCGCGCTCCC
TGCCCACCTACTTATATCTGCTGATTTCTTTATTTCTCGGTCCCGCGCTCCC

<-I ORF2 <-I trpE-C2
v 7195

TGA
TGA
TGA

Fig. 2E

7/19

10 20 30 40 50 60
MNNMSFAAPMGSRPCALGLFCCCSSCFCLCCPRHRPVSRLAAVVGAAAVPAVVSGVTGL
X::::: :::
MNNMWFAAPMGSPPCALGLFCCCSSCFCLCCPRHRPVSRLAAVVGAAAVPAVVSGVTGL
10 20 30 40 50 60

406.4-2

70 80 90 100 110 120
ILSPSQSPIFIQPTPSPPMSPLRPGLLVFANPPDHSAPLGVTRPSAPPLPHVVDLPQLG
::::::::::: .: ::::::::::: .: ::::: .: ::::::: .: ::::::: .: :::
ILSPSQSPIFIQPTPLPQTLPLRPGLDLAFANQPGHLAPLGEIRPSAPPLPPADLPQPG
70 80 90 100 110. 120

PRRZ
::X
LRRZ

Fig. 3

8/19

Fig. 4A

10 20 30 40 50 60
 MRPRPILLLMFLPMLPAPPGQPSGRRGRRSGGSGGFWGDRVDSQPFAIPYIHPTN
 X::::::::::: 10 20 30 40 50 60
 MRPRPLLLFLFLPMLPAPPTGQPSGRRGRRSGGTGGGFWGDRVDSQPFAIPYIHPTN
 10 20 30 40 50 60

70 80 90 100 110 120
 PFAPDVTAAAGAGPRVRQPARPLGSAWRDQAQRPAVASRRRPTTAGAAPLTAVAPAHDT
 ::::::::::::::::::::: 70 80 90 100 110 120
 PFAPDVAASGSGPRLRQPARPLGSTWRDQAQRPSAASRRPATAGAAALTAVAPAHDT
 70 80 90 100 110 120

130 140 150 160 170 180
 PVPDVDSRGAILRRQYNLSTSPLTSSVATGTNLVLYAAPLSPLLPLQDGNTNTHIMATEAS
 ::::::::::::::::::::: 130 140 150 160 170 180
 PVPDVDSRGAILRRQYNLSTSPLTSSVASGTNLVLYAAPLNPPPLQDGNTNTHIMATEAS
 130 140 150 160 170 180

C-2

190 200 210 220 230 240
 NYAQYVARATIRYRPLVPNAVGGYAIISISFWPQTTTPTSVDMNSITSTDVRILVQPGI
 ::::::::::::::::::::: 190 200 210 220 230 240
 NYAQYVARATIRYRPLVPNAVGGYAIISISFWPQTTTPTSVDMNSITSTDVRILVQPGI
 190 200 210 220 230 240

250 260 270 280 290 300
 ASELVIPSERLHYRNQGWRSVETSGVAEEEATSGLVMLCIHGLVNSYTNTPYTGALGLL
 ::::::::::::::::::::: 250 260 270 280 290 300
 ASELVIPSERLHYRNQGWRSVETSGVAEEEATSGLVMLCIHGPVNSYTNTPYTGALGLL
 250 260 270 280 290 300

SG3

310 320 330 340 350 360
 DFALELEFRNLTPGNTNTRVSRYSSSTARHRLRRGADGTAELTTAATRFMKDLYFTSTNG
 ::::::::::::::::::::: 310 320 330 340 350
 DFALELEFRNLTTCTNTNTRVSRYSSSTARHS-ARGADGTAELTTAATRFMKDLHFTGLNG
 310 320 330 340 350

370 380 390 400 410 420
 VGEIGRGIALTLFNLADTLLGGLPTELISSAGGQLFYSRPVVSANGEPTVKLYTSVENAQ
 ::::::::::::::::::::: 60 370 380 390 400 410
 VGEVGRGIALTLLNLADTLLGGLPTELISSAGGQLFYSRPVVSANGEPTVKLYTSVENAQ


430 440 450 460 470 480
 QDKGIAIPHDIDLGESRVVIQDYDNQHEQDRPTPSPAPSRPFSVLRANDVLWLSLTAAEY
 ::::::::::::::::::::: 20 430 440 450 460 470
 QDKGVAIPHDIDLGDSRVVIQDYDNQHEQDRPTPSPAPSRPFSVLRANDVLWLSLTAAEY

9/19

490 500 510 520 530 540
DQSTYGSSTGPVYVSDSVTLVNVATGAQAVARSLDWTKVTLDGRPLSTIQQYSKTFFVLP
480 490 500 510 520 530
DQSTYGSSTGPVYISDSVTLVNVATGAQAVARSLDWSKVTLDGRPLPTVEQYSKTFFVLP
550 560 570 580 590 600
LRGKLSFWEAGTTKAGYPNYNTTASDQLLVENAAGHRVAISTYTTSLGAGPVSISAVAV
540 550 560 570 580 590
LRGKLSFWEAGTTKAGYPNYNTTASDQILIEAAGHRVAISTYTTRLGAGPVAISAAAV
406.3-2
610 620 630 640 650
LAPHSALALLEDTLDYPARAHTFDDFCPECRPLGLQGCAFQSTVAELQRLKMKVGKTR
600 610 620 630 640 650
LAPRSALALLEDTFDYPGRAHTFDDFCPECRALGLQGCAFQSTVAELQRLKVKVGKTR

Fig. 4B

10/19

**Fig. 5**

11/19





Fig. 6A

Fig. 6B



12/19




Fig. 7

13/19




Fig. 8

14/19




Fig. 9

1 2

SDS-PAGE




Fig. 10

15/19





Fig. 11A

Fig. 11B



16/19

Isolates: 1 2 3 4 5 6 7 8 9 10
 Solubility: 1 S 1 S 1 S 1 S 1 S 1 S
 110 - - - - - - - - - -
 84 - - - - - - - - - -
 47 - - - - - - - - - -
 33 - - - - - - - - - -
 24 - - - - - - - - - -




Fig. 12




Fig. 13

10 20 30

Mexican (SEQ ID NO:18) ANQPGHLAPLGEIRPSAPPLPPVADLPQPGLRR
Burma (SEQ ID NO:17) ANPPDHSAPLGVTRPSAPPLPHVVVDLPQLGPRR

10 20 30

Fig. 16

18/19

1 2 3 4 5 6




Fig. 14A




Fig. 14B

19/19




Fig. 15